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Preface
The goal of the immune system is to protect the body from invaders, such as cancer 
cells. In an ideal situation, tumors would constitute a target for the activated patient 
host immune response. However, by engaging in dynamic interactions with the 
healthy host cells and multiple components of the local tumor microenvironment 
(TME), cancer cells can eventually escape this detection. 
Dendritic cells (DCs) are central in controlling effective induction of anti-tumor 
immunity. Success of this stimulation hinges upon the activation status of DCs. 
Defective or impaired DC activation facilitates tolerance towards cancer cells, 
while fully functional DCs strongly promote cytotoxic T cell activation. Growing 
knowledge on the immunosuppressive mechanisms that accompany tumor 
progression indicates that the TME is the main artificer of the defective activation 
of DCs. In this line, the first objective of this thesis was to broaden our knowledge 
on the impact of tumor-driven immunosuppression on human DCs; and to study 
two distinct anti-cancer strategies that have the potential to restore DC activation. 
Because of the lack of physiological complexity of two-dimensional (2D) cell 
monolayers, the second part of this thesis aims at exploring novel techniques that 
will contribute to our understanding of the complexity of in vivo tissues. In particular, 
I exploited the power of three-dimensional (3D) human skin melanoma models, to 
mimic the cell biological context and the heterotypic crosstalk of the TME, while 
having the benefit of the controlled lab environment that supports cell function. 
Moreover, I applied an innovative imaging technique, to accurately assess immune 
cell infiltrates in human primary melanomas.
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Dendritic cells: key players in anti-cancer response
The goal of the immune system is to protect the body from invaders: external 
invaders, such as pathogens or viruses, but also internal invaders, such as cancer 
cells. The immune system can be distributed across two basic components: the 
innate and the adaptive immune system. Dendritic cells (DCs) are the most potent 
antigen presenting cells (APCs) and provide a functional link between innate and 
adaptive immune responses 1,2. This requires a number of discrete steps. Firstly, in 
their immature state, DCs must take up take up and process tumor proteins into 
antigens (Ags), which can be encountered in situ or delivered to the DCs ex vivo as 
part of a therapeutic vaccine 3. This has to be coupled to an activation or maturation 
signal to the DC. Next, these matured, tumor-antigen presenting DCs migrate 
towards the lymphoid organs, where they induce antigen-specific T cell responses 
that target the tumor (Figure 1) 4,5. 
Priming of naïve T cells into antigen-specific effector T cells by DCs requires 
four signals: (I) engagement of a T cell receptor (TCR) with a peptide-major-
histocompatibility complex (MHC) on the DC, and (II) the right balance between 
expression of co-stimulatory molecules on the DC surface (such as CD40, CD80 and 
CD86) that activate T cell proliferation; and co-inhibitory molecules that attenuate 
T cell activation. Co-inhibitory molecules are expressed both on T cells, such as 
the receptors programmed cell death-1 (PD-1) and the cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4), and on DCs, such as the ligands PD-ligand 1 (PD-L1) 
and PD-ligand 2 (PD-L2) 4,6-12. (III) A third signal is provided by cytokines secreted 
by the DCs, which regulate the differentiation of naïve T cells into different subsets 
of effector T cells, in particular CD4+ T helper cells. This process results in the 
differentiation towards a Th1, Th2, Th9, Th17 or regulatory T cell (Treg) phenotype 13. 
Lastly (IV), environmental cues from the DCs, such as DC-processed metabolites, 
provide T cells with a signal to home and migrate to certain tissues 14. Efficient anti-
tumor responses are believed to require CD8+ cytotoxic (killer) T cells but recent 
data indicate that induction of CD4+ T helper cells also aid in clinical efficacy 15. 
Conversely, DCs may also trigger antibody- and natural killer (NK) cell responses, 
which may also contribute to anti-tumor immunity 16,17. 
Dendritic cell subsets
DCs encompass very heterogeneous cell populations 18-20. This level of heterogeneity 
relates to their origin, anatomical localization, phenotype and function. There are 
two major types of DCs in humans and mice: lymphoid-derived or plasmacytoid 
DCs (CD11c-, pDCs) and myeloid-derived DCs (CD11c+, mDCs) 11,21,22. In steady 
state, pDCs reside in the blood and in lymphoid organs (bone marrow, spleen, 
15
lymph nodes). In response to inflammation and release of ‘danger’ signals, pDCs 
accumulate in peripheral tissues at the site of damage. pDCs are central in anti-
viral immunity, as they produce high amounts of type I interferons in response to 
viral infection 21,23. The other class of DCs, mDCs, comprises several DC subsets. 
In human skin, the epidermis contains Langerhans cells (LCs), whereas the dermis 
hosts CD1a+ DCs and CD14+ DCs. In humans, CD16+ DCs, CD1c+ (BDCA1) DCs and 
CD141+ (BDCA3) DCs are found circulating in the blood. Human CD1c+ DCs and 
CD141+ DCs share homology with mouse CD11c+ DCs, expressing either CD11b or 
CD8/CD103, respectively 11,22,24,25. 
Tumors engineer an immunosuppressive microenvironment 
that hampers their eradication by the immune system 
In an ideal situation, cancer cells would constitute a target for the activated patient 
host immune response. Recent studies indicate that early tumors can be eliminated 
or contained by the immune system; however, by a process involving immunoediting, 
tumor cells can eventually escape this detection 26. They do so by: 
1. hiding from immune surveillance (upregulation of CD47 and downregulation of 
MHC molecules)
Figure 1. Dendritic cells have the potential to stimulate anti-tumor immunity. (1) Tissue-resident 
immature dendritic cells (DCs) patrol the environment for signs of danger, such as tumor cells. 
(2) DCs engulf tumor-derived particles and process them into antigens (ags) for presentation on 
MHC molecules (3). Following ag-processing, (4) DCs undergo maturation and migrate towards 
the lymph node, where they induce the activation of tumor-specific T lymphocytes. (5) Activated 
effector T cells disseminate and home to pheripheral tissue to kill cancer cells and eradicate 
the tumor.
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2. inhibiting immune cell function and inducing tolerance to the tumor 
(immunosuppressive cytokines secretion; expression of inhibitory molecules, 
such as PD-L1)
3. recruiting suppressive immune cells that hamper T cell function (including Tregs)
4. producing tumor growth enhancing factors (such as vascular endothelial growth 
factor, VEGF)
5. modulating the activity of ECM-modifying enzymes that facilitate tumor 
dissemination (matrix metalloproteases, MMPs)  27-31. 
These acquired functional capabilities allow cancer cells to survive, proliferate and 
metastasize 27-31. With this intricate picture in mind, researchers have started to 
describe tumors as “aberrant” organs, whose complexity is comparable to that of 
normal healthy tissues. Thus, in order to unravel the biology of cancer, researches 
need to comprehend the primary role of the tumor microenvironment (TME). The TME 
is the dynamic milieu of cellular and acellular components that comprise the tumor 
exists. The TME consists of tumor cells, recruited normal cells (such as fibroblasts, 
endothelial cells and infiltrating immune cells) embedded in an extracellular matrix 
(ECM) that provides functional and structural support for tumor growth (Figure 2).
Evidence shows that infiltrating immune cells can be either beneficial or 
detrimental to patients, depending on their nature. Indeed, immune infiltrates are 
heterogeneous and vary between tumor types and from patient to patient. Different 
immune cell types can be found infiltrating a tumor, including macrophages, DCs, 
distinct T lymphocytes subsets, B cells and NK cells. 
The presence of tumor infiltrating lymphocytes (TILs) has been associated with 
improved survival of patients with prostate, breast, colorectal, ovarian cancer or 
melanoma 32-36. This can be attributed to the secretion of chemokines, by tumor 
cells and other infiltrating immune cells in the TME, which attract relevant immune 
cells into the tumor. Chemokines, such as CX3CL1 (also known as fractalkine), CCL5, 
CXCL9 and CXCL10 are associated with infiltration of memory T cells and effector 
T cells into the tumor, as well as prolonged disease-free survival and overall survival. 
By contrast, recruitment of immunosuppressive immune cell types, such as Tregs, 
myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages 
(TAMs), hampers anti-tumor immunity and is associated with decreased survival of 
cancer patients 37-39. These cells produce cytokines with anti-inflammatory activities, 
such as IL-10 and TGFβ, which inhibit the function of effector immune cells and pro-
angiogenic effects, including VEGF, to promote metastatic dissemination.
Because of the complexity of the TME, understanding the heterotypic interactions 
that occur at the tumor site is of utmost importance. These interactions are in fact 
key regulators of tumorigenesis and escape of immune surveillance, which are in 
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turn an essential requirement for tumor progression. Amongst a variety of tumor-
mediated inhibitory mechanisms, signalling through the surface protein CD47 has 
recently received considerable attention. Part of this thesis aims at investigating 
the effects of CD47 expression on tumor cells and its ability to interfere with DC 
function, as a strategy for immunosurveillance escape. 
Inhibitory signalling through CD47: a ”don’t eat me” alert for 
immunoevasion
CD47 (also known as integrin associated protein, IAP) is a 50kDa cell surface protein 
belonging to the immunoglobulin (Ig) superfamily. It comprises a glycosylated 
N-terminal domain, a pentaspanin transmembrane domain and a cytoplasmic tail. 
CD47 was first identified on erythrocytes as an important regulator of homeostasis. 
Newly developed erythrocytes that enter blood circulation express high levels of 
CD47 on the cell membrane. This prevents these young healthy red blood cells 
(RBCs) from being cleared from the bloodstream by phagocytes. As they age, 
erythrocytes lose CD47 expression, which facilitates RBCs turnover, as cells lacking 
CD47 are rapidly engulfed by macrophages and DCs40,41. 
Inhibition of phagocytosis is mediated by CD47-engagement to signal regulatory 
protein alpha (SIRPα) receptor on the surface of professional and non-professional 
phagocytes 42-44. SIRPα (also known as SHPS-1 and CD172a) belongs to the Ig family 
of cell surface glycoproteins and is highly expressed on myeloid DCs, macrophages, 
fibroblasts, endothelial cells and neurons. In steady state, the binding of CD47 
to SIRPα, is an important mechanism for maintenance of homeostasis. Hence, by 
preventing clearance of healthy normal cells by phagocytes, CD47/SIRPα interaction 
contributes to keeping DC activation under control 42,45,46. Lack of CD47 expression 
in murine RBCs (CD47-/- RBCs), or SIRPα blockade with monoclonal antibodies, were 
sufficient to make RBCs a target for engulfment by DCs. This subsequently stimulated 
DC maturation and activated an adaptive immune response 41. Surprisingly, mice 
lacking CD47 or its receptor, SIRPα, were protected from autoimmune diseases. 
This seemed to be explained by the fact that absence of signalling through SIRPα 
causes chronic activation of DCs, which eventually culminates in their exhaustion 
and clearance from the body 42,47.
Despite initial evidence as a removal marker of aged RBCs, CD47 exerts this 
distinct “don’t eat me” function on virtually all cells in the body. Particularly, malignant 
cells from solid and hematopoietic tumors express higher levels of CD47 than their 
normal counterparts 48. Additionally, increased CD47 expression on tumor lesions 
appears to be an independent, poor prognostic predictor for survival and tumor 
refractoriness in distinct haematological or solid malignancies 48-51. In accordance 
with this notion, subcutaneous injection of malignant cells, expressing high levels 
19
of CD47, resulted in tumor growth and metastasis formation; whereas absence of 
CD47 dramatically reduced tumor volume and risk of dissemination 48,52. Researchers 
have therefore hypothesized that the “don’t eat me” CD47/SIRPα interaction is a 
common strategy that enables cancer cells to elude immune recognition, through 
evasion of phagocytosis (Figure 3). This hypothesis was confirmed by the finding 
Figure 3. “Don’t eat me” signal CD47 contributes to immunosuppression. Upregulation of the 
“don’t eat me” signal CD47 on tumor cells inhibits dendritic cell (DC) function. In particular, by 
engaging its receptor on DCs, SIRPα, CD47 blocks tumor-cell engulfment by DCs. This hampers 
DC maturation and impedes the activation of effector anti-tumor specific T cells (top). Blockade of 
CD47/SIRPα pathway, using monoclonal antibodies targeting either CD47 or SIRPα, restores tumor 
uptake by DCs, DC maturation and stimulation of T cells for tumor eradication.
20
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that targeting of CD47 by monoclonal antibodies abrogated tumor cell uptake 
by macrophages 43,49,53. Similarly, blockade of  SIRPα on macrophages increased 
phagocytosis of CD47high leukemia cells to a level comparable to that of CD47-
lacking cells52. 
Altogether, these observations suggest that the inhibitory CD47/SIRPα axis 
may play a critical role in supporting cancer progression. Thus, interfering with this 
interaction may prove to be a powerful tool in the treatment of various tumors. 
The three dimensions of cancer
In the previous sections, we discussed the complex nature of cancer. Within the 
TME, malignant cells are in continuous dynamic interactions with the healthy host 
tissue cells and the ECM. These tight connections are meticulously coordinated by 
intrinsic signalling crosstalk between cancer cells, as well as extrinsic interactions 
with other cell types and multiple components of the TME. Tumor niches have 
been increasingly recognized as influencing cancer cell resistance to therapies. 
Nevertheless, our knowledge on the intricate network of mechanisms of the TME 
is still scarce. Unravelling this interplay is essential for understanding, and eventually 
reversing, tumor-mediated immunosuppression, thus realizing the goal of targeted 
cancer treatments.
Life isn’t flat: the need for complexity in cancer research
Over the past decades, a vast array of cancer model systems has been devised to 
study the TME, each presenting unique strengths and flaws. These models range 
from two-dimensional cell monolayers (2D) to animal models. 
Culture of human primary cells and immortalized tumor cell lines in 2D have greatly 
contributed to our knowledge about cancer, are easy to expand and require limited 
handling. Nevertheless, 2D models lack tissue specific architecture, mechanical and 
biochemical cues, as well as cell-cell and cell-matrix communications, as found in in 
vivo tissues (Table 1). This may trigger false findings by forcing cells to adapt to an 
artificial, flat and rigid surface and lead to biased conclusions 54. 
On the other side of the coin, animal models seem an advantageous system in 
which to mimic disease complexity. However, there are many ethical considerations 
related to animal testing and they sometimes fail to reflect human biology 55,56. 
Many forms of cancer lack a validated animal model, including skin cancer, such as 
melanoma 57,58. The most striking issue related to animal use in the development of 
anti-tumor therapies relates to the fact that such animal models only poorly predict 
human immune response. Indeed, anticancer drugs, entering preclinical phases for 
investigating mode of action and risk assessment, often fail to reach clinical trials 59. 
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Together, these limitations strongly indicate the necessity for improved models 
for cancer research. These models should, on the one hand, be in line with the 3Rs 
guidelines (reduction, refinement and replacement of animals in experiments); and, 
on the other hand, offer the complexity of real human tissues 60,61.  
Three-dimensional (3D) human tissue culture models
The potential power of a human culture system that faithfully mimics the in vivo 
situation, while having the benefit of the controlled lab environment that supports cell 
function, has inspired researchers to develop three-dimensional (3D) human tissue 
culture models (also referred to as engineered tissue models, tissue equivalents or 
organotypic models).
One of the main advantages of 3D cultures is the possibility to study cells in 
their “original” environment (Table 1). The ECM that embeds cells under natural 
conditions stabilizes the structure of the tissue, but it also represents a framework 
for cells, allowing cellular communication, growth and propagation into all three 
dimensions. Therefore, culture of cells on 2D culture dishes or in 3D matrices directly 
affects cellular development, migration profile, shape and function. Growth of 
ovarian epithelial cells in 3D induces histological morphology that is reminiscent 
of the tumor type from which they are derived. These characteristics are lost 
when the same cells are cultured in 2D 62. Additionally, cells cultured in 3D display 
distinct gene expression profiles when compared to the exact same cells grown 
Table 1. Advantages and limitations of culture models ‘at a glance’
Culture 
model Advantages Limitations
2D •	 Accessibility of human immortalized  
cell lines and primary cells of different 
origins
•	 Easy to expand, require limited handling
•	 Possibility of co-culturing two different 
cell types
•	 Lack of specific tissue architecture
•	 Absence of mechanical and biochemical  
cues, as well as cell-cell and cell-matrix 
interactions
•	 Lack of physiological relevance of cell culture 
supports (i.e. plastic flasks or glass supports) 
3D •	 Providing dimensional and architectural 
complexity that is highly similar to  
that of the in vivo tissue 
•	 Platforms for co-culture of three  
(or more) different cell types
•	 Possibility to titrate cell number and ratio 
•	 Supplying sites for studying cell-cell/cell-
matrix interactions and effects  
of the stromal environment
•	 Time and cost effective alternatives  
to the use of lab animals (also related  
to ethical issues)
•	 “Technical hurdles”
Defined culture period: a maximum of a 
few weeks (as compared to in vivo studies).
Difficult handling of constructs.
Limited supply of human biopsies to isolate 
cellular and matrix tissue components
•	 Lack of blood flow and, in general, immune 
compartment
22
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in monolayers 63,64. Specific cell-cell, cell-ECM interactions and biological factor 
(oxygen/nutrients/waste) gradients drive changes in intracellular signal transduction. 
These changes eventually reflect diversities in phenotype, proliferation rates, cell 
migration and metabolic functions 54,65,66. In turn, genetic and functional changes 
occurring within a cell can cause an intercellular feedback to the other cells present in 
the microenvironment. So far, the mechanisms regulating these feedback loops have 
been mostly investigated in 2D co-culture systems, with obvious limitations to their 
applicability 67. A notable benefit offered by the advent of 3D culture technology is 
the possibility to create a multi-cellular environment, with potentially no restraints 
in the amount and type of cells used.
Besides those advantages, 3D culture systems also present some limitations. 
Handling of such models requires advanced technical skills, and long-term 
optimization is compulsory for developing tissue equivalents that closely mimic 
in vivo microenvironment. Just as importantly, some technical hurdles have to be 
overtaken, like human leukocyte antigen (HLA) matching and the lack of a blood 
and lymphatic systems. HLA matching is especially important when studying 
the activation of T lymphocytes by antigen-presenting cells, expressing MHC 
molecules for (tumor) antigen-presentation. In order to overcome the lack of 
circulation, attempts have been made to engineer collagen matrices containing a 
microvasculature network of endothelial cells 68. Additionally, 3D models that are 
built using matrix components and primary cells isolated from tissue, are reliant on 
a regular supply of fresh human biopsies (obtained as surgical waste material) of 
adequate size. This obviously limits the applicability of 3D engineered tissue cultures 
as high-throughput platforms for drug testing. 
Despite those restrictions, such models represent a unique tool for prolonged 
dynamic investigation of “living” tissues and cell interactions. Currently, the use 
of 3D models is being explored in many fields for in vitro assessment of disease 
biology, ranging from dermatological research to infectious diseases and cancer 69-74. 
Among those, human tissue equivalents of skin have received great attention. The 
skin is the largest organ in the body and the first line of defense against pathogens. 
Therefore, development of 3D models of human skin may bring remarkable 
progresses in treatment of skin disorders, including the most aggressive form of 
skin cancer, melanoma. State-of-the-art of skin- and melanoma-engineered models 
is summarized in the following paragraph.
State-of-the-art of human 3D engineered tissue models of skin biology 
and cancer
Over the past thirty years, protocols for generating 3D human skin equivalents have 
been refined and optimized, paving the way for advances in the investigation of skin 
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biology, disease pathology and therapeutics 75-77,93,99 .These 3D human skin models 
resemble the basic architecture of real skin. They consist of a dermal compartment, 
providing structural support to the reconstructed skin, and an epidermal 
compartment, containing epidermal cells (keratinocytes) and other skin-associated 
cells, such as melanocytes or their malignant counterpart (melanoma cells) (Table 2).
Table 2. An overview of 3D models of human skin, pre-malignant skin and melanoma 
Dermal 
compartment
Cellular 
components Limitations of the model Ref.
M
o
d
el
s 
o
f 
hu
m
an
 s
ki
n
Rat-tail or 
bovine 
collagen type I
KCs
Fibroblasts
Mo-LCs143
Mo-DDCs143
(immune cells co-seeded 
with KCs)
RAW264.7 murine 
macrophages144
(in a co-culture transwell system) 
Animal-derived collagen matrix.
Fibroblasts deposit collagen IV 
(BM components), however it is 
not uniform.
Refs. 86,145: no immune cells. 
Ref 139: murine-human co 
culture.
86,143-145
Superimposed 
fibroblast-
derived sheets
KCs
Fibroblasts
Fibroblast-deposition of 
collagen requires 35 days of 
culture.
No immune cells. 
146
Artificial scaffold 
embedded 
in agarose-
fibronectin gel 
KCs
Fibroblasts
Mo-DCs
Artificial scaffold, not 
representative of real tissue.
147
DED KCs
Fibroblasts86
CD4+ T lymphocytes87
Ref 86: No immune cells.
Ref 87: No stromal 
compartment.
86,87
M
o
d
el
s 
o
f 
sk
in
 w
it
h 
m
el
an
o
cy
te
s
Rat-tail or bovine 
collagen type I
KCs
Fibroblasts
Melanocytes
Ref 143: Poor epidermal 
differentiation (absence of 
Stratum Granulosum and 
Stratum Corneum).
No immune cells. 
79,148
DED KCs
Fibroblasts
Melanocytes
No immune cells.
Ref 91: No stromal 
compartment.
91,95
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Many 3D skin models were generated using bovine or rat-tail collagen type I as 
dermal substrates 78. These matrices were soon after enriched with stromal cells, 
such as fibroblasts. The presence of fibroblasts in the dermal compartment, where 
they secrete large amounts of growth factors, was shown to be crucial for proper 
proliferation and differentiation of skin cells 79. However, these collagen matrices 
are not suitable for long-term cultures, due to their predisposition for contraction. 
Moreover, they are not representative of the “real” human skin microenvironment, 
as they introduce non-human ECM components and do not retain a native BM 
structure 80. Fibroblasts cultured for several weeks, under specific conditions, can 
secrete their own ECM, as well as a basal membrane (BM) equivalent (consisting of 
collagen IV and laminin) 81-83. Therefore, fibroblast sheets can be stacked to build 
layers of dermis83.  The major drawback of these procedures is, however, the long 
culture period (up to four weeks) required to obtain a fibroblast-derived dermis 80. In 
order to have a more physiological skin substitute, attempts were made to generate 
skin equivalents using ex vivo dermis 84. The use of ex vivo or de-epidermized dermis 
(DED) to grow keratinocytes was first described by Ponec et al 85. DED is obtained 
Table 2. An overview of 3D models of human skin, pre-malignant skin and melanoma 
Dermal 
compartment
Cellular 
components Limitations of the model Ref.
M
o
d
el
s 
o
f 
m
el
an
o
m
a
Rat-tail or
bovine 
collagen type I
KCs
Fibroblasts
Melanoma cell lines 
Animal-derived collagen matrix.
No immune cells
70,79,98
Superimposed 
fibroblast-
derived sheets
KCs
Fibroblasts
Endothelial cell line (HUVEC)
Melanoma cell lines
Fibroblast-deposition of 
collagen requires 35 days of 
culture.
No immune cells
83
Alvetex scaffold 
embedded 
in fibroblast-
secreted matrix
KCs
Fibroblasts
Melanoma cell lines 
Artificial scaffold, not 
representative of real tissue.
No immune cells
80
DED KCs
Fibroblasts93
Melanoma cell lines
No immune cells 93,96
BM, basal membrane; DCs, dendritic cells; DED, de-epidermized extracellular dermis; KCs, 
keratinocytes; mo-DCs, monocyte-derived dendritic cells; mo-LCs, monocyte-derived Langerhans cells.
Continued
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from skin isolated from patients undergoing corrective breast or abdominal wall 
surgery. Following separation of the dermis from the epidermis, further processing 
eliminates cellular components from the dermal compartment. This human acellular 
DED maintains intact the structural and biological characteristics of human ECM. 
It consists of proteoglycan and fibrous proteins, which include collagen, elastin, 
fibronectin and laminin. DED preserves basal membrane (BM) proteins and can be 
manipulated to include stromal and immune cells 86,87.
The possibility of manipulating enginereed skin models to include different cell 
types makes them a powerful platform to investigate many disorders that affect 
human skin. Organotypic skin models with patient-derived keratinocytes have 
been extensively used for studying molecular mechanisms controlling inflammatory 
diseases, such as psoriasis or dermatitis 71,74,88-90.   
Primary immune cells, isolated from blood or tissues, have a limited lifespan 
when cultured in vitro. For this reason, organotypic skin models that encompasses 
stromal- and immunocompetence are scarce. In vitro-derived human dendritic 
cells and Langerhans cells, embedded in artificial matrices, were shown to acquire 
migratory properties upon UV irradiation or treatment with the skin sensitizer, 
dinitrochlorobenzene (DNCB), suggesting a functional activity in response to stress 
stimuli.  Thus far, the most advanced model of inflammatory skin diseases, reports 
the effective cross-talk between keratinocytes and T lymphocytes. This epidermal-
immune cell interaction resulted in a psoriasiform inflammation, which was mediated 
by the release of soluble factors by activated CD4+ T cells. Inflammation could 
be reverted by addition of anti-inflammatory drugs, targeting either keratinocytes 
(trans-retinoic acids) or T cells (Cyclosporin A) 71. 
The potential of such models can also be translated to the field of cancer 
research, for investigation of the malignant transformation of melanocytes, the 
melanin pigment-producing cells of the skin; as well as for unraveling mechanisms 
that control melanoma progression and escape from immunesurveillance.
In skin reconstructs, melanocytic cells from different stages of progression 
(normal to metastatic) show remarkable consistency in their physical distribution, 
growth and migration patterns, as would be expected from healthy skin and patients 
with melanoma. Normal melanocytes home to the basement membrane, where they 
are found located within the basal keratinocytes without apparent proliferation 91. 
Moreover, normal melanocytes retain the ability to undergo pigmentation in response 
to ultraviolet irradiation 92. Organotypic melanoma models mimic different stages of 
melanoma progression and confirm clinical observations: early radial growth phase 
(RGP) primary melanomas proliferate predominantly in the suprabasal area of the 
epidermis; whereas, vertical growth phase (VGP) and metastatic melanomas (MM) 
disrupt basal membrane components and invade into the dermis 78,80,93-98.
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Initial dissemination of melanoma cells occurs through entry into the vasculature 
and colonization at distal sites. Additionally, the uncontrolled proliferation of 
malignant cells requires increased supply of nutrients and oxygen from the blood 
flow. In order to study the angiogenic potential of melanoma cells in a physiologically 
relevant context, researchers have established a microvascular network using 
HUVEC cells in Fb-derived matrices. Tumor cell lines derived by metastatic sites 
secreted high levels of vascular endothelia growth factor (VEGF) and displayed a 
potent proangiogenic effect, as compared to cells derived from primary sites 83. 
The microvasculature network formed in the presence of MM was more complex, 
branched and dense. Moreover, they could also observe proximity of tumor cells 
and endothelial cells.
Altogether, these observations reinforce the hypothesis that organotypic skin 
models have the power to mimic the (tumor) microenvironment because of their 
three-dimensionality and multiparametric tailorability. Moreover, those studies 
demonstrate the applicability of such models to study the pathogenesis of 
skin inflammation and cancer. We believe that addition of stromal and immune 
compartments within 3D melanoma models will be pivotal for uncovering the 
importance of the TME in cancer development, control and treatment. 
Dying the “right way” for inducing anti-tumor responses 
During the past decade, studies have highlighted how cancer cells modulate the 
immune system in their local microenvironment. This is a requirement for tumor 
progression, as it allows the tumor to hide from or evade immune responses. 
Despite this escape from immunosurveillance, ample evidence shows that it 
is possible to induce specific anti-tumor immune responses either naturally 
(spontaneous) or therapeutically. Therefore, the aim of anti-cancer treatments is 
to activate, or reactivate, the immune system in cancer patients for therapeutic 
benefit. Recent studies have described the beneficial effects of chemotherapy-
induced immunogenic cell death (ICD), and have shed new light on the mechanisms 
of action that determine the efficacy of chemotherapeutic drugs. 
Chemotherapy induces immunogenic cell death
Cancer is commonly considered a disease driven by genetic changes that cause 
uncontrolled proliferation and invasion of malignant cells29. A recently discovered 
defining requirement for cancer initiation and progression is evasion of anti-tumor 
immune responses. Nonetheless, most conventional anti-cancer therapies, such as 
chemotherapy, aim at the rapid destruction of dividing tumor cells, by targeting 
mechanisms important for cell division 99. This leads to apoptosis of transformed cells, 
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a process initially thought to be immunologically-silent 99. However, recent studies 
have shown that in mice with a functional immune system, chemotherapeutic drugs 
are more effective in eradicating tumors than in mice lacking a functional immune 
system 100,101. This immunological effect relies on the ability of certain anti-cancer 
therapeutics to evoke cellular stress, which eventually culminates in the induction 
of an immunogenic form of apoptosis, also known as ICD (Figure 4) 102-104. The term 
’immunogenicity’ describes the capacity of an agent, be it a cell or a pathogen, to 
induce an immune response and relies on the combination of two factors: antigenicity 
and adjuvanticity 105,106. Expression of tumor specific Ags (antigenicity), that differ 
from their normal counterparts, per se is not sufficient to initiate a robust anti-tumor 
response 105. Cells undergoing ICD are characterized by the release of ‘danger’ 
signals during and after cell death, referred to as damage associated molecular 
patterns (DAMPs) 107,108. These DAMPs are normally sequestered within living cells, 
but once secreted or exposed on the cell surface, they stimulate inflammatory 
responses (adjuvanticity) 103,108. In the original landmark studies, ICD was defined 
by three types of ‘danger’ signals: secretion of ATP, exposure of calreticulin (CRT), 
and release of high mobility group protein-1 (HMGB1) 103,104. These ICD-associated 
DAMPs serve different purposes in modulation of the immune system and can 
Figure 4. Effects of immunogenic cell death induction on dendritic cells. Treatment with im-
munogenic cell death (ICD) inducers, such as platinum-based chemotherapeutics, activates an 
ER-mediated stress response in cancer cells that culminates with immunogenic apoptosis. Dying 
cancer cells emit ‘danger’ signals that can (1) recruit dendritic cells (DCs) to the site of inflammation, 
(2) mediate engulfment of tumor-derived particles by DCs, (3) stimulate DC activation. Together, all 
these events eventually result in DC maturation that elicits potent anti-tumor immune responses. 
DC, dendritic cell; Pt, platinum.
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be grouped in ‘recruitment’ (ATP), ‘engulfment’ (CRT) and ‘activating‘ (HMGB1) 
signals 109,110. Accumulating preclinical evidence suggests that release of DAMPs is 
crucial for the induction of effective anti-tumor immune responses. These DAMPs 
exert their functions by engaging pattern recognition receptors (PRRs), expressed on 
the surface of APCs, in particular DCs 111. As proposed by Tesniere et al., ICD-related 
DAMPs act as “keys” on the “locks” (DC receptors) that stimulate DC maturation, 
for unlocking effective anti-tumor immune responses 85. Maturation of DCs is a 
multistep process that requires three distinct events. Secretion of ‘recruitment’ 
molecules by cells undergoing ICD has a chemoattractant effect, facilitating DC 
influx into the site of tissue damage 111. Subsequently, ‘engulfment’ signals direct Ag 
uptake by DCs 112. The process of ICD is further characterized by the passive release 
of ‘activating’ signals, which stimulate DC maturation 113. Following Ag uptake and 
processing, mature DCs migrate to lymph nodes. Here, they present captured Ags 
via MHC-I molecules to naïve CD8+ T cells leading to the induction of Ag-specific 
cytotoxic responses 104. 
Sensing danger signals: ATP recruits DCs
Nucleotides serve as a universal source for intracellular energy transfer. Under 
stressful conditions (such as inflammation, mechanical or ischaemic injury, apoptosis, 
or necrosis), cells can release nucleotides from the intracellular compartment 
to the extracellular milieu 114. When released into the extracellular space, the 
triphosphonucleotide ATP, no longer acts as an energy carrier, rather it functions 
as a chemotactic agent and signalling molecule, by interacting with specific 
membrane-bound nucleotide receptors 114. Passive release of ATP during necrosis 
or its active secretion in immunogenic apoptosis thus functions as a “find me“ 
signal, regulating immune cell recruitment to the site of damage and contributing 
to inflammation 114-116. Recognition of ATP by DCs is mediated by the purinergic 
class 2 receptor (P2R) subtypes, P2YRs and P2XRs 114,117,118. Human and mouse studies 
identified PY2Rs as the main sensors for immature, but not mature, DC recruitment 
mediated by ATP; P2XRs on the other hand played a minor role 103,107-111. This could 
be explained by the observation that signalling via the two best-characterized 
receptors, P2Y2 and P2X7, is dependent on the extracellular concentration of 
ATP. P2Y2 receptors have a higher affinity for low (nanomolar) concentrations of 
extracellular ATP, whereas P2X7 receptors only respond to high (micromolar) ATP 
doses 119. This difference suggested that P2 receptors mediate chemoattraction in 
two ways. In the early stages of apoptosis, where the cell membrane is still intact and 
about 2% of the cellular ATP is released, P2Y2 receptors regulate attraction of tissue-
resident immune cells. This ATP-mediated recruitment of immune cells may act as 
a positive feedback loop for immune stimulation. Activation of purinergic receptor 
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signalling on local immune cells by ATP can, in turn, induce these cells to release 
high amounts of ATP, which leads to recruitment of distant cells towards the site of 
inflammation 117,120 By contrast, P2X7 receptors play a minor role in chemoattraction, 
but are mainly involved in regulation of DC activation. In particular, the ATP-P2X7 
axis might induce release of pro-inflammatory cytokines by DCs recruited to or 
located in close proximity to damaged cells, where higher ATP concentrations can 
be detected in the extracellular space 112. 
Clearing the threat: Calreticulin, an ”eat me” signal that mediates cell 
engulfment by DCs
Calreticulin is an endoplasmic reticulum (ER)-associated multi-functional chaperone 
molecule, which regulates protein folding, maturation and trafficking 121. Moreover, 
it also plays a central role in intracellular calcium homeostasis 122. Under certain 
specific forms of cell damage or cell death, endogenous calreticulin (endo-CRT) 
translocates to the cell surface (ecto-CRT) 123. The presence of ecto-CRT on the 
surface of damaged or dying cells flags them for uptake by APCs and is a classic 
‘hallmark’ of ICD 123. Certain chemotherapeutic drugs, such as anthracyclines, 
oxaliplatin and bortezomib, were shown to augment ecto-CRT expression 123,124. 
Antracycline-treated murine CT26 cells, exposing ecto-CRT, were efficiently taken 
up by moDCs. In contrast, inhibition of CRT/receptor interaction (via blocking 
antibodies or transcript knock down), abolished the phagocytosis of dying tumor 
cells by murine moDCs 123. Human primary effusion lymphoma cells, killed with the 
anticancer drug bortezomib, were taken up more efficiently by human immature 
moDCs, compared to live cells 125. Similar observations were found in an in vitro 
study using various tumor cell lines and primary tumor cells, treated with a panel of 
chemotherapeutics 126,127. APCs express several receptors capable of recognizing 
ecto-CRT, one of these being the low-density lipoprotein receptor-related protein 1 
(LRP1), also known as CD91 128,129,130. CD91 is a type 1 transmembrane protein and 
regulates cell signalling processes, by binding to multiple proteins (up to 40 ligands 
have been identified so far) 131.  The exact binding site(s) for ectoCRT within CD91 
have not been identified yet 132.
Launching the immune system: ATP and HMGs, triggers for DC activation 
In addition to the chemoattractant role described earlier, extracellular ATP can act 
as a regulator of immune responses, by modulating DC phenotype and function 133. 
ATP may indeed initiate a Th1 immune response upon cellular damage and also 
curtail severe inflammation by promoting Th2 responses or tolerance. In particular, 
in vitro stimulation of moDCs with millimolar (1-5mM) ATP concentrations skewed 
the immune reaction towards a Th1 response, by enhancing secretion of IL-1β, 
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TNFα and IL-12 by DCs 134,135. On the other hand, micromolar (up to 500µM) ATP 
concentrations impaired functional DC maturation in favor of a Th2 or tolerogenic 
immune, by increasing surface expression of the co-stimulatory molecules, CD80, 
CD83, CD86, but inhibiting pro-inflammatory cytokines release 134-136. Additionally, 
potentiation of cytokine production, in particular of IL-12, was observed as long as 
IL-12 concentrations, under ATP stimulation, remained below a specific threshold 
value; while inhibition was observed when more IL-12 was released 137. Although 
evidence exists on the effects on P2XRs and P2Y11Rs on DC maturation, given the 
number of purinergic receptor subtypes expressed by DCs and the lack of specific 
agonists or inhibitors for each subtype, it has been difficult to unequivocally identify 
which receptors are involved in a given cellular response.
Another class of molecules involved in DC stimulation upon induction of ICD 
is represented by the small chromosomal high mobility group (HMG) proteins. 
HMG proteins bind to DNA strands and in doing so increase flexibility, facilitate 
remodeling and ensure proper transcriptional regulation, by recruiting transcription 
factors and endowing chromosomes with nuclease sensitivity 138. Despite their 
nuclear localization, components of the HMGB and HMGN families can be passively 
released into the extracellular environment at later stages of cell death; whereas 
cells undergoing non-immunogenic apoptosis retain HMGB1 and HMGN1 inside cell 
membranes 139,140. When released in the extracellular milieu, HMGB1 and HMGN1 
facilitate activation of APCs and the onset of an inflammatory response 139. HMGB1 
and HMGN1 are ligands of toll-like receptor 4 (TLR4), a PPR broadly expressed on 
human DCs 22,23,139,141,130. During anti-cancer chemotherapy, the HMGB1/TLR4 signaling 
pathway is crucial for cross presentation of dying tumor cells by DCs and the efficacy 
of anti-cancer chemotherapy in mice 141. In line with this notion, the loss-of-function 
Asp299Gly polymorphism of TLR4 in breast cancer patients was associated with a 
faster relapse after anthracycline-based chemotherapy, as compared to patients 
carrying the wild type TLR4 allele 141,142. HMGN1 was also shown to activate DCs 
and thus stimulate immune responses. The HMGN1/TLR4 pathway activated the 
NF-κB–dependent production of the pro-inflammatory cytokines IL-6, IL-1β and TNF 
by mouse bone-marrow derived DCs. Also, in vitro incubation of human moDCs with 
HMGN1 upregulated the expression of co-stimulatory molecules (CD80, CD83 and 
CD86) and MHC antigen-presentation complexes 139.
A lot of effort has been devoted into increasing our understanding of the 
molecular parameters that govern ICD. However, we are just beginning to 
characterize the complex interactions of immunogenic DAMPs with their receptors 
that lead to robust antitumor immunity. For most of the “non-classical”-ICD DAMPs, 
evidence is based on a relatively limited number of studies, mostly performed with 
murine APCs or with human monocytes or in vitro generated moDCs. Definitely, 
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more research is needed to clearly define the role of those, as well as other DAMPs 
in ICD-mediated induction of anti-tumor immunity. Understanding the molecular 
pathways of ICD-DAMP interplay in DCs, is pivotal to the exploitation of these 
principles in order to increase the efficacy of immunogenic inducers, and to develop 
new strategies for cancer therapy. 
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Scope of this thesis 
Tumor progression and resistance to anti-cancer therapies require interplay between 
cancer cells, host tissue cells and the EMC, within the tumor microenvironment. 
As a result, cancer cells can elude antitumor immunity or induce tolerogenic 
responses. Some of the key events that lead to immunosuppression originate from 
the interaction of tumor cells with DCs. DCs are master switches of immunity and 
tolerance. Hence, signals provided by DCs, upon interaction with cancer cells, 
dictate the fate of an anti-tumor response. Following uptake of tumor particles, 
DCs can exhibit a malfunctioning phenotype. These “defective” DCs are no 
longer available to alert the immune system to cancer. A promising strategy to 
support DC function involves the switch of an immunosuppressive state into an 
immunostimulatory state. 
The first aim of my thesis was to study the interplay between tumor cells and 
human naturally-occurring DC subsets; and to explore potential strategies to revert 
tumor-mediated immunosuppression. 
The second aim of my thesis was to investigate DC-tumor cell interaction in a 
3D model that mimics the in vivo tumor microenvironment. To this aim I developed 
an in vitro 3D skin model of human melanoma as a tumor model for studying this 
interaction. This model is amenable to titration of different cellular components 
and to application for many in vitro investigative approaches. Using this model, 
tumor growth, immune cell function as well as tumor-immune cell interactions can 
be studied. 
Thesis outline
An increasing number of conventional chemotherapeutic compounds were recently 
found to possess immunostimulatory properties. In Chapter 2, I explored the 
effect of two of the most used platinum compounds, oxaliplatin and cisplatin, 
in the induction of an immunostimulatory form of cancer cell death, also known 
as immunogenic cell death (ICD). Next, I assessed whether platinum-induced 
ICD affected phenotype and function of human naturally occurring DC subsets. 
Interestingly, I show that human DCs differ in their capacity to respond to ICD 
signals and eventually stimulate T cell responses. In Chapter 3, I expanded these 
observations, hypothesizing that the combination of platinum-induced ICD with 
blocking of inhibitory mechanisms, by antibody-based immunotherapy, might 
cooperate and overcome tumor-mediated immunosuppression. In particular, I set 
out to investigate the effect of shifting the balance between inhibitory ”don’t eat me” 
signals, by means of CD47 signaling, while enhancing ICD-induced ”eat me” signals 
(such as Calreticulin) on tumor cells. To study cancer-host cell interactions under 
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conditions that mimic the in vivo situation, I developed an immunocompetent 3D 
human melanoma model, of which the details are described in Chapter 4. My results 
demonstrate that this novel 3D model is a promising tool for direct observation of 
the interplay between melanoma cells and DCs. Moreover, in Chapter 5, I exploited 
multispectral imaging to assess immune cell infiltrates in human primary melanomas. 
This innovative imaging technique combines imaging with spectroscopy to obtain 
accurate information about quantitative expression data and tissue distribution of 
different cell types within the TME. Finally, in Chapter 6, the findings of this thesis 
are discussed and future perspectives are outlined.  
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Abstract 
Chemotherapeutics, including the platinum compounds oxaliplatin (OXP) and 
cisplatin (CDDP), are standard care of treatment for cancer. Although chemotherapy 
has long been considered immunosuppressive, evidence now suggests that 
certain cytotoxic agents can efficiently stimulate anti-tumor responses, through 
the induction of a form of apoptosis, called immunogenic cell death (ICD). ICD is 
characterized by exposure of calreticulin and heat shock proteins (HSPs), secretion 
of ATP and release of high mobility group box 1 (HMGB1). Proper activation of the 
immune system relies on the integration of these signals by dendritic cells (DCs). 
Studies on the crucial role of DCs, in the context of ICD, have been performed using 
mouse models or human in vitro-generated monocyte-derived DCs, which do not 
fully recapitulate the in vivo situation. 
Here, we explore the effect of platinum-induced ICD on phenotype and function 
of human blood circulating DCs. Tumor cells were treated with OXP or CDDP and 
induction of ICD was investigated. We show that both platinum drugs triggered 
translocation of calreticulin and HSP70, as well as the release of ATP and HMGB1. 
Platinum treatment increased phagocytosis of tumor fragments by human blood 
DCs and enhanced phenotypic maturation of blood myeloid and plasmacytoid DCs. 
Moreover, upon interaction with platinum-treated tumor cells, CD1c+ DCs efficiently 
stimulated allogeneic proliferation of T lymphocytes. Together, our observations 
indicate that platinum-treated tumor cells may exert an active stimulatory effect 
on human blood DCs. In particular, these data suggest that CD1c+ DCs are critical 
mediators of immune responses induced by ICD. 
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Introduction 
Platinum-based chemotherapy is currently approved as first-line treatment for several 
malignancies, including colon and testicular cancer 1. Besides a direct cytotoxic 
effect on tumor cells, some chemotherapeutic compounds are now recognized to 
have beneficial effects on the immune system, which may contribute to their clinical 
effectiveness 2-7. Accordingly, a number of anti-cancer drugs, including the platinum-
based compound oxaliplatin (OXP), were shown to be more effective against tumors 
established in immunocompetent, as opposed to immunodeficient mice 5. This was 
predicated on the ability of these drugs to induce a form of cell death that activated 
the immune system and promoted anti-tumor immune responses. As such, these 
agents are referred to as immunogenic cell death (ICD)-inducers 8. 
ICD-inducers cause severe cell stress, which activates distinct molecular 
pathways that can result in the induction of apoptosis 4. Classically, ICD requires 
three molecular events, which may or may not be linked. First is the translocation of 
chaperone molecule calreticulin from the lumen of the endoplasmic reticulum (ER) 
to the cell surface (ecto-CRT) 9, 10. Ecto-CRT serves as an “eat me” signal that marks 
tumor cells for engulfment by phagocytic cells 9. Second is the active secretion of 
ATP into the extracellular environment, which acts as a chemoattractant for immune 
cells and directs the differentiation of myeloid precursors into inflammatory cells 11, 12. 
Thirdly, release of high mobility group box 1 (HMGB1) into the extracellular milieu, 
which is required for optimal induction of T cell-mediated anti-tumor responses 13. 
Other than the three ‘hallmarks’ of ICD, the ER-resident chaperones, heat shock 
proteins (Hsp) Hsp70 and Hsp90, are exposed on the membrane of cells undergoing 
severe stress. These molecules are not included in the canonical definition of ICD, 
nevertheless they also act as danger signals and might contribute to the stimulation 
of antigen-presenting cells (APCs) 14.
Induction of a systemic tumor-specific immune response by ICD requires the 
recognition and integration of these separate signals (ecto-CRT, ATP and HMGB1) 
into one command that drives T cell activation. Dendritic cells (DCs) are one of 
the main cell types that serve this role. They are the main APCs that link innate 
and adaptive immunity. DCs can encounter tumor cells in two ways. Firstly, the 
chemoattractants ATP and HMGB1 induce intratumoral recruitment of DCs 11. 
Secondly, tumor cells that have detached from the tumor bulk are likely to enter 
blood circulation, facilitating their spread to distant locations in the body 15. In the 
blood stream, these circulating tumor cells (CTCs) can encounter blood-circulating 
DCs. Platinum-induced exposure of ICD-markers might contribute to make CTCs 
“visible” and more sensitive to DC recognition. Indeed, treatment with well-
known ICD-inducers, anthracyclines, induced ecto-CRT expression on CTCs in 
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vivo 16. Chemotherapy treated-tumor cells are engulfed by immature DCs, which 
then undergo maturation. Mature DCs process and present tumor antigens to 
naïve cytotoxic lymphocytes, prompting anti-tumor responses7, 16 . Accordingly, 
perturbation of key elements of adaptive immunity, such as in vivo depletion of 
dendritic cells (DCs), or knockout of DC receptors, resulted in failure to prime an 
anti-tumor response in chemotherapy-treated mouse models 5, 13, 17.
There are two major DC subsets circulating in human peripheral blood, 
myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) 18. Classically, myeloid DCs 
are subdivided into CD16+, CD1c+ and CD141+ DCs, based on the expression 
of specific surface molecules 19. However, genome-wide expression profile 
analysis recently suggested that CD16+ DCs may represent a particular subset 
of monocytes, with DC-like properties 20. For simplicity we will refer to them as 
CD16+ DCs. Transcriptional, phenotypic and functional studies highlight significant 
differences between human blood DCs, suggesting a biological specialization of 
these DC subsets 21, 22. Despite the great interest that ICD has gained in the past 
decade, the role of naturally occurring human DCs, especially for DCs that circulate 
in the blood, in this process is poorly understood, as most studies have been 
performed in murine models or with in vitro generated monocyte-derived DCs 
(moDCs) 11, 23. Here we study induction of ICD in human tumor cells by two of the 
most widely used platinum compounds, OXP and cisplatin (CDDP), and how that 
affects human DC subsets. We report that, at clinically relevant concentrations, 
both compounds induced apoptosis of tumor cells, which was accompanied by 
the expression and release of ICD-associated molecules. Exposure of tumor cells 
to platinum drugs resulted in increased uptake of tumor fragments by naturally 
occurring blood DCs and stimulated DC maturation. Surprisingly, only CD1c+ DCs 
were subsequently able to drive T cell proliferation. 
Materials & Methods 
Cell culture, transduction and stable cell line 
Cells were cultured at 37°C, 5% CO2. Human testicular carcinoma (2102EP and 
833KE) and murine colon carcinoma (CT26) cell lines were cultured in RPMI 
1640 (Gibco, Thermo Fisher Scientific, catalog# 42401-018), supplemented 
with 10% fetal calf serum (FCS, Greiner bio-one) and Ultra-glutamine (Lonza, 
catalog# BE17-605E/U1). Human melanoma (BLM and BLM-GFP) and colorectal 
adenocarcinoma (Caco-2) cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco, 31966-021), with 5% or 20% FCS, respectively. The Lenti6/
Block-iT-shScramble (GFP) vector was a kind gift of Prof. Peter Friedl (RIMLS, 
The Netherlands). The specific scramble shRNA sequence has no homology to 
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any known mammalian gene. BLM cells were infected with lentiviral vector and 
(10µg/ml) polybrene and incubated at 37°C, 5% CO2, overnight. Then medium 
was refreshed and cells were analyzed after 72h of treatment. Stable cell line was 
selected with 5µg/ml blasticidin.
Cell death induction and quantification 
Tumor cells were treated with oxaliplatin (OXP, lot# R01730), cisplatin (cis-
diamminedichloroplatinum(II), CDDP, lot# PR00202) (both Accord) or mitoxantrone 
(MTX, Sandoz, lot# D50333A) to induce cell death. Cell death was assessed by 
double staining with annexin V fluorescein isothiocyanate-FITC (AnnV-FITC, BD 
Bioscience, catalog# C34554) and DAPI (Sigma-Aldrich, catalog# 32670). Briefly, 
cells were collected, washed with PBS and incubated with AnnV-FITC (1:40), 
CaCl2 (1M, 1:666) in PBS on ice, in the dark for 15min. An equal volume of DAPI in 
PBS (final concentration 1:2000) was added immediately prior measurement by 
flow cytometry. 
Flow cytometric analysis of ecto-CRT and ecto-HSP70 
6x104 tumor cells were let adhere in 24-well plates and treated with OXP or CDDP 
for 24 or 48 hours. Subsequently, cells were harvested with cold TEN buffer (40 mM 
Tris, 150 mM NaCl, 10 mM EDTA, pH 7.8), transferred to a 96-well plate and washed 
twice with PBA. After incubation with a Fc-receptor blocking buffer (2% human 
or murine serum in PBS, 15min at 4°C) cells were stained for 30min at 4°C with 
a primary antibody in PBA, followed by extensive washing and incubation with 
an Alexa488-conjugated monoclonal secondary antibody (Goat-anti-Mouse IgG1, 
Life Technologies, catalo#A-21121) in PBA for 20min at 4°C. Isotype-matched IgG 
antibodies were used as control. Surface expression of CRT (anti-CRT, clone ab2907, 
Abcam, catalog# ab2907; anti-CRT-PE, clone FMC 75, Enzo Life Sciences, catalog# 
ADI-SPA-601PE-F) and Hsp70 (anti-HSP70, clone C92F3A-5, Enzo Life Sciences, 
catalog# ADI-SPA-810-D) was analyzed by flow cytometry (Suppl. Table 1).
Detection of ATP and HMGB1 release 
Tumor cells (6x104) were adhered in 24-well plates in 1ml of heat-inactivated 
complete medium and treated with OXP or CDDP for 24h or 48h. Supernatants were 
collected, dying floating cells removed by centrifugation and supernatants frozen 
immediately. ATP secretion was measured with the ENLITEN ATP Assay (Promega, 
catalog# FF2000) according to the manufacturer’s protocol. HMGB1 release was 
assessed by enzyme-linked immunosorbent assay (ELISA, IBL International, catalog# 
ADI-SPA-810-D) according to manufacturer’s instructions. 
51
Isolation of human blood immune cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats obtained 
from healthy volunteers (Sanquin) and purified via centrifugation over a ficoll density 
gradient (Axis-Shield) in SepMate tubes (Stemcell technologies). Isolation of human 
blood DC subsets was achieved by a sequence of negative and positive selection 
steps using magnetic beads (Human CD16+ Monocyte Isolation Kit, catalog# 130-
091-765; Human CD1c+ (BDCA-1) Dendritic Cell Isolation Kit, catalog# 130-090-506; 
Human CD304+ (BDCA-4/Neuropilin-1) MicroBead Kit, catalog# 130-090-512; all 
Miltenyi Biotec). DC purity was assessed by staining with primary labeled antibodies 
(see also Suppl. Table 1): anti-CD1c-PE (Miltenyi biotec, clone AD5-8E7, catalog# 
130-090-508), anti-CD11c-APC (Miltenyi biotec, clone MJ4-27G12, catalog# 130-
092-412), anti-CD20-APC (eBioscience, clone 2H7, catalog# 17-0209), anti-CD15-
FITC (Miltenyi biotec, clone VIMC6, catalog# 130-081-101), anti-CD56-PE (IQ 
Products, clone MOC-1, catalog# IQP-114R), anti-CD123-APC (Miltenyi biotec, clone 
AC145, catalog# 130-090-901) and anti-CD303-PE (Miltenyi biotec, clone AC144, 
catalog# 130-090-511). Purity levels higher than 98% were achieved, determined 
by flow cytometry. Peripheral blood leukocytes (PBLs) were isolated from PBMCs 
by depletion of monocytes via adherence to plastic culture flasks (1 hour at 37°C). 
Floating cells (PBLs) were collected and resuspended in X-VIVO-15 medium (Lonza, 
catalog# BE04-418Q) supplemented with 2% human serum (HS, Sanquin).
Microarray data
For the analysis publically available affymetrix, CEL files containing expression data 
of resting human pDCs, CD1c+ and CD16+ were downloaded from ArrayExpress 
(accession: E-TABM-34). Data have been published by others 50. Raw files were 
processed in the R programming environment and intensity values across the 
different datasets were normalized using the RMA normalization function of the affy 
package 51. Specific annotation packages for human were used to map array probe 
identifiers to corresponding species specific gene symbols. In case of redundant 
probes, the probes with highest summed intensity of all samples were considered. 
The normalized log2 transformed datasets was z-scored (setting the data to a 
mean=0 and a variance=1) and heat maps were generated using freely availably 
GeneE program (http://www.broadinstitute.org/).
Immunofluorescence
For evaluation of CRT expression, BLM cells were cultured on glass coverslips and 
treated overnight with 50µM OXP, 66µM CDDP, 1uM MTX or left untreated. Cells 
were washed, fixed in 0.25% paraformaldehyde (PFA) in PBS for 5min at RT. Cells 
were blocked and subsequently incubated with wheat germ agglutinin-biotinylated 
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(WGA) for 45min at 4°C. After extensive wash, cells were stained with primary anti-
CRT antibody (Abcam, clone ab2907, Suppl. Table 1) in cold confocal laser scanning 
microscope (CLSM) buffer (3% bovine serum albumin, 50mM Glycine in PBS) for 
30min at RT, followed by incubation with secondary Alexa conjugates in cold CLSM 
blocking buffer, for 20min at RT. Cells were then fixed in 4% PFA/PBS for 20min at 
RT. Nuclei were stained with DAPI (1:3000) in CLSM for 5min at RT.  Samples were 
imaged with an Olympus FV1000 Confocal Laser Scanning Microscope. Images were 
analyzed using the open source-imaging platform, Fiji (imageJ 64 Bit for Windows). 
Co-cultures and uptake assays 
Tumor cells were stained with 2µM of the fluorescent probe 5(6)-Carboxyfluorescein 
diacetate N-succinimidyl ester (CFSE, Invitrogen, Thermo Fisher Scientific, catalog# 
C34554), according to manufacturer’s instructions. Fluorescently–labelled (CFSE 
or GFP) tumor cells were seeded in T75 flasks (Corning), adhered and treated with 
OXP or CDDP. After treatment, tumor cells (5x105 cells, target) and DCs (5x105 
cells, effector) were cocultured at a 1:1 ratio in Falcon tubes (BD Falcon) in X-VIVO-
15 supplemented with 2% HS (final concentration 1x106/ml). Co-cultures were 
stained with an APC-labeled primary antibody recognizing a specific DC surface 
marker (CD11c for CD1c+ and CD16+ DCs, CD123 for pDCs; see also Suppl. Table 1) 
and analyzed by flow cytometry. Extent of phagocytosis was determined as the 
percentage of double positive events (i.e. CD11c+ or CD123+-APC/GFP+ or CFSE+). For 
blocking experiments, tumor cells were pre-incubated (30min at 4°C) with blocking 
agents or negative controls: CRT blocking peptide (20 µg/mL, MBL International, 
catalog# JM-3077BP-50), irrelevant gp100 peptide272-300 (20 µg/mL, JPT), anti-CD91 
(20 µg/mL, Thermo Fisher Scientific, clone 8G1, catalog# MA1-27198) or IgG1,k 
(20 µg/mL, Biolegend, clone MG1-45). Extra volume blocking agents or matched 
controls were added to co-cultures at same final concentration. 
Flow cytometric analysis of DC maturation 
Phenotypical assessment of DC maturation after 48h of coculture with tumor cells 
was performed by flow cytometry. Briefly, cells were washed in PBA, incubated 
with Fc-receptor blocking buffer (2% HS in PBS, 15min at 4°C) and subsequently 
stained with primary antibodies in PBA (30min at 4°C). Monoclonal directly labeled 
anti-human antibodies used were (Suppl. Table 1): anti-CD11c-APC (Miltenyi biotec, 
clone MJ4-27G12, catalog# 130-092-412), anti-CD123-APC (Miltenyi biotec, clone 
AC145, catalog# 130-090-901), anti-CD80-PECy7 (BD Pharmingen, clone L307.4, 
catalog# 561135), anti-CD86-PECy7 (BD Pharmingen, clone 2331, catalog# 561128), 
anti-HLA-ABC-PE (BD Pharmingen, clone G46-2.6, catalog# 555553) and anti-HLA-
DR-PE (BD Pharmingen, clone G46-6, catalog# 555812). Appropriate isotype controls 
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were included.  Geometric mean fluorescence intensity (GeoMFI) of maturation 
markers was assessed on CD11c+ (for CD1c+ and CD16+ DCs) or CD123+ (for pDCs) 
populations. As a positive control, DCs were stimulated with poly I:C (CD1c+ and 
CD16+ DCs, 2 µg/mL, Enzo Life Science, catalog# ALX-746-021-M005) or R848 (pDCs, 
4 µg/mL, Enzo Life Science, catalog# ALX-420-038-M025). To improve in vitro pDC 
viability, IL-3 (10 ng/mL, Cellgenix, catalog# 1002-050) was added to culture medium. 
Cytokine quantification 
Supernatants from tumor cell-DC cocultures (18 hours) were collected, dying 
floating cells removed by centrifugation and supernatants frozen immediately for 
detection of secreted cytokines. Human Th1/Th2 cytokines (IFN-γ,  IL-2, IL-4, IL-5, 
IL-10, IL-12 (p70), TNF-α and TNF-β) were quantified with a multiplex FlowCytomix 
kit (eBioscience, BMS810FF) according to the manufacturer’s instructions.
DC sorting and Mixed Lymphocyte Reaction (MLR) 
Tumor-DC co-cultures were established as described above. After wash in cold wash 
buffer (PBS/0.1% BSA/5mM EDTA) and incubation in Fc-receptor blocking buffer (2% 
HS in wash buffer, 15min at 4°C), cells were stained with sterile primary antibodies in 
wash buffer (20min at 4°C). The following antibodies were used (Suppl. Table 1): anti-
HLA-DR-PECy7 for all subsets (BD Biosciences, clone L243, catalog# 335813), anti-
CD1c-PE for CD1c+ DCs (Miltenyi biotec, clone AD5-8E7, catalog# 130-090-508), 
anti-CD16-APC for CD16+ DCs (Miltenyi biotec, clone VEP13, catalog# 130-098-101) 
and anti-CD304-PE for pDCs (Miltenyi biotec, clone AD5-17F6, catalog# 130-090-
533). Sorting of DCs was performed using a Fluorescence Activated Cell Sorter 
Aria (FACSAria, BD Bioscience), based on FSC/SSC properties and positivity for DC 
markers (Suppl. Fig 5). Allogeneic PBLs were stained with 5µM CFSE (Invitrogen), 
according to manufacturer’s instructions and added to the sorted DCs at a ratio 
of 5:1 (Lymphocytes:DCs), for an additional period of 5 days, in 2% HS X-VIVO-15. 
After 5 days, co-cultures were stained with a primary anti-CD3-BV421 antibody 
(BD Horizon, clone SK7, catalog# 563798) and analyzed by flow cytometry. The 
percentage of proliferating T cells (CD3+) was determined by assessing CFSE dilution 
in the fraction of CD3+ cells.
Statistical analysis 
Unless otherwise indicated, experiments were performed at least three times, 
yielding comparable results. Data were analyzed by means of Prism v. 5.03 
(GraphPad Software). Statistical significance was assessed by One-way Anova, 
followed by a Dunnett’s post-test or Two-way Anova, followed by a Bonferroni’s 
post-test, as appropriate. P-values <0.05 were considered as statistically significant. 
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Results 
Cisplatin and oxaliplatin induce a form of cancer cell death consistent 
with ICD 
Up till now most studies on induction of ICD by platinum compounds, OXP and 
CDDP were performed in mouse models and little is known about the ability of 
platinum compounds to induce ICD in human tumor cells5, 9. We investigated the 
molecular hallmarks of platinum-induced cancer cell death in vitro. We treated 
human colon (Caco2), testicular (833KE and 2102EP) and melanoma (BLM) cell lines 
with increasing, clinically relevant doses of OXP or CDDP and studied cell death 
using Annexin V and DAPI staining. Both OXP and CDDP decreased viability of BLM 
cells in a time- and dose-dependent manner (Fig 1a,b), as indicated by increased 
phosphatidylserine exposure and stronger nuclear DAPI staining. Similar cytotoxicity 
was observed for 833KE, 2102EP and Caco-2 cells (data not shown). Given the 
chemosensitivity of testicular carcinoma cells, 833KE and 2102EP cell lines were 
treated with lower drug concentrations, compared to the other cell lines studied. 
Despite sharing similar mechanisms of action, OXP, but not CDDP, was previously 
described to trigger exposure of ecto-CRT on the murine colon cancer cell line 
CT26 5. Surprisingly, we observed similar, if not stronger translocation of ecto-CRT 
after BLM and Caco-2 cells were exposed to CDDP compared to OXP (Fig 1c,d; 
Suppl. Fig 1b). Analysis of expression kinetics on BLM cells showed that ecto-CRT 
was detected as early as 1 hour after treatment and its exposure was dose- and 
concentration dependent (Fig 1c, Suppl. Fig 1a). On the other hand, OXP and CDDP 
had less marked effects on the translocation of ecto-CRT in 833KE, 2102EP and 
CT26 cell lines, at time and dosage tested (Fig 1d,e; Supp. Fig 1b,c). 
In order to simulate the pharmacokinetics of platinum treatment, which is 
administered intravenously and remain in the body for a few hours 24, we exposed 
cells to OXP or CDDP for 8 hours, washed away the drug and cultured the cells for 
an additional 40 hours under drug-free conditions. This short-term drug exposure 
to OXP or CDDP dose-dependently decreased viability of BLM cells and induced 
ecto-CRT expression (Fig 1f,g), similar to long-term (48 hours) treatment (Fig 1b,c). 
Next, we measured the expression of Hsp70, ATP and HMGB1 on different tumor 
cell lines treated with platinum drugs. Both OXP and CDDP induced translocation 
of Hsp70 (ecto-Hsp70) to the cell surface of human BLM, 833KE and 2102EP cells, 
as well as the murine CT26 cell line as observed using flow cytometry (Fig 2a-c, 
Suppl. Fig. 2a,d). Concurrent with increased ecto-HSP70, we observed increased 
secretion of ATP (Fig 2d-f, Suppl. Fig. 2b) and HMGB1 (Fig 2g-i, Suppl. Fig. 2c,e) in 
the supernatant of platinum-treated tumor cells. In all, we show that both OXP and 
CDDP cause apoptosis of human tumor cells, with the concomitant translocation 
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of ecto-CRT and ecto-HSP and the extracellular release of ATP and HMGB1. These 
results suggest that both platinum compounds induce a form of cell death that fulfils 
the requirements for immunogenic apoptosis. 
Human DCs preferentially phagocytose platinum-treated tumor cells in 
a CRT-dependent manner 
We investigated whether platinum-induced ecto-CRT had an effect on the 
recognition and uptake of tumor cells by human blood DCs 9. First, we examined 
whether treatment with platinum drugs led to increased interaction between tumor 
cells and human blood DCs using confocal microscopy. For this experiment, the 
human melanoma cell line BLM was modified to stably express the fluorescent 
protein GFP (hereafter referred to as BLM-GFP). Untreated BLM and BLM-GFP 
showed no difference in surface expression of calreticulin (CRT). Furthermore, 
platinum-treatment induced comparable upregulation of CRT on both BLM and 
BLM-GFP (Suppl. Fig 3a). Tumor cells were left untreated or treated with OXP or 
CDDP for 48 hours and then co-cultured with CD1c+ DCs for 3 hours. We observed 
increased interaction between DCs and tumor cells treated with CDDP or OXP 
compared to untreated cells (Fig 3a, b). Based on the fact that tumor cells are several 
orders of magnitude larger than blood DCs, we hypothesized that DCs, in contrast 
to macrophages, do not ingest whole tumor cells but only subcellular fragments of 
these cells. To evaluate whether fragments of platinum-treated cells are preferentially 
Figure 1. Sensitivity of tumor cell lines to platinum drugs and platinum-mediated exposure of 
ecto-CRT. (A, B) Frequency of apoptotic (Annexin V+ DAPI-) and secondary necrotic (Annexin V+ 
DAPI+) BLM cells after treatment with OXP or CDDP. Human melanoma BLM cells were cultured 
with platinum drugs or left untreated, for 24h or 48h. Cells were stained with Annexin-V-FITC and 
DAPI and analyzed by flow cytometry. Data are presented as representative contour plot (A) or 
mean±SEM (at least n=2, performed in duplicates) (B). (C, E, F) CRT exposure was assessed on 
Annexin V+ DAPI- cells after treatment with OXP or CDDP by flow cytometry. BLM cells were treated 
as described above. Data are relative mean±SEM (at least n=3, in duplicates) (C). Representative 
histograms show CRT expression (MFI) on human colon (Caco-2) and testicular (833KE and 2102EP) 
cancer cell lines following 24h of treatment with OXP or CDDP. Caco-2 were treated with 15µM 
of OXP or CDDP; 833KE and 2102EP were treated with 6.3µM OXP or 8.3µM CDDP. Isotype (grey 
line), control (grey filled histogram), treatment (black thick line) (E). Exposure of CRT on murine 
colon cancer CT26 cells was assessed after 24h of treatment with 15µM of OXP or CDDP. Data 
are means of duplicates of one representative experiment (F). (D) CRT expression was confirmed 
by confocal microscopy. BLM cells were stained with an anti-CRT antibody and the membrane 
marker, wheat germ agglutinin (WGA). Scale bar 10 µm. (G, H) Frequency of apoptotic vs. necrotic 
cells (G) and CRT exposure (H) on BLM cells, after short-term (8h) drug exposure to OXP or CDDP, 
at indicated doses. Results are mean±SEM (n=3 in duplicates). Significance was determined with 
One-way ANOVA, *P < 0.05, ***P < 0.001, as compared to control (CTRL) cells. 
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taken up by the three human DC subsets examined in this study, we established in 
vitro co-cultures of platinum-treated tumor cells and DCs. Tumor cells were exposed 
to OXP or CDDP. Concentration and duration of treatment with platinum drugs were 
specifically chosen for each cell line in order to maximize induction of ICD hallmarks, 
while maintaining cell viability at the start of the co-culture. Fluorescently labelled-
tumor cells were co-cultured with DCs for 24 or 48 hours. Uptake of untreated versus 
OXP- or CDDP-treated tumor cells was assessed by flow cytometry (Fig 3c-f, Suppl. 
Figure 3). In order to distinguish between binding of tumor cells fragments to the 
cell membrane of DCs and active uptake, we performed co-culture experiments at 
4°C versus 37°C, respectively.  As shown in Figure 3c, DCs are capable of taking 
up (37°C) fragments of tumor cells. In contrast, there is a low level of binding 
(4°C) of tumor fragments to DCs, which did not increase upon treatment (Fig 3c, 
Suppl. Fig 3c). Furthermore, while there was a considerable increase in the uptake 
of platinum treated cells between 24 and 48 hours of co-culture, uptake of control 
cells was not markedly increased in time (Fig 3d).
Distinct DC subsets have different capacities to phagocytose soluble and cell-
associated tumor antigens22. We therefore tested the capacity of CD1c+ DCs, CD16+ 
DCs and pDCs to take up OXP- or CDDP-treated tumor cells. Treatment of BLM cells 
with CDDP led to a significant increase in the uptake of tumor fragments by all DC 
subsets. Plasmacytoid DCs were the least efficient DC subset in engulfing tumor-
derived particles, whereas CD1c+ and CD16+ DCs were more proficient (Fig 3e). 
These results were consistent across different cell lines (833KE, 2102EP and Caco2) 
used in the co-culture with CD1c+ and CD16+ DCs (Fig 3f). OXP was less potent than 
CDDP in inducing uptake of BLM cells (Fig 3e), in contrast to the other cell lines 
tested, for which OXP was slightly more potent than CDDP (Fig 3f). These differences 
might be due to differences in drug uptake in the different cell lines.
We wondered whether uptake of tumor fragments was solely dependent on 
CRT expression and thus performed the uptake experiment in the presence of a 
CRT-blocking peptide 25, 26. An irrelevant peptide (derived from gp100) or a mouse 
isotype antibody were used as negative controls (Fig 4a, Suppl. Fig 3d). As expected, 
the irrelevant peptide, as well as, the non-specific IgG control, did not affect 
phagocytic ability of CD1c+ DCs. However, engagement of ecto-CRT with a CRT-
blocking peptide completely abolished uptake of tumor cells, including those treated 
with platinum drugs. This observation confirmed the crucial role played by CRT in 
directing tumor cell fragment uptake. The most commonly described receptor for 
ecto-CRT is the low-density lipoprotein receptor-related protein 1 (LRP1), also known 
as CD91 27. The expression of CD91 on distinct human blood circulating DC subsets 
has not been characterized before, thus we analyzed CD91 expression on CD1c+ 
DCs, CD16+ DCs and pDCs by flow cytometry. Monocytes (CD14+) were previously 
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Figure 2. Platinum drugs induce release of immunogenic signals for DCs stimulation. (A, B, C) 
Surface expression of Hsp70 on BLM (A), 2102EP (B) and CT26 (C) cells, after platinum treatment, 
was assessed on Annexin V+ DAPI- cells by flow cytometry. Cells were cultured with OXP or CDDP 
at indicated doses, for 24h (2102EP and CT26) or 48h (BLM). Data are presented as mean (n=2). 
(D, E, F) Extracellular ATP was measured by luciferase assay, in supernatants of cells cultured as 
described above. Results represent relative means±SEM (at least n=2, done in duplicates). (G, 
H, I) Elisa detection of HMGB1 release in supernatant of cells cultured as described above. Data 
are means±SEM (at least n=2). Significance was determined with One-way ANOVA, *P < 0.05, 
**P < 0.01, ***P < 0.001, as compared to control (CTRL) cells.
shown to express CD91 and were used as a positive control (Fig 4b) 28. Both CD1c+ 
and CD16+ DCs, as well as monocytes, clearly expressed the ecto-CRT receptor. 
On the other hand, and consistent with the low uptake of chemotherapeutically 
induced tumor cell fragments, pDCs showed little-to-no expression of CD91. We 
observed a similar trend looking at the transcriptomes of these DC subsets (Fig 4c). 
mRNA levels of CD91 were highest in CD16+ and CD1c+ DCs, whereas pDCs showed 
the lowest expression. Subsequent blocking of CD91 on CD1c+ DCs, with a specific 
anti-CD91 blocking antibody, however, did not affect phagocytosis of tumor cells, 
despite its high expression levels (Fig 4d). To complement this analysis, we also 
investigated the expression of alternative receptors for ecto-CRT. Both the scavenger 
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Figure 3. Platinum-treatment increases phagocytosis of tumor cells by human DC subsets. (A, 
B) BLM-GFP cells were treated with 15µM OXP or CDDP for 48h and co-cultured with CD1c+ 
DCs (pre-labeled with PKH26) for 3h. Representative confocal image (A) and quantification (B) of 
BLM-DC interactions. A total of 5 images per sample were taken and the number of interactions 
was normalized over the number of DC and BLM cells present in the image. Data represent 
mean±SEM of 1 representative experiment. (C) Percentage of uptake (48h co-culture, 37°C, grey 
bar) of 15µM OXP or CDDP treated-BLM cells by CD1c+ DCs versus binding (4°C, white bar). Values 
are relative to binding of control (CTRL) BLM cells and show mean (n=2). (D) Representative contour 
plot of control (CTRL) or platinum treated-BLM cells uptake by CD1c+ DCs upon 24 or 48 hours of 
co-culture. (E, F) Percentage of phagocytosis of BLM (E), 833 KE, 2102 EP, Caco2 (F) human tumor 
cell lines by different DC subsets (CD16+, CD1c+ and pDCs). BLM and Caco-2 were treated with 
15µM of OXP or CDDP for 48h; 833KE and 2102EP were treated with 6.3µM OXP or 8.3µM CDDP 
for 24h. CTRL (white bar) or treated tumor cells (grey or black bars) were co-cultured with DCs for 
48h and extend of uptake was assessed by flow cytometry. The graph shows the mean±SEM (at 
least n=2, in duplicate). Significance was determined by Two-way ANOVA, **P < 0.01, ***P < 0.001, 
as compared to CTRL cells. 
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receptor class-A (SR-A, also known as CD204) and the scavenger receptor expressed 
by endothelial cell-1 (SREC-I) were reported to bind ecto-CRT29, 30. Transcriptomic 
analysis of SR-A and SREC-I revealed that these receptors are variably expressed on 
blood DC subsets, with CD1c+ DCs again showing the highest expression (Fig 4c). 
Taken together, our data demonstrate that blood DCs take up platinum-treated 
tumor cells more efficiently than untreated cells and this uptake is strictly dependent 
Figure 4. Human DCs take up platinum-treated tumor cells in a CRT-dependent manner. (A) 
Percentage of uptake of 15µM OXP or CDDP treated-BLM cells by CD1c+ DCs. Control or treated 
tumor cells were co-cultured with DCs in the presence of isotype (white bar), CRT blocking peptide 
(grey bar) or irrelevant tumor antigen (gp100) peptide (black bar) for 2h. Extent of uptake was 
assessed by flow cytometry. Data show means of duplicates of one representative experiment. 
(B) Representative histograms showing CD91 expression on human monocytes (CD14+) and DCs 
(CD16+, CD1c+ and pDCs). Isotype (grey filled histogram), anti-CD91 (black thick line). (C) Heatmap 
of relative mRNA expression levels of genes in human DC subsets. Heatmap shows the normalized 
expression of genes (Z-scores) in CD16+, CD1c+ and pDCs. Data are represented from 3 healthy 
donors. (D) Representative contour plot of CTRL or CDDP (15µM, 48h) treated-BLM cells uptake 
by CD1c+ DCs upon functional blocking of CD91 on DCs. BLM cells and DCs were co-cultured 
overnight in the presence of isotype control or CD91-blocking antibody. Percentage of phagocy-
tosis was assessed by flow cytometry. 
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on CRT exposure. Additionally, while we observed uptake of tumor fragments by 
all DC subsets, they differentially express receptors capable of binding ecto-CRT.
Phagocytosis of platinum-treated tumor cells induces maturation of 
human DC subsets
Next, we investigated whether the CRT-mediated uptake of tumor cells fragments 
may lead to DC maturation. The transcriptomes of DCs for receptors that sense 
danger signals released by dying tumor cells were assessed. CD1c+ DCs showed 
the highest mRNA expression levels of the P2RY2 (recognizing ATP), LOX-1 (HSPs) 
and RAGE (HMGB1) receptors; as well as, of the common receptors for HSPs and 
HMGB1 (TLR2) (Fig 4c). Exceptions were P2RX7 (ATP) and TLR4 (HSPs and HMGB1), 
for which CD16+ DCs had higher mRNA expression levels (Fig 4c). On the other hand, 
pDCs showed the lowest expression of all these receptors on mRNA level (Fig 4c). 
Following co-culture with platinum treated tumor cells, we measured surface 
expression of several markers on DCs, involved in antigen presentation and co-
stimulation (Fig 5). As a positive control, DCs were stimulated with TLR ligands (poly 
I:C (pI:C) or R848). Co-culture of DCs with platinum-treated BLM cells induced a 
significant upregulation of co-stimulatory molecules, CD80 and CD86. Although 
pDCs were less efficient in taking up tumor fragments (Fig 3e), upregulation of co-
stimulatory molecules (CD80 and CD86) was more prominent in pDCs than CD1c+ 
or CD16+ DCs (Fig 5a), despite the lower expression of receptors recognising the 
dying cell fragments on these cells. In addition, we analyzed the expression of major 
histocompatibility complex (MHC) classes I and II, required for antigen presentation 
to T cells. Platinum-treatment only moderately influenced MHC I and II expression 
on DC subsets (Fig 5b). We observed similar effects of platinum treatment for 
2102EP (Fig 6a,b) and 833KE (Fig 6c,d) cells co-cultured with CD1c+ or CD16+ DCs.
In addition to phenotypical maturation, we tested cytokine secretion in the 
supernatant of tumor-DC co-cultured overnight upon induction of ICD (Fig 5c,d). 
CD1c+ DCs markedly increased the production of the proinflammatory cytokine, 
TNF-α, as well as the anti-inflammatory cytokine, IL-10, in response to interaction 
with both OXP- and CDDP treated BLM cells. On the other hand, CD16+ DCs and 
pDCs showed no significant response to platinum-treated tumor cells. Furthermore, 
we could not detect any IL-2, IL-4, IL-5, IL-12, TNF-β and IFN-γ (data not shown).
Platinum-treated tumor cells stimulate human CD1c+ DCs to induce a 
T cell response
Co-culture of DCs with different platinum-treated tumor cell lines (BLM, 2102 EP 
and 833KE) led to uptake of tumor cells and subsequent maturation of DC. Next, 
we investigated the ability of these mature DCs to stimulate allogeneic T  cell 
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proliferation. Proliferation of CD3+ T cells was quantified by measuring CFSE dilution 
in a Mixed Lymphocyte Reaction (MLR) (Fig 7a, Suppl. Fig 5). As shown in Fig 7b, 
Figure 5. Phagocytosis of platinum-treated BLM cells induces maturation of human DC subsets. 
(A, B) The expression of maturation markers on DC subsets (CD16+, CD1c+ and pDCs) following 48h 
of co-culture with control or platinum treated BLM cells. DC stimulated with TLR ligands (4µg/ml 
R848 for pDCs and 2µg/ml poli(I:C) for CD16+ and CD1c+) were used as positive controls. The 
expression levels were determined by flow cytometry and depicted as GeoMFI values, relative to 
those of the co-culture with control tumor cells (coCTRL). The graphs show the mean±SEM (n=7). 
Significance was determined by One-way ANOVA, * P< .05, **P < 0.01, ***P < 0.001. (C, D) TNF-α 
and IL-10 production was analyzed in supernatants of overnight co-cultured pre treated-BLM and 
DCs by a multiplex FlowCytomix kit. Significance was determined by two-tailed t-test, * P< .05.
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Figure 6. Phagocytosis of platinum-treated testicular cancer cells induces maturation of human 
DC subsets. The expression of maturation markers on DC subsets (CD16+, CD1c+ and pDCs) 
following 48h of co-culture with control or platinum treated 2102EP (A, B) or 833KE (C, D) cells. 
The expression levels were determined by flow cytometry and depicted as GeoMFI values, relative 
to those of the co-culture with control tumor cells (coCTRL). The graphs show the mean (n=2).  
CD16+ DCs were not able to induce significant T cell proliferation in any of the 
conditions tested. On the other hand CD1c+ DCs co-cultured with OXP- or CDDP-
treated tumor cells, showed a significant increase in T cell proliferation compared to 
untreated cells. Plasmacytoid DCs were able to induce allogeneic T cell proliferation 
but there was no difference between pDCs co-cultured with untreated cells or 
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platinum-treated cells. Altogether these results seem to suggest that CD1c+ DCs 
are most effectively activated by tumor cells undergoing ICD and might have the 
potency to drive subsequent immune responses.
Discussion 
The human immune system plays a fundamental role in tumor recognition and control 31. 
Recent advances, including the discovery of immunogenic cell death (ICD) and its 
contribution to clinical efficacy, suggest that durable clinical responses to chemotherapy 
require the presence of a functional immune system3, 32, 33. DCs are the key cells in this 
scenario, as they are required to kick-start effective adaptive immune responses 34-36.
Here, we study the function of the three most abundant human blood circulating 
DCs (CD1c+ DCs, CD16+ DCs and pDCs) in ICD induced by the platinum drugs 
oxaliplatin (OXP) and cisplatin (CDDP). We observed that, contrary to previous 
reports, both drugs were able to induce expression of the three hallmarks of ICD: 
CRT exposure, secretion of ATP and release of HMGB1. Furthermore, we show that 
all three DC subsets preferentially take up fragments derived from platinum-treated 
tumor cells and subsequently undergo phenotypical maturation. 
Although the first compounds discovered to initiate an immunogenic form of 
apoptosis were structurally similar and all belonged to the class of the anthracyclines, 
the list of ICD inducers has since been expanded 5, 37-40. Previously, Tesniere et al. 
found that the platinum drug CDDP fails to initiate ICD by itself, despite its similarity 
in structure and function to the ICD-inducer OXP 4, 5. Nonetheless, CDDP was 
converted into an ICD inducer by exogenous co-administration of Cxcl2 (ortholog 
of the human pro-inflammatory cytokine/chemokine IL-8) 41. Here we show that 
CDDP, as well as OXP, could upregulate exposure of ecto-CRT and induce release 
of ATP and HMGB1 in human tumor cells of distinct origins. Our observation that the 
human melanoma cell line BLM secretes high amounts of IL-8 (data not shown) could 
be a possible explanation for the discrepancy between our study and the results 
of Tesniere et al. This suggests that different cell lines may have distinct intrinsic 
potentials to emit immunogenic signals. In apparent accordance with this notion, 
UV irradiation has been described to induce ICD in murine models, yet it failed to 
do so in human cancer cell lines tested in another study 23, 40. 
In addition to the three ICD hallmarks described above, surface translocation of 
the heat shock protein Hsp70 could expand the general definition of ICD 23, 39. We 
here report that both OXP and CDDP were able to upregulate expression of Hsp70 
in various human tumor cell lines. 
Treatment of human tumor cells with OXP or CDDP increased uptake of tumor 
fragments by all three human DC subsets. As previously reported 22, CD1c+ and 
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CD16+ DCs efficiently phagocytosed cell fragments, whereas pDCs showed lower 
uptake capacity. This uptake was dependent on ecto-CRT, however blocking of 
the CRT receptor did not abrogate tumor cell fragment uptake, suggesting that 
other receptors might be involved. The multi-ligand scavenger receptors SR-A 
(CD204) and scavenger receptor expressed by endothelial cell-1 (SREC-I), have been 
proposed to be involved in ecto-CRT binding 29, 30. Our transcriptome analysis of 
blood DC subsets confirms that SR-A and SREC-I are expressed on distinct human 
DCs 42. The presence of these alternative receptors might explain why blocking of 
CD91 did not diminish the uptake. Furthermore, we cannot exclude the possibility 
that there may be more receptors involved in ecto-CRT binding and that these 
have yet to be described. More research is required to reveal which receptor is 
responsible for CRT mediated uptake on human DC-subsets.
The human DC population is characterized by high degree of heterogeneity 
that reflects their phenotypical and functional properties, as well as their location 
in the body43. Consequently, DCs can interact with tumor cells in multiple ways. 
Immature DCs populate peripheral tissues and organs, where they are committed 
to (tumor) antigen capture43. In addition, myeloid and plasmacytoid DC subsets are 
found circulating in the blood, where they may encounter CTCs that have detached 
from the primary tumor and entered into the bloodstream18. Furthermore, DCs can 
home to and infiltrate tumors. As an example, inflammatory dendritic cells (inflDCS), 
were described as a distinct subset of DCs originating from in situ differentiation 
of monocytes recruited to the site of inflammation44. In mice, monocytes were 
recruited into the tumor bed within 12 hours following mitoxantrone treatment, 
and differentiated into inflDCs. Addition of a neutralizing antibody against CD11b 
abrogated activation of tumor-specific CD8+ T cells, indicating that DCs play a 
central role in ICD-mediated initiation of anti-tumor responses 11. In this perspective, 
distinct DC subsets might be relevant as cellular mediators of ICD. Among blood DC 
populations, CD141+ DCs are also equipped with the potent ability to cross-prime 
cytotoxic T lymphocytes 22. However, their scarce frequency represents a major 
hurdle in investigating their role in many aspects of DC biology. 
Stimulation of an effective T cell response is determined by several critical steps. 
These involve (tumor) antigen uptake, processing and (cross)-presentation, as well as 
phenotypical and functional maturation of DCs 45, 46. Murine DCs were reported to 
upregulate maturation-associated markers upon phagocytosis of bortezomib-treated 
colon cancer cells 47. Similar effects were observed for human moDCs that were co-
cultured with Idarubicin- or Bortezomib-treated tumor cell lines 23, 39. Accordingly, we 
showed that interaction of OXP- or CDDP-treated tumor cells with blood DC subsets 
induced phenotypical maturation of DCs, observed as upregulation of co-stimulatory 
molecules (CD80 and CD86). In line with previous observations 22, although pDCs were 
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less able to take up antigens from their environment than other subsets, they efficiently 
matured and induced high levels of co-stimulation.  Despite strong phagocytic ability 
and induction of maturation, CD16+ DCs appeared to be the least efficient inducers of 
T cell responses, probably due to their minimal cross-presenting capacity 22. This seems 
to be in accordance with the hypothesis that CD16+ DCs may share some biological 
functions with DCs, yet they are more similar to monocytes, based on the comparison of 
their gene expression profiles 20. The most effective response was observed for CD1c+ 
DCs. Notably, CD1c+ DCs were the only DC subset that, in response to interaction with 
platinum-treated tumor cells, secreted TNF-α and IL-10, cytokines typically induced 
upon exposure to different maturation stimuli48,49. This myeloid DC population was 
capable of engulfing platinum-treated tumor cells, responding to activatory signals 
and inducing T cell proliferation. In support of the functional observations, our 
transcriptomic analysis revealed that CD1c+ DCs had higher expression of DC receptors 
sensing danger signals released by dying tumor cells, on mRNA levels as compared to 
the other two DC subsets. Appropriately, deficiency or loss-of-function mutations of 
genes encoding these receptors, was shown to compromise the efficacy of anti-cancer 
chemotherapy, stressing their crucial role in ICD 5, 13, 17. 
In summary, we have investigated for the first time the role of the three most 
abundant human blood DC populations (CD1c+ DCs, CD16+ DCs and pDCs) in the 
context of ICD and show that only CD1c+ DCs were capable of inducing allogeneic 
T cell response in vitro. Moreover, we expanded the list of ICD inducers, showing 
that - similarly to OXP - CDDP induces a form of tumor cell death consistent with 
ICD. Together, these observations point towards an active stimulatory effect of 
platinum-treated tumor cells on DCs that naturally occur in the human body and 
may contribute to the translation of current knowledge on ICD into clinical settings.
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Supplementary materials
Supplementary Figure 1. Platinum-treatment increases exposure of ecto-CRT on tumor cells. 
(A) Gating strategy for assessment of cell viability and expression of surface DAMPs (CRT and 
Hsp70). Cells were gated on live cells. Ecto-CRT and Hsp70 expression was assessed on DAPI- cells. 
(B) Representative flow cytometry histogram of the kinetics of the expression of ecto-CRT on BLM 
cells after treatment with OXP, CDDP or MTX. (C) Representative replicate histograms showing 
CRT expression (MFI) on human colon (Caco-2) and testicular (833KE and 2102EP) cancer cell lines, 
following 24h of treatment with OXP or CDDP. Isotype (grey line), control (grey filled histogram), 
treatment (black thick line) (D). Exposure of CRT on murine colon cancer CT26 cells was assessed 
after 24h of treatment with OXP or CDDP. Data show duplicates of one representative experiment.
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Supplementary Figure 2. Detection of immunogenic DAMPs released by melanoma, testicular and 
colon cancer cells upon platinum-treatment. (A, B, C) Surface expression of Hsp70 on BLM, 2102EP 
and CT26 cells, after platinum treatment, was assessed by flow cytometry on AnnexinV+/DAPI- cells. 
(D, E, F) Extracellular ATP and HMGB1 release in supernatants of platinum-treated cells. Histograms 
show separate replicates (A-C, E, F) or mean of duplicates (D) of independent experiments.  
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Supplementary Figure 3. Dendritic cells actively take up tumor-derived fragments. (A) Gating 
strategy for tumor cell binding and uptake. Tumor cells, prelabeled with CFSE or expressing the flu-
orescent protein GFP, were co-cultured with DC subsets. Before assessment of binding/uptake, DCs 
were incubated with antibodies recognizing CD11c (APC), for CD16+ and CD1c+ DCs, or CD123 (APC), 
for pDCs. Extent of binding/uptake was assessed by gating on DCs and analyzing the percentage of 
APC+ CFSE+ (or GFP+) double positive events. (B) Expression of CRT on BLM versus BLM-GFP cells, as 
assessed by flow cytometry. Cells were left untreated or treated with CDDP for 48h. (C) DCs actively 
take up tumor-fragments as shown by percentage of uptake (37°C, grey bar) of platinum treated-BLM 
cells by CD1c+ DCs versus binding (4°C, white bar). Histograms show values relative to binding of 
control (CTRL) BLM cells of 2 independent experiments. (D) Control or platinum-treated BLM cells 
were co-cultured with CD1c+ DCs in the presence of isotype (white bar), CRT blocking peptide (grey 
bar) or irrelevant tumor antigen (gp100) peptide (black bar) for 2h and percentage of uptake was 
assessed by flow cytometry. Data show separate duplicates of one experiment. 
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Supplementary Figure 4. Maturation of CD16+ DCs and CD1c+ DCs following phagocytosis of 
platinum-treated testicular cancer cells. The expression of maturation markers on CD16+ DCs and 
CD1c+ DCs following 48h of co-culture with control or platinum-treated 2102EP or 833KE cells. 
Histograms show separate duplicates of independent experiments.
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Supplementary Figure 5. Gating 
strategy for the sorting of human 
blood DC subsets. (A) Before Flu-
orescence-activated cell sorting 
(FACS), co-cultures of tumor cells 
and DCs were incubated with 
antibodies recognizing HLA-DR 
(PE-Cy7), CD16 (APC), CD1c (PE), 
CD304 (PE). DCs were sorted from 
tumor cells based on the expression 
of HLA-DR in addition to CD16, 
CD1c and CD304 to obtain CD16+ 
DCs, CD1c+ DCs and pDCs, respec-
tively. (B) Yield and percentage of 
isolated cells from one representa-
tive experiment are shown.    
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Supplementary Table 1. List of antibodies (listed following order of appearance in M&M)
Antibody Clone Supplier Cat no. Dilution (Application)
anti-CRT ab2907 Abcam ab2907 1:100 (FACS) 
1:50 (Confocal)
anti-CRT-PE FMC 75 Enzo Life Science ADI-SPA-601PE-F 1:100 (FACS)
anti-HSP 70 C92F3A-5 Enzo Life Science ADI-SPA-810-D 1:100 (FACS)
anti-CD1c-PE AD5-8E7 Miltenyi biotec 130-090-508 1:100 (FACS; Sorting)
anti-CD11c-APC MJ4-27G12 Miltenyi biotec 130-092-412 1:25 (FACS)
anti-CD20-APC 2H7 eBioscience 17-0209 1:25 (FACS)
anti-CD15-FITC VIMC6 Miltenyi biotec 130-081-101 1:25 (FACS)
anti-CD56-PE MOC-1 IQ Products IQP-114R 1:25 (FACS)
anti-CD123-APC AC145 Miltenyi biotec 130-090-901 1:25 (FACS)
anti-CD303-PE AC144 Miltenyi biotec 130-090-511 1:25 (FACS)
anti-CD91α A2MRα-2 Invitrogen 37-3800 1:50 (FACS)
anti-CD80-PECy7 L307.4 BD Pharmingen 561135 1:12 (FACS)
anti-CD86-PECy7 2331 BD Pharmingen 561128 1:48 (FACS)
anti-HLA-ABC-PE G46-2.6 BD Pharmingen 555553 1:8 (FACS)
anti-HLA-DR-PE G46-6 BD Pharmingen 555812 1:8 (FACS)
anti-HLA-DR-PECy7 L243 BD Biosciences 335813 1:100 (Sorting)
anti-CD16-APC VEP13 Miltenyi biotec 130-098-101 1:66 (Sorting)
anti-CD304-PE AD5-17F6 Miltenyi biotec 130-090-533 1:66 (Sorting)
anti-CD3-BV421 SK7 BD Horizon 563798 1:50 (FACS)
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Abstract 
Tumor progression is dependent on the ability of tumor cells to either elude anti-
tumor immunity or induce tolerance against the tumor. Some of the key events that 
lead to subversion of anti-cancer immune responses originate from the interaction 
of tumor cells with host immune cells, in particular dendritic cells (DCs). DCs are 
master regulators of tolerance and immunity. Hence, signals provided by DCs, upon 
interaction with cancer cells, dictate the fate of an anti-tumor response. Interaction 
between DCs and tumor cells lead to uptake of tumor-derived fragments, after 
which DCs can display a ”defective” phenotype resulting in induction of tolerance 
rather than effective anti-tumor immunity. Tumor cell uptake by DCs is regulated by 
the balance of “don’t eat me” (e.g. CD47) versus “eat me“ (e.g. Calreticulin, CRT) 
signals expressed on cancer cells. In this study, we set out to investigate the effect 
of shifting this balance by inhibiting ”don’t eat me” signals, while enhancing ”eat 
me” signals on tumor cells. We measured uptake of tumor material by the naturally 
occurring human blood DC subset, CD1c+ DCs and assessed DC maturation. We 
demonstrated that either CD47 blockade or CRT upregulation by platinum drugs 
increased tumor cell uptake by DCs. Consequently, the uptake of these treated cells 
induced phenotypical CD1c+ DC maturation, measured by upregulation of the co-
stimulatory molecule CD86 and major histocompatibility complex class II (MHC II). 
Moreover, we observed that blocking of CD47 cooperates with platinum-treatment 
in increasing CD86 expression on CD1c+ DCs compared to either treatment alone, 
albeit tumor uptake was not markedly enhanced. We therefore suggest that 
combining CD47 blockade with chemotherapy might contribute to reverting tumor-
mediated suppression of DC maturation, eventually restoring DC activation and 
induction of T cell proliferation.  
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Introduction 
Cancer development and progression is dependent on the ability of tumor cells to 
either elude antitumor immunity or induce a tolerogenic response1. Tumor-mediated 
subversion of immune responses can occur at different levels. The establishment of 
a tumor microenvironment (TME) can inhibit antigen presentation, halt immune cell 
activity and recruit suppressive immune cells, such as myeloid-derived suppressor 
cells (MDSCs) or tumor-associated macrophages2. Moreover, it is now evident that 
the failure of the immune system, to build protection against tumor cells, strongly 
depends on the signals provided by antigen presenting cells (APCs) to effector 
immune cells3,4. 
Dendritic cells (DCs) are the main professional APCs and they are necessary 
to control and balance tolerance and immunity. Immature DCs patrol peripheral 
tissues, sample antigens and undergo a series of phenotypical and functional 
changes, which can convert immature DCs into efficient stimulators of naïve 
T cells, favoring the development of Th1 responses. Alternatively, phenotypically 
or functionally-impaired DCs can induce tolerogenic mechanisms4,5. DCs encompass 
a heterogeneous class of immune cells that differ in phenotype, localization and 
functional specialization6. Human blood contains two major DC subtypes, myeloid 
(mDCs) and plasmacytoid (pDCs) DCs7. pDCs are the principal mediators of antiviral 
immunity as they produce large amounts of type I interferons (IFNs) in response 
to viral stimuli. Myeloid DCs can be subdivided into CD16+ DCs, CD1c+ DCs and 
BDCA3+ DCs, and have been well characterized as efficient antigen-presenting cells 
and inducers of adaptive immunity8. 
DCs in the TME are found in immature state, characterized by low level of surface 
expression of co-stimulatory molecules, as well as, altered cytokine profiles3,5. There 
are two main mechanisms that hamper efficient DC function in the TME. Firstly, a 
suppressive cytokine milieu characterized by the production of VEGF, IL-10, IL-6, 
TGF-β, which contribute to blockade of DC activation and/or desensitization of 
mature DCs3,9. Secondly, engagement of inhibitory receptors (e.g. signal regulatory 
protein α (SIRPα) on DCs10-13. Upon SIRPα ligation, both murine and human DCs 
displayed a distinct immature phenotype, characterized by down-regulation of 
co-stimulatory molecules and impaired cytokine production. Moreover, these 
“defective” DCs were unable to stimulate T cell responses10-13. 
SIRPα is a type I transmembrane receptor of the IgG superfamily, expressed on 
neurons, endothelial cells and professional phagocytes (monocytes, macrophages 
and DCs)14 and binds to the ubiquitous transmembrane protein CD47 (also known 
as integrin-associated protein, IAP)15. CD47 is expressed on all hematopoietic cells, 
where it prevents cell clearance by phagocytes and as a result is often referred to 
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as a “don’t eat me” signal16,17. However, CD47 was also found markedly upregulated 
in solid and hematopoietic tumors, representing a potential mechanism of escape 
from immunosurveillance18. 
CD47-SIRPα interaction regulates DC function by activating two distinct 
downstream signalling pathways. SIRPα generates a negative signal via its two 
intracellular immunoreceptor-based inhibition motifs (ITIMs) and the recruitment 
of SRC homology 2 domain-containing phosphatases (SHP-1 and/or SHP-2), which 
ultimately cause inhibition of phagocytosis16,19,20. Alternatively, SIRPα physically 
associates with JAK2 and phosphorylated-STAT3, resulting in the activation of the 
JAK/STAT signaling cascade and subsequent down-regulation of inflammatory 
immune responses21-23. 
Besides “don’t eat me” signals, cells (especially dying cells) can also express 
“eat me” signals such as calreticulin (CRT), which flags these cell for engulfment by 
phagocytes24,25. Whether a cell is taken up by phagocytes or not depends on the 
balance between these “eat me” and “don’t eat me” signals. CRT is a chaperone 
molecule residing in the lumen of the endoplasmic reticulum (ER)26,27. Under 
conditions that cause extensive ER stress, CRT translocates and become exposed 
on the cell surface (ecto-CRT)26,27. Viable cells can also express low amounts of 
ecto-CRT, but this is not sufficient to overcome CD47 expression and induce 
cellular uptake25. Upregulation of ecto-CRT is one of the “hallmarks” (in addition 
to heat shock proteins (HSPs), ATP and high mobility group box 1, HMGB1) that 
defines a form of immunologically active apoptosis, known as immunogenic cell 
death (ICD)28. 
Anti-cancer therapies inducing ICD include treatment with the platinum 
chemotherapeutics, oxaliplatin (OXP) and cisplatin (cis-diamminedichloroplatinum, 
CDDP)27,29.  We recently reported that after treatment with OXP or CDDP human 
tumor cells were engulfed more efficiently by human blood DCs. Increased uptake 
was dependent on upregulation of ecto-CRT on tumor cell surface, as demonstrated 
by complete abrogation of phagocytosis upon CRT blockade. Following uptake 
of platinum-treated tumor cells, all tested DC subsets underwent phenotypical 
maturation, however CD1c+ DCs showed to be the most efficient blood DC subtype 
in promoting T cell proliferation in the context of ICD (Chapter 2 of this thesis). 
Based on these observations, we aimed at exploring the effect of blocking 
the inhibitory “don’t eat me” signal CD47, while enhancing the expression of the 
activating “eat me” signal ecto-CRT, on tumor cells. Thus, we investigated whether 
changes in the balance between “eat me” and “don’t eat me” signals would affect 
phenotype and function of naturally occurring blood CD1c+ DCs. We report that, 
functional blockade of CD47, with the monoclonal antibody B6H12 on live tumor 
cells, was able to promote melanoma cell engulfment by CD1c+ DCs. Additionally, we 
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show that CD47 blockade has the potential to revert tumor-mediated suppression 
of DC maturation. Similar effects were observed when CD1c+ DCs were co-cultured 
with platinum-treated tumor cells, known to express high levels of ecto-CRT. Finally, 
combination of CD47 blockade with platinum treatment displayed a synergistic 
effect on DC-mediated tumor cell uptake and upregulation of the maturation 
marker, CD86 on CD1c+ DCs. Taken together, our findings suggest that blocking 
CD47 in the context of chemotherapy-induced ICD might potentiate activation of 
CD1c+ DCs and eventually result in a stronger stimulation of anti-tumor immunity.
Materials & Methods 
Cell culture, transduction and stable cell line
Human melanoma cells, BLM and BLM-GFP, were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM, Gibco), supplemented with 5% fetal calf serum and 5% 
CO2 humidified air at 37°C. The Lenti6/Block-iT-shScramble (GFP) vector was a kind 
gift of Prof. Peter Friedl (RIMLS, The Netherlands). The sequence of this construct 
does not match any known mammalian genes. BLM cells were infected with lentiviral 
vector and (10µg/ml) polybrene and incubated at 37°C, 5% CO2, overnight. Then 
medium was refreshed and cells were analyzed after 72h of treatment. Stable cell 
line was selected with 5µg/ml blasticidin.
Isolation of human blood immune cells and generation of moMfs and moDCs
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats 
obtained from healthy volunteers (Sanquin) and purified via centrifugation over 
a ficoll density gradient (Axis-Shield) in SepMate tubes (Stemcell technologies). 
Isolation of human blood DC subsets was achieved by a sequence of negative and 
positive selection steps using magnetic beads (Human CD1c+ (BDCA-1) Dendritic 
Cell Isolation Kit, Miltenyi Biotec). DC purity was assessed by staining with 
primary labeled antibodies: anti-CD1c-PE (Miltenyi biotec, clone AD5-8E7), anti-
CD11c-APC (Miltenyi biotec, clone MJ4-27G12) and anti-CD20-APC (eBioscience, 
clone 2H7). Purity levels higher than 98% were achieved, determined by flow 
cytometry. Monocyte-derived macrophages (moMFs) and monocyte-derived 
DCs (moDCs) were obtained as follow. Monocytes were isolated by adherent 
selection of PBMCs and cultured in RPMI 10% FCS, supplemented with GM-CSF 
and IL-4 (moDCs) or GM-CFS (moMfs) for 5 days. Peripheral blood leukocytes 
(PBLs) were isolated from PBMCs by depletion of monocytes via adherence to 
plastic culture flasks (1 hour at 37°C). Floating cells (PBLs) were collected and 
resuspended in X-VIVO-15 medium (Lonza) supplemented with 2% human serum 
(HS, Sanquin).
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Co-cultures and uptake assays 
Tumor cells were stained with 2 µM of the fluorescent dye 5(6)-Carboxyfluorescein 
diacetate N-succinimidyl ester (CFSE, Invitrogen, Thermo Fisher Scientific), 
according to manufacturer’s instructions. Tumor cells and APCs (blood CD1c+ DCs, 
moMfs or moDCs) were co-cultured at either 1:1 or 1:4 ratio in Falcon tubes (BD 
Falcon) in X-VIVO-15 supplemented with 2% HS (final concentration 1x106 cells/ml). 
Co-cultures were stained with an APC-labelled anti-CD11c antibody and analyzed 
by flow cytometry. Extent of phagocytosis was determined as the percentage 
of double positive events (i.e. CD11c+-APC/GFP+ or CD11c+-APC/CFSE+). For 
blocking experiments, tumor cells were pre-incubated (30min at 4°C) with blocking 
agents or negative controls: anti-CD47 blocking (B6H12) and non-blocking (2D3) 
antibodies, 20 µg/mL, both eBioscience) or IgG1,k (20 µg/mL, Biolegend). Extra 
volume of blocking agents or matched controls were added to co-cultures at same 
final concentration. 
Flow cytometry 
Phenotypical assessment of DC maturation after co-culture with tumor cells 
was performed by flow cytometry. Briefly, cells were washed in PBA, incubated 
with Fc-receptor blocking buffer (2% HS in PBS, 15min at 4°C) and subsequently 
stained with primary antibodies in PBA (30min at 4°C). Monoclonal directly labeled 
anti-human antibodies used were: anti-CD11c-APC (Miltenyi biotec), anti-CD80-
PECy7 (BD Pharmingen), anti-CD86-APC (BD Pharmingen), anti-MHC I-PE (BD 
Pharmingen) and anti-MHC II-APC (BD Pharmingen). Appropriate isotype controls 
were included.  
For detection of surface expression of CD47 on human melanoma cells and 
SIRP-α on CD1c+ DCs, moMfs and moDCs, cells were stained with an anti-CD47 
antibody (B6H12, eBioscience) and an anti-CD172a (Biolegend), respectively, as 
described above. Following incubation with primary antibodies and extensive wash, 
cells were incubated with Goat-anti-mouse Alexa488 or Goat-anti-mouse Alexa674 
secondary antibodies. 
DC sorting and Mixed lymphocyte reaction (MLR) 
Tumor-DC co-cultures were established as described above. After wash in cold 
wash buffer (PBS/0.1% BSA/5mM EDTA) and incubation in Fc-receptor blocking 
buffer (2% HS in wash buffer, 15min at 4°C), cells were stained with sterile primary 
antibodies in wash buffer (20min at 4°C). The following antibodies were used: 
anti-MHC II-PECy7 (BD Biosciences, clone L243), anti-CD1c-PE (Miltenyi biotec, 
clone AD5-8E7). Sorting of DCs was performed using a Fluorescence Activated 
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Cell Sorter Aria (FACSAria, BD Bioscience), based on FSC/SSC properties 
and positivity for DC markers. Allogeneic PBLs were stained with 5 µM CFSE 
(Invitrogen), according to manufacturer’s instructions and added to the sorted DCs 
at a ratio of 5:1 (Lymphocytes:DCs), for an additional period of 5 days, in 2% HS 
X-VIVO-15. After 5 days, co-cultures were stained with a primary anti-CD3-BV421 
antibody (BD Horizon, clone SK7) and analyzed by flow cytometry. The percentage 
of proliferating T cells (CD3+) was determined by assessing CFSE dilution in the 
fraction of CD3+ cells.
Cytokine quantification 
Supernatants from tumor cell-DC co-cultures (18 hours) were collected, dying/
floating cells were removed by centrifugation and supernatants frozen immediately 
for detection of secreted cytokines. Human cytokines were quantified with a 
multiplex FlowCytomix kit (eBioscience, BMS810FF) according to the manufacturer’s 
instructions.
Platinum treatment of tumor cells 
Fluorescently–labelled (CFSE or GFP) tumor cells were seeded in T75 flasks 
(Corning), adhered and treated with oxaliplatin (OXP) or cisplatin (cis-
diamminedichloroplatinum(II), CDDP) (both Accord). 
Confocal microscopy 
CFSE-labelled BLM cells were co-cultured with PKH26-labelled CD1c+DCs as 
described above, in the presence of IgG or blocking anti-CD47 (B6H12) antibody, 
at a final concentration of 20µg/ml. After 2h of incubation, DC-BLM cultures 
were let adhere on poly-L-lysine coated glass slides for 1h, carefully washed 
and fixed with 4% paraformaldehyde (PBS) in PBS. Uptake of CFSE-BLM-derived 
particles by CD1c+ DCs was analyzed with a Laser Scanning Confocal microscope 
(Olympus). A total of 6 images per sample were taken and the number of DCs 
engulfing tumor-fragments was normalized over the number of DCs present in 
the image. 
Statistical analysis 
Unless otherwise indicated, experiments were performed at least three times, 
yielding comparable results. Data were analyzed using Prism v. 5.03 (GraphPad 
Software). Statistical significance was assessed by paired t-test. P-values <0.05 were 
considered as statistically significant. 
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Results 
Melanoma cells suppress maturation and activation of CD1c+ DCs 
Tumor cells can affect DC maturation and function, both via secretion of inhibitory 
soluble factors and via contact-dependent mechanisms9,17,24,30,31. The majority of 
the studies that investigated tumor-mediated DC suppression have utilized either 
murine DCs or human in vitro-differentiated monocytes-derived DCs (moDCs). 
These models have some limitations as they lack many characteristics of human 
DCs found in vivo25. Therefore, we aimed to investigate the influence of human 
melanoma cells on phenotype and function of human CD1c+ DCs, in vitro. We co-
cultured freshly-isolated CD1c+ DCs with melanoma BLM cancer cells, at different 
DC-to-tumor cell ratios (1:1 and 1:4) for 48 hours, and measured the extent of 
DC maturation by flow cytometry (Fig 1a). The co-culture with melanoma cells 
caused a drastic down-regulation of co-stimulatory (CD80, CD86) and major 
histocompatibility complex class I and II (MHC-I, MHC-II) molecules on CD1c+ DCs. 
This marked inhibitory effect of tumor cells on DC maturation was observed already 
at the lowest DC-to-tumor cell ratio (1:1) tested, suggesting a high suppressive 
potency of BLM cells (Fig 1a). 
Next, we evaluated the effect of co-culture with BLM cells on pro- and anti-
inflammatory cytokine secretion by CD1c+ DCs, represented by the secretion 
of TNF-α and IL-10 respectively (Fig 1b). Consistent with the inhibition of DC 
maturation, melanoma cells suppressed the production of the pro-inflammatory 
cytokine TNF-α and induced a minor but significant increase in IL-10 secretion. 
Furthermore, we could not detect any IL-2, IL-4, IL-5, IL-12, TNF-β and IFN-γ (data 
not shown). Because an altered activation status of DCs is often responsible for 
impaired T cell stimulatory activity, we tested whether CD1c+ DCs co-cultured 
alone or with BLM melanoma cells, had different capacity to induce T cell 
proliferation. Proliferation of CD3+ T cells was quantified by measuring CFSE 
dilution in a mixed lymphocyte reaction (MLR) (Fig 1c). As expected, interaction 
between melanoma cells and DCs markedly suppressed the capacity of CD1c+ DCs 
to induce allogeneic T cell activation. Collectively, these data demonstrate that 
melanoma cells are capable of altering DC activation status and restrain functional 
ability of CD1c+ DCs. 
CD47 blockade enhances uptake of live tumor cells by CD1c+ DCs and 
restores DC maturation 
Overexpression of CD47 by tumor cells has been suggested as a possible mechanism 
of immune evasion in general and impaired DC function in particular10,11,23. We 
wondered whether this mechanism might be involved in the immunosuppressive 
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effect we observed in our BLM melanoma - CD1c+ DCs co-cultures. We started by 
screening several human melanoma cell lines for their CD47 surface expression, 
using flow cytometry analysis. All melanoma cell lines tested expressed high levels 
of CD47 (Fig 2a). BLM cells had the highest CD47 expression and were used in 
subsequent experiments. 
CD47 was reported to exert its inhibitory effects by engaging SIRPα on APCs27. 
We measured surface expression of SIRPα on CD1c+ DCs, as well as on in vitro 
monocyte-derived macrophages (moMfs) and moDCs (Fig 2b). 
If CD47-SIRPα interaction is one of the immune-evasive mechanisms responsible 
for the inhibition of DC activation, we hypothesized that addition of a blocking 
antibody would, at least partially, rescue DC immunosuppression. We therefore 
established co-cultures of BLM melanoma cells and CD1c+ DCs, in the presence 
of a CD47 blocking mAb (B6H12) or isotype IgG1,k control (Fig 3). We tested the 
Figure 2. Expression of CD47 and SIRPα. (A) Representative histograms showing surface expres-
sion of CD47 on different human melanoma cell lines (KO-Mel, SK-Mel, BLM, MeWO, Mel603 and 
Mel624). (B) Representative histograms showing surface expression of SIRPα on blood CD1c+ DCs, 
moMfs and moDCs). Isotypes (grey filled histogram), anti-CD47 or anti-SIRPα antibody (black line). 
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effect of CD47 blockade on the capacity of human APCs to engulf CFSE–labeled 
BLM-derived fragments. The positive effect of CD47 blockade has been previously 
described for macrophages and in vitro differentiated DCs13,31,32, human moMfs or 
moDCs were included as additional controls (Fig 3a). We confirmed that moMfs 
have the highest ability to take up CFSE+-tumor fragments at baseline (in the 
presence of control antibody IgG1,k, which does not block CD47-SIRPα interaction). 
Lower phagocytosis rate than moMfs was observed for CD1c+ DCs and moDCs, 
which were equally potent phagocytes at baseline. Interestingly, CD47 blockade 
with the B6H12 mAb, led to a higher increase in CD1c+ DC mediated uptake of 
CFSE+-tumor fragments, indicating that these naturally circulating blood DCs had 
captured BLM-derived particles with more efficiency (Fig 3a), when compared 
to moDCs and moMfs. Increased engulfment of CFSE+ BLM-derived fragments 
by CD1c+ DCs, upon blocking of CD47, was confirmed by confocal microscopy 
(Fig 3b). To further verify that CD47-SIRPα interaction negatively regulates CD1c+ 
DCs function, we used an additional mAb (2D3) directed against CD47, but which 
is known not to block CD47-SIRPα interaction, and measured tumor cell uptake and 
DC maturation by flow cytometry (Fig 3c,d).  As shown in Fig 3c and 3d, disruption 
of CD47-SIRPα interaction counteracted the inhibitory pathway regulated by SIRPα 
and resulted in significantly higher uptake and increased surface expression of 
the co-stimulatory molecule CD86, as compared to isotype IgG1,k control or 
non-blocking 2D3 antibody. Notably, the expression level of CD86 upon CD47 
blockade was almost as high as the expression measured on DC cultured alone, 
thus not exposed to the immunosuppressive effect of BLM cells (Fig 3d). Although 
less prominent, the beneficial effect of CD47 blockade was also observed for 
MHC-II (Fig 3d).
Altogether, our findings demonstrate that functional blocking of CD47 on tumor 
cells increased their engulfment by human CD1c+ blood DCs. This was accompanied 
by high expression of DC maturation markers, supporting the observation that 
disruption of CD47-SIRPα interaction counteracts the immunosuppression induced 
by melanoma cells. 
Platinum treatment rescues DC maturation and function
We previously reported that tumor cell death induced by treatment with the 
platinum chemotherapeutics, oxaliplatin and cisplatin, was characterized by the 
surface upregulation of CRT molecule on BLM cells, as well as the release of 
the inflammatory mediators, HSPs, ATP and HMGB1. Moreover, we showed that 
enhanced interaction of platinum-treated BLM melanoma cells and CD1c+ DCs, 
and subsequent engulfment of tumor fragments, were dependent on ecto-CRT 
expression. In turn, platinum-mediated ICD of BLM cells, induced upregulation of 
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Figure 3. CD47 blockade enhances uptake of live tumor cells by CD1c+ DCs and restores DC mat-
uration. CFSE-labeled BLM cells and different APCs were co-cultured for 2 hours in the presence 
of isotype control (IgG1,k) or anti-CD47 (B6H12) blocking antibody (final concentration 20µg/ml). 
(A) Representative dot plot of live BLM cells uptake by CD1c+ DCs, moMFs and moDCs upon 
functional blocking of CD47 on tumor cells. Percentage of phagocytosis was assessed by flow 
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co-stimulatory molecules and functional activation of blood CD1c+ DCs (Chapter 2 of 
this thesis). Given the ability of OXP and CDDP to induce ICD, we hypothesized that 
co-culture of DCs with platinum-treated BLM cells might shift the balance between 
‘eat me’ and ‘don’t eat me’ signals and thus reverting the immunosuppressive 
effects induced by the interaction with live tumor cells. We pre-treated BLM cells 
with clinical relevant concentrations of OXP or CDDP for 48 hours. We aimed at 
investigating the sole role of platinum treatment on tumor cells, excluding any direct 
effect of the chemotherapeutics on DCs. To this purpose, we removed any excess 
of drugs by extensive washing and fed untreated, OXP- or CDDP-treated BLM cells 
to blood CD1c+ DCs for 48 hours (Fig 4). Platinum treatment induced upregulation 
of ecto-CRT on BLM cells (Fig 4a) and enhanced tumor-fragment uptake by blood 
CD1c+ DCs (not shown). We then analyzed the surface expression of co-stimulatory 
(CD80, CD86) and major histocompatibility complex class I and II (MHC-I, MHC-II) 
molecules on blood CD1c+ DCs (Fig 4b). As shown in Fig 1a, live tumor cells had 
a dramatic effect on the activation status of DCs. However, induction of ICD by 
platinum treatment reversed this suppression, with a notable effect at the level 
of co-stimulation (CD80 and CD86) (Fig 4b). The effect of platinum-treatment 
observed for MHC-I and MHC-II was less strong, yet it indicates that interfering 
with the activation of tumor-mediated immunoevasive mechanisms has beneficial 
consequences on DC maturation. 
Furthermore, we checked how platinum treatment affected DC-mediated T cell 
proliferation (Fig 4c). We established blood CD1c+ DCs-allogeneic CD3+ T cells 
co-cultures and performed an MLR assay, as described in Fig 1c. Blood CD1c+ DCs 
were pre-cultured with untreated or platinum-treated BLM cells, or alone in culture 
medium, for 48 hours, prior addition to CD3+ T cells. Treatment of melanoma cells 
with either OXP or CDDP, restored DC-mediated T cell proliferation, counteracting 
the inhibition caused by live tumor cell-DC interaction. 
cytometry. (B) Representative confocal image (magnification 40X). Arrowheads indicate uptake 
of CFSE-BLM-derived particles by CD1c+ DCs (pre-labeled with PKH26). A total of 6 images per 
sample were taken and the number of DCs engulfing tumor-fragments was normalized over the 
number of DCs present in the image. Data represent means of triplicates±SEM of 1 representative 
experiment. (C) Percentage of uptake of BLM-CFSE cells by CD1c+ DCs (2h co-culture), in the 
presence of IgG1,k, non-blocking anti-CD47 (2D3) or blocking anti-CD47 (B6H12) mAbs. Final con-
centration 20µg/ml. The graph shows the means±SEM (n≥2 triplicate samples). (D) Representative 
histograms showing surface expression of maturation markers, CD86 and MHC-II on CD1c+ DCs 
co-cultured with BLM cells for 24h.. Isotype (light grey filled histogram), IgG1,k (red), anti-CD47 
(2D3, green), anti-CD47 (B6H12, purple), DCs alone (black). Significance was determined with 
paired t-test.*P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 4. Platinum treatment rescues DC maturation and function. (A) Representative 
histogram showing surface expression of ecto-CRT on BLM cells treated with OXP or CDDP for 
48h. Isotype (light grey filled histogram), untreated (CTRL, black), OXP (green), CDDP (red). (B) 
Expression of maturation markers on CD1c+ DCs following 48h of co-culture with untreated or 
platinum-treated BLM cells. Expression levels were determined by flow cytometry and depicted 
as GeoMFI values, relative to DCs cultured in medium. The graphs show mean±SEM (n=5). 
(C) Mixed lymphocyte reaction to determine T cell proliferation induced by CD1c+ DCs upon 
co-culture with (un)treated tumor cells. FACS sorted DCs were co-cultured with allogeneic 
CFSE-labeled pheripheral blood lymphocytes (PBLs) for 5 days. Percentage of proliferated CD3+ 
T cells, relative to those cultured in medium alone. Data are means±SEM of at least triplicates 
of n=3. Significance was determined with paired t-test.*P < 0.05, **P < 0.01, ***P < 0.001, as 
compared to DCs cultured in medium.
Potential cooperation of CD47 blockade and platinum treatment 
We showed that tumor-mediated immunosuppression could be subverted either 
by blocking of CD47 on live BLM cells or upregulating ‘eat me’ signals like ecto-
CRT by inducing immunogenic tumor cell death. We therefore hypothesized 
that combination of these two therapeutic approaches might cooperate and 
potentiate their beneficial effects on DC stimulation. Firstly, we checked whether 
platinum treatment could influence CD47 expression on melanoma cells. BLM 
cells were treated with 15µM OXP or CDDP for 24 hours and surface CD47 
expression was analysed by flow cytometry. Surprisingly, we observed that 
OXP and CDDP were equally capable to upregulate CD47 expression on tumor 
cells (Fig 5a). We previously reported that CDDP was more potent than OXP 
in triggering uptake of BLM cells. Here, we compared the ability of CD1c+ DCs 
to engulf live (CTRL) or CDDP-treated BLM cells in the presence of a blocking 
anti-CD47 (B6H12) mAb or isotype control, in vitro (Fig 5b). We confirmed 
that CDDP-treated BLM cells were taken up more efficiently by CD1c+ DCs 
when CD47 was not functionally blocked, as compared to CTRL cells. Similarly, 
CD47 blockade facilitated phagocytosis of live BLM cells, in comparison to 
IgG1,k. Interestingly, CD47 blockade in combination with CDDP treatment 
strengthened, albeit not dramatically, tumor cell engulfment by CD1c+ DCs, as 
compared to either therapy alone (Fig 5b). Moreover, flow cytometry analysis 
of DC maturation showed that, functional blockade of CD47 in combination 
with chemotherapy markedly increased the expression of the co-stimulatory 
molecule CD86 (Fig 5c).
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Figure 5. Potential synergistic effects of 
CD47 blockade and platinum treatment. (A) 
Representative histogram showing surface 
expression of CD47 on BLM cells treated 
with OXP or CDDP for 24h. Isotype (light grey 
filled histogram), untreated (CTRL, black), OXP 
(green), CDDP (red). (B) Relative uptake of 
BLM-GFP cells by CD1c+ DCs (48h co-culture), 
in the presence of IgG1,k or blocking anti-CD47 
(B6H12) mAbs. Final concentration 20µg/
ml. The graph shows the means±SEM (n=2 
duplicate samples). (C) Expression of CD86 on 
CD1c+ DCs in co-culture with untreated or plat-
inum-treated BLM cells. Expression levels were 
determined by flow cytometry and depicted as 
GeoMFI values, relative to DCs cultured with 
untreated (CTRL) BLM cells in the presence 
of IgG1,k. One representative experiment 
is shown. Significance was determined with 
paired t-test.*P < 0.05, **P < 0.01, ***P < 0.001.
Discussion 
Dendritic cells play a key role in the regulation of the immune system5 The nature of 
signals delivered by DCs, upon encounter with (tumor) antigens, determines the fate 
of the immune response. Molecular mechanisms responsible for initiating immune 
reactions or inducing tolerance are tightly interconnected and may be considered 
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two sides of the same coin4,5,28. Tumor cells have developed several mechanisms 
to evade immunosurveillance, including taking advantage of regulatory signalling 
pathways, to evade phagocytosis and possibly halt initiation of anti-tumor responses3. 
Here, we investigated the interaction between melanoma cells and human CD1c+ 
DCs naturally circulating in the blood. We observed that, co-culture with live tumor 
cells affected expression of co-stimulatory molecules and function of CD1c+ DCs. 
Phenotypical and functional changes on DCs resulted in diminished capacity to 
drive T cell proliferation. Our observations are in accordance with other studies 
performed on human in vitro-generated moDCs or murine DCs9,23,24,31. Co-culture 
of moDCs with primary cells or tumor cell lines caused an immature phenotype in 
DCs, stimulated IL-10 production and inhibited TNF-α secretion, eventually causing 
T cell unresponsiveness23,31. Similarly, maturation and activation of murine splenic 
DCs were impaired by culture with melanoma cells24. 
A putative mechanism responsible for tumor-mediated DC suppression relies on 
the interaction between CD47 on live tumor cells and SIRPα on DCs12. Engagement 
of SIRPα by CD47 was suggested to activate two distinct downstream signaling 
pathways. CD47-SIRPα can signal through the ITIM-SHP-1 complex that transmit 
an anti-phagocytic signal; in addition, it can also trigger STAT3 phosphorylation 
that is linked to an immature APC phenotype and secretion of IL-1023,33. The dual 
role of CD47-SIRPα interaction is mediated by two adjacent but distinct binding 
regions for CD47 on SIRPα34. Whether the boosting of tumor fragments uptake 
by CD47 blocking mAb (B6H12), interferes with the activation of only one or both 
SIRPα-downstream mechanisms remains unclear23. In our study, we confirmed that 
engagement of CD47 by the B6H12 mAb, but not by a matched isotype control or 
the non-blocking anti-CD47 (2D3) mAb, restored engulfment of tumor cell fragments 
by different human APCs, such as moMfs, moDCs and naturally-occurring blood 
CD1c+ DCs. Moreover, only functional disruption of the CD47-SIRPα interaction using 
the B6H12 mAb, reversed tumor-mediated inhibition of CD1c+ DCs maturation. 
Activation of the STAT3 signalling pathway is known to be involved in regulation of 
CD86 and MHC-II expression33. Tumor-mediated CD86 down-regulation was fully 
rescued by the addition in co-culture of the blocking B6H12 mAb. Upregulation of 
MHC class II molecule was also enhanced, albeit to a lesser extent. This difference 
might be dependent on the kinetics of expression of the two maturation markers 
and analysis of DC phenotype at a later time point would help clarifying this point. 
CD47 is a marker of self for all hematopoietic cells. Therefore, it is not surprising that, 
human APCs co-express SIRPα and CD4710,35. In our co-culture experiments, melanoma 
cells were pre-incubated with CD47 blocking mAb. After CD47 blocking, melanoma cells 
were fed to CD1c+ DCs, and extra volume of anti-CD47 mAbs or isotype controls were 
added to tumor-DC co-cultures, at the same final concentration. Binding of mAbs to 
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specific cellular receptors is a dynamic process. Thus, it is likely that CD47 on DCs could 
compete with CD47 on tumor cells for the binding of anti-CD47 unbound molecules. 
Engagement of CD47 on human moDCs, by blocking mAb or CD47-FC fusion protein, 
was reported to negatively regulate moDC maturation and IL-12 production12,35. For 
this reason, we can suggest that knockdown of CD47 on tumor cells or SIRPα on DCs, 
would further support the hypothesis that CD47-SIRPα interaction is one of the crucial 
mechanisms regulating tumor-mediated suppression of CD1c+ DCs.
Phagocytosis relies on the balance between anti-phagocytic (“don’t eat me”) 
and pro-phagocytic (“eat me”) signals on target cells. The inhibitory action of CD47 
is counterbalanced by ecto-CRT, translocated to the surface of tumor cells upon ER 
stress. We recently reported that platinum-treatment upregulated ecto-CRT on the 
surface of melanoma cells and enhanced tumor-cell uptake by blood CD1c+ mDCs. 
Moreover, interaction with platinum-treated tumor cells induced CD1c+ DCs activation 
and T cell proliferation. Here we show that, in a similar way to CD47 blockade, 
platinum-treatment rescued tumor-mediated suppression of DC maturation, which 
in turn restored induction of CD3+ T cells by DCs proliferation. Although crucial to 
facilitate cellular uptake by phagocytes, ecto-CRT alone is not sufficient to stimulate 
DC maturation and function36. Additional activating signals expressed on or released 
by tumor cells are required to strengthen DC stimulation. In our previous report, we 
showed that both OXP and CDDP led to upregulation of HSPs, as well as passive 
release of ATP and secretion of HMGB1REF. We believe that induction of ICD is likely 
to be strong enough to overcome the suppressive mechanisms employed by tumor 
cells, thus explaining the beneficial effect of platinum treatment observed.
In contrast to the favourable impact of CD47 blockade or chemotherapy alone 
on DC-mediated phagocytosis, we showed that addition of the blocking (B6H12) 
anti-CD47 mAb, to co-culture of DCs with platinum-treated BLM cells, did not 
potentiate the chemotherapic effect on BLM uptake by CD1c+ DCs. We postulate 
that increased expression of ecto-CRT on dying tumor cells dominates over the 
blockade of CD47. Consequently, combination of the two therapeutic approaches 
did not lead to increased uptake. We observed a higher expression of CD47 on cells 
treated with platinum drugs; however, this effect alone does not indicate whether 
CD47 is still able to engage SIRPα. On live cells, in fact, CD47 is evenly distributed, 
whereas it clusters into patches on apoptotic cells37-39. Clustering per se does not 
seem to affect binding to SIRPα, but it is proposed that CD47 loses its ability to 
activate SIRPα, thereby preventing uptake of apoptotic cells38. The mechanisms 
governing redistribution and functional inactivation have not been elucidated yet.
Studies performed on xenograft mouse models of hepatocellular carcinoma 
or leukemia, suggested that combination of CD47 blockade and treatment with 
chemotherapeutic drugs (sorafenib, doxorubicin or cytarabine), might exert synergistic 
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effects on suppression of tumor growth, as compared to either therapies alone40,41,42. 
When designing combination therapies, sequence and doses of both anti-CD47 and 
chemotherapeutics have to be carefully determined, in order to prevent undesired 
effects on the immune response. Researchers showed that in vivo administration 
of chemotherapy, following anti-CD47 blockade had deleterious effect on the host 
immune response to the tumor. In contrast, when chemotherapy treatment was given 
prior to anti-CD47 mAbs, this preserved host memory response against relapsing 
tumors43. These observations seem to be in line with our results, showing a marked 
upregulation of CD86 on the surface of blood CD1c+ DCs upon interaction with BLM 
cells pre-treated with platinum drugs, in addition to functional blocking of CD47.
Altogether, we report that interaction with tumor cells transmits a negative signal 
to naturally circulating human blood CD1c+ DCs that have impaired ability to establish 
adaptive responses. Evidence suggests that SIRPα-engagement by CD47 might be 
responsible for the immunosuppressive effect observed10,13,23. In addition we show 
that shifting the balance between inhibitory “don’t eat me” and activating “eat me” 
signals via CD47 blockade, either alone or in combination with chemotherapy, has 
the potential to revert tumor-mediated immunosuppression. This might contribute 
to enhance the immunogenicity of melanoma cells and promote activation of CD1c+ 
DCs, in favour of the induction of a robust anti-tumor immune response. 
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Abstract 
Melanoma is the most aggressive form of skin cancer. Due to the ability to build a 
microenvironment that supports tumor progression, melanoma cells are capable of 
evading the immune system. Pre-clinical mouse models and conventional in vitro 
two-dimensional (2D) studies have shed light on important aspects of melanoma 
immunobiology. However, standard cultures fail to capture the complexity of the 
real tissue architecture. Besides, given the ethical concerns and the questionable 
translational character of murine models to human biology, a more physiologically 
relevant model, that closely resembles the in vivo features of human melanoma, 
is required. Here, we present a novel human three-dimensional (3D) immuno-
competent engineered skin model of melanoma.  This model is based on the 
co-culture of different cell types using a deepidermized acellular dermis (DED) as 
an extracellular matrix scaffold. In order to reconstitute the skin melanoma tissue 
microenvironment, primary keratinocytes are co-seeded with melanoma cells onto 
the DED. Keratinocytes differentiate into a fully developed epidermis and tumor 
cells emulate melanoma invasion in the underneath dermal compartment. Primary 
fibroblasts and CD1c+ dendritic cells were incorporated into the acellular dermis 
to expand the organotypic model into a functional melanoma microenvironment. 
The repopulated DED provides an adequate support that guarantees cell survival, 
migration and function of all cell types. Histological analysis demonstrated that 
the reconstructed microenvironment displays morphological features of primary 
melanoma and showed the correct spatial cell distribution. Two-photon imaging 
revealed that the dendritic cells are able to actively migrate, interact with tumor cells 
and sample tumor-derived microparticles. These results highlight the applicability of 
our 3D reconstructed human melanoma microenvironment to explore the interplay 
between malignant, non-malignant cells and the immune system. We propose 
that our 3D melanoma skin model has the potential to provide a unique tool for 
generating “living” skin melanoma tissue, and may play an instrumental role in the 
identification of new therapeutic targets for immunotherapy.
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Introduction
Progressive tumor growth and development of metastases are dynamic processes, 
which rely upon the establishment of complex interactions between malignant 
cancer cells and the non-transformed host cells of the tumor microenvironment 1, 2. 
Communication of malignant cells with the normal tissue cellular and extracellular 
components plays a critical role in determining the fate of tumor progression and 
activation of an effective antitumor immunity 1. Accordingly, pre-clinical and clinical 
observations demonstrated that  cancer cells foster a ‘tolerizing’ microenvironment, 
characterized by chronic inflammation, recruitment and infiltration of immune 
cells, and the activation of a plethora of immunosuppressive mechanisms 1. These 
mechanisms not only impede effective anti-tumor immunity, but also are responsible 
for tumor resistance to chemo- and immunotherapy 3. 
Melanoma is amongst the most lethal types of tumor of the skin 4. This form of 
skin cancer is caused by the malignant transformation of melanocytes, the epidermal 
cells responsible for the production of melanin pigment 4. Although in the past 
decades we have seen a remarkable progress in the understanding of melanoma 
immunobiology, knowledge on the intricate network of mechanisms that regulate 
tumor-mediated immunosuppression is still lacking 3. 
Most of the studies that aimed at dissecting melanoma-host immune cell 
interactions were performed using in vitro two-dimensional (2D) co-culture of 
cells in monolayers. These studies provided insights into many aspects of the 
mechanisms regulating the fate of immune response to the tumor, however the 2D 
nature of these models ignores the relevant structural and functional complexity 
of in vivo tissues 5. In fact, monolayer systems are limited by the lack of a large 
number of contacts between cell types and by the absence of a physiologically 
relevant extracellular matrix (ECM), which affects cell function and response to 
microenvironmental stimuli  6. Thus, conventional studies are hampered by the 
difficulties in culturing cells in 2D and extrapolating these findings to the three-
dimensional tumor microenvironment (3D TME). 
To identify determinants of melanoma progression in a more physiologically 
relevant system, researchers have relied on mouse models. However, there are 
considerable obstacles that complicate the use of these in vivo models for melanoma 
research 7. Besides the ethical issue of using animals for the investigation of tumor 
biology, both the histological and immunological differences between rodent and 
human skin often challenge the interpretation of data obtained by in vivo studies 7. 
Therefore, in vitro systems that provide organizational complexity that is between 
the 2D (co-)culture of cells and organ cultures in vivo have attracted considerable 
attention in the research field 8, 9. 
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In vitro tissue-engineered skin models or human skin equivalents (HSEs) 
are informative and manipulable systems, which can bring together melanoma 
cells with other relevant cells of the tissue microenvironment, in a context that 
recapitulates the characteristics of human skin cancer lesions 10.  In these models, 
human epidermal cells and melanoma cell lines, with different invasive capacities, 
are seeded onto fibroblasts-enriched, animal-derived collagen matrices 11-13. Others 
have developed organotypic models based on acellular, de-epidermized human 
dermis (DED) or self-assembled living sheets made with human fibroblasts secreting 
their own ECM, to obtain a model that more closely resembles the multifaceted 
skin tissue14-17. Despite the substantial contribution in the field, currently available 
melanoma skin equivalents are lacking in one important aspect: the immune 
compartment 18. Melanoma is considered one of the most immunogenic cancer 
types. Thus, any model intending to investigate melanoma progression in the 
context of the tumor microenvironment should also consider the involvement of 
the immune system. 
We have successfully adapted an existing in vitro 3D model of melanoma17, 
which lacked stromal and immune components, into an immunocompetent 
tissue-engineered melanoma skin equivalent. This model is build from primary 
human keratinocytes and immortalized human melanoma cells seeded onto a de-
epidermized human dermis (DED). Primary human dermal fibroblasts and immune 
cells, such as CD1c+ dendritic cells (DCs), were incorporated into the acellular 
dermal compartment. Histological analysis of tissue sections showed the correct 
spatial distribution of the cells within the reconstructed tissue microenvironment, 
demonstrating that melanoma model closely recapitulates tumor growth as 
observed in human lesions. Live imaging with two-photon microscopy revealed 
that the reconstructed environment supports cell survival, migration and function 
of both malignant and immune cells of the TME. 
We here present, for the first time to our knowledge, a novel human 
immunocompetent 3D melanoma engineered skin tissue that has the potential 
to provide a unique tool for generating “living” skin melanoma tissue, for the 
investigation of cellular interplays within the TME. Unraveling these complex intra- 
and intercellular communications may ultimately pave the way to the identification 
of new therapeutic targets for immunotherapy. 
Materials & Methods 
Cell culture, transduction and stable cell line development 
Human melanoma cells, BLM and BLM-GFP, were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM, Gibco), supplemented with 5% fetal calf serum and 5% 
108
A
 n
o
v
e
l 3D
 h
u
m
A
n
 m
e
lA
n
o
m
A
 sk
in
 m
o
D
e
l
4
CO2 humidified air at 37°C. The Lenti6/Block-iT-shScramble (GFP) vector was a kind 
gift of Prof. Peter Friedl (RIMLS, The Netherlands). The sequence of this construct 
does not match any known mammalian genes. BLM cells were infected with lentiviral 
vector and (10µg/ml) polybrene and incubated at 37°C, 5% CO2, overnight. Then 
medium was refreshed and cells were analyzed after 72h of treatment. A stable cell 
line was selected with 5µg/ml blasticidin.
Isolation of cellular and extracellular matrix human skin components 
Generation of de-epidermized dermis (DED) and isolation of human primary 
keratinocytes from human abdominal skin, derived from donors who underwent 
surgery for abdominal wall correction, was performed as previously described 19. 
Briefly, human skin was incubated for five to ten minutes in phosphate-buffered 
saline (PBS) at 56°C to allow separation of the epidermis from the dermis. 
DED was obtained by incubating the dermis for one month in PBS containing 
gentamicin (0.5 mg/ml; Life Technologies, Inc.) and antibiotic/antimycotic (Life 
Technologies, Inc.) at 37°C. Continuous cycles of freezing and thawing ensured 
the depletion of all living cells in the dermis. Punches were prepared from this 
DED using a 8-mm biopter and frozen for further use. IHC staining of heparan 
sulfate and collagen type IV, two typical basal layer components, demonstrated 
that DED still contained an intact basal membrane 20. Keratinocytes were isolated 
from the epidermal layer by trypsin treatment for 16 to 20 hours at 4°C, and 
then cultured in the presence of irradiated (3295 cGy for 4.10 minutes) mouse 
fibroblasts 3T3 cells. 3T3 cells were seeded at a concentration of 3x104 cells 
per cm2 in Greens medium, which consisted of two parts Dulbecco’s modified 
Eagle’s medium (Life Technologies), one part of Ham’s F12 medium (Life 
Technologies), 10% fetal bovine serum (Hyclone), L-glutamine (4 mmol/L; Life 
Technologies, Inc.), penicillin/streptomycin (50  IU/ml; Life Technologies, Inc.), 
adenine (24.3 μg/ml; Calbiochem, San Diego, CA), insulin (5 μg/ml; Sigma, 
St. Louis, MO), hydrocortisone (0.4 μg/ml; Merck, Darmstadt, Germany), 
triiodothyronine (1.36 ng/ml, Sigma), cholera toxin (10-10 mol/L, Sigma). The 
next day keratinocytes were added at a concentration of 5x104 cells per cm2. 
Keratinocytes-3T3 cells co-cultures were maintained for three days in Greens 
medium. Thereafter, medium was replaced by Greens medium containing 
epidermal growth factor (EGF, 10 ng/ml; Sigma), cells were expanded until 
90% confluence and stored in the liquid nitrogen. Keratinocytes were used 
at passage one or two in the model. Adult human dermal fibroblasts were 
purchased by ATCC and maintained in Fibroblast medium (3:1 DMEM: Ham’s 
F12 Nutrient Mixture, Gibco) supplemented with 10% FCS, and expanded until 
80% confluence. Passages three to nine were used for the experiments.
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Isolation of human blood immune cells Peripheral blood mononuclear cells (PBMCs) 
were isolated from buffy coats obtained from healthy volunteers (Sanquin) and 
purified via centrifugation over a ficoll density gradient (Axis-Shield) in SepMate 
tubes (Stemcell technologies). Isolation of human blood DC subsets was achieved 
by a sequence of negative and positive selection steps using magnetic beads 
(Human CD1c+ (BDCA-1) Dendritic Cell Isolation Kit, Miltenyi Biotec). DC purity was 
assessed by staining with primary labeled antibodies: anti-CD1c-PE (Miltenyi biotec, 
clone AD5-8E7), anti-CD11c-APC (Miltenyi biotec, clone MJ4-27G12) and anti-
CD20-APC (eBioscience, clone 2H7). Purity levels higher than 98% were achieved, 
determined by flow cytometry. Before injection into the dermal compartment of 
the melanoma skin equivalent for microscopy assessment, CD1C+ DCs were labeled 
with the membrane dyes PKH26 or CFSE (2uM, Sigma) according to manufacturers’ 
protocols and resuspended in X-VIVO-15 medium (Lonza) supplemented with 2% 
human serum (HS, Sanquin).
Generation of three-dimensional human skin melanoma model 
Human melanoma skin equivalent was generated as described before with minor 
modifications 17. Briefly, 8mm punch biopsy of decellularized deepidermized 
dermis (DED) was seeded with human primary keratinocytes, dermal fibroblasts 
and myeloid CD1C+ DCs and melanoma cells from the human metastatic BLM 
cell line (Fig 1). Fibroblasts were incorporated in the DED using the centrifugal 
seeding procedure. The DED was placed carefully basal membrane side down 
on a transwell insert in a 24-well plate (24-wells ThinCert, Greiner Bio-One) and 
0.15x106  fibroblasts were seeded onto the reticular side of the DED in Fibroblast 
complete medium. The plate was centrifuged for one hour at 500rpm. After 
centrifugation, DED was maintained in Fibroblast complete medium for three days 
at 37°C, to allow fibroblast distribution and migration into the reticular and papillary 
dermal layers. After three days of culture, the DED was turned basal membrane 
side up in the transwell insert and seeded with different ratios of keratinocytes 
and BLM cells (KC:BLM = 5:1, 10:1, 25:1 and 50:1). The melanoma skin equivalent 
was cultured submerged for three days in PONEC medium containing 5% serum 
(PONEC 5% medium), to allow proliferation of keratinocytes and tumor cells. 
PONEC 5% medium consists of two parts Dulbecco’s modified Eagle’s medium 
(Life Technologies, Inc.), one part of Ham’s F12 medium (Life Technologies, Inc.), 
5% calf serum (Hyclone), L-glutamine (4 mmol/L; Life Technologies, Inc.), penicillin/
streptomycin (50 IU/ml; Life Technologies, Inc.), adenine (24.3 µg/ml; Calbiochem, 
San Diego, CA), insulin (0.2 µmol/l; Sigma, St. Louis, MO), hydrocortisone (1 µmol/l; 
Merck, Darmstadt, Germany), triiodothyronine (1.36 ng/ml, Sigma), cholera toxin 
(10-10 mol/L, Sigma), ascorbic acid (50µg/ml; Sigma). Thereafter, the skin equivalent 
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was shifted to the air-liquid interface and cultured for seven days in PONEC medium 
without serum, supplemented with keratinocyte and epidermal growth factors 
(PONEC 0% medium), during which a fully differentiated epidermal layer is formed. 
PONEC 0% medium consists of two parts Dulbecco’s modified Eagle’s medium 
(Life Technologies, Inc.), one part of Ham’s F12 medium (Life Technologies, Inc.), 
L-glutamine (4 mmol/L; Life Technologies, Inc.), penicillin/streptomycin (50 IU/ml; 
Life Technologies, Inc.), adenine (24.3 µg/ml; Calbiochem, San Diego, CA), L-serine 
(1mg/ml; Sigma), L-carnitine (2 µg/ml, sigma), bovine serum albumin lipid mix 
(palmitic acid 25 µmol/l; arachidonic acid 7 µmol/l; linoleic acid 15µmol/l; vitamin E 
0.4µg/ml; all from Sigma), insulin (0.1 µmol/l; Sigma, St. Louis, MO), hydrocortisone 
(1 µmol/l; Merck, Darmstadt, Germany), triiodothyronine (1.36 ng/ml, Sigma), cholera 
toxin (10-10 mol/L, Sigma), ascorbic acid (50 µg/ml; Sigma), keratinocyte growth factor 
(5 ng/ml, Sigma), epidermal growth factor (2 ng/ml, Sigma). After culturing the 
skin equivalent air-exposed for seven days, 0,1x106 PKH26-labeled CD1C+ DCs were 
microinjected into the dermis using glass microneedles. Glass microneedles were 
prepared by pulling 1mm OD glass capillaries (World precision instruments, Inc.) 
with a vertical needle pipette puller (Kopf), which reproducibly pulls needles with 
desired geometries according to programmable parameters. Needles were broken 
open with a razor blade just behind their tip and filled from the distal end with 12µl 
cell suspension using microloader tips (Eppendorf). Microneedles were attached 
to a needle holder, which was connected via an air tubing system to a manual 
syringe pump (BD). Microinjection was performed using air pressure. Care was taken 
not to allow the broken glass microneedle to rupture the dermis. Incorporation 
of fluorescently labeled CD1c+ DCs was immediately confirmed by observing the 
injected dermis under a fluorescent microscope. Immunocompetent melanoma skin 
equivalents were cultured for additional 48 hours at 37°C in PONEC 0% medium. 
Immunohistochemistry 
Formalin fixed human skin equivalents were processed for routine histology. Sections 
were stained with hematoxilin-eosin (H&E) or processed for immunohistochemical 
staining. Following antigen retrieval with EDTA, sections were stained with primary 
antibody incubation (anti-CD45, Dako); staining was developed using a DAB staining kit. 
Image acquisition 
Epifluorescent images of whole skin models were acquired, at fixed distances in 
depth (z-step size=10μm), using an automated brightfield multi-color epifluorescence 
microscope (Leica DMI6000B, Leica , Germany). Immunohistochemical staining 
of whole tissue slides were imaged using Vectra Intelligent Slide Analysis System 
(Version 2.0.8, PerkinElmer Inc.). All time-lapse experiments were performed using 
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a multiparameter multiphoton microscope (TriMScope-II, LaVision BioTec, Bielefeld, 
Germany) on a temperature-controlled stage (37°C). 4D time-lapse recordings were 
acquired by sequential scanning with 950 nm (eGFP and PKH26) and 1090 nm  (SHG), 
with a sampling rate of 1 frame/2min over periods of 2-4h. 
Image processing 
Images were analyzed using the open source-imaging platform, Fiji (imageJ 64 Bit 
for Windows). Mosaic images were stitched using the Stitch Grid/Collection plugin. 
Z-volumes containing DCs were quantified using individual slices of epifluorescent 
images acquired at 10μm z-resolution. For DC motility and DC-tumor cell interactions, 
drifts in time-lapse recordings were corrected using the Correct 3D drift plugin. If 
necessary, images were scaled and adjusted for brightness and contrast to enhance 
visualization. Immunohistochemical images, taken at the Vectra sytem, were analyzed 
with the image analysis software, InForm (Version 2.1, PerkinElmer Inc.). 
Statistical analysis 
Significance between groups is established using T-test performed in Graphpad 
Prism.
Results
Skin melanoma model displays morphological features of primary 
human melanoma
Generation of the human skin melanoma model is depicted in Fig. 1a. Primary human 
fibroblasts (Fbs) are seeded onto the reticular dermal side (opposite to papillary side 
and basal membrane) of an acellular, de-epidermized dermis (DED) via centrifugal 
force (day 1). This is followed by a 3-days culture to allow Fbs migration and distribution 
through the collagen fibers of the DED (Suppl. Fig 1a). In order to reconstitute 
melanoma in a fully developed epidermis, primary human keratinocytes (KCs) and 
immortalized human melanoma cells are seeded onto the basal membrane (papillary 
side) of the fibroblast-repopulated DED (day 4). KCs and melanoma cells are cultured 
sub-merged for 3 days, to allow KCs proliferation and distribution of cancer cells in 
the epidermal layer. Subsequently, differentiation of KCs is achieved by culturing the 
organotypic model for additional 7 days, at the air-liquid interphase (day 7). When 
a fully developed epidermal layers is formed, freshly isolated, primary CD1c+ DCs 
are injected into the dermal compartment (day 14). The 3D skin melanoma model 
is cultured air-exposed for further 2 days, thus for a total culture period of 16 days 
(Fig 1a). In order to mimic melanoma growth in the skin model, we co-cultured KCs 
with BLM melanoma cells, at different KC-to-tumor cell ratios. Immunohistochemistry 
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Figure 1. 3D Skin melanoma model displays morphological features of human melanoma. 
A Schematic representation of the generation of human skin melanoma organotypic model. B His-
tological comparison of tissue sections obtained from primary tumor (left) and skin melanoma 
model (right). Hematoxylin and eosin staining. Scale bar 100μm. 
analysis of model tissue sections and comparison to primary human tumor biopsies 
showed that extensive proliferation of melanoma cells, as observed at low KC:tumor 
cell ratios, negatively affected the morphology of the epidermal layer. Co-seeding 
large amounts of fast-diving melanoma cells with epidermal cells, in fact, caused the 
tumor cells to outnumber KCs, thereby affecting KC differentiation and preventing 
the formation of the five characteristic epidermal strata (Suppl. Fig 1b). The optimal 
cell seeding concentration, defined as the amount of KCs and melanoma cells that 
preserves epidermal differentiation and morphology, while allowing proliferation of 
tumor cells, was found to be 25:1 (Fig 1b, Suppl. Fig 1b). Furthermore, we noticed 
that BLM cells, seeded on DEDs in a mixed KC-tumor cell suspension, spontaneously 
relocated in the basal layer of the epidermis, where they developed into tumor nests 
and infiltrate the underneath dermis (Fig 1b). Taken together, these observations 
show that the 3D skin melanoma mimics the growth of tumor cells, closely resembling 
morphological features of malignancy-associated human skin.
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Melanoma model supports DC survival and motility 
Human CD1c+ DCs, pre-labeled with a cell tracking dye (CFSE or PKH), were 
injected into the dermal compartment of a fully differentiated melanoma skin 
model (day 14; Fig 1a). Distribution and migration of CD1c+ DCs was monitored 
for up to 48 hours with advanced imaging techniques. In order to confirm the 
presence of fluorescently-labeled CD1c+ DCs in the dermis, melanoma skin models 
were imaged with an inverted epifluorescence microscope, approximately 2h after 
DC injection (Fig 2 a, b). First, we identified the area in the dermis in which the DCs 
were injected, which appeared as a cloud of fluorescent cells (Fig 2a, left). Next, 
we measured the extension (depth or z-volume) of the dermal region in which we 
could find CD1c+ DCs and scanned the whole area that contained the fluorescent 
cells (Fig 2b, middle). In order to monitor DC distribution through the dermal 
compartment over time, we repeated the analysis 48 hours after DC injection 
(Fig 2a, right and Fig 2b). We observed that the region of the dermis containing 
DCs was more extensive after 48h (97.29±11.06), as compared to 2h average 
(154.7±14.97) after injection, thus suggesting that DCs disseminated across a 
broad area over time (Fig 2b). We thus predicted that DCs actively migrated 
throughout the dermal layer. We used live two-photon microscopy to confirm 
motility and assess longevity of CD1c+ DCs in our melanoma skin model (Fig 2c-g). 
Combination of fluorescent signal (for live-cell visualization) with second harmonic 
generation (SHG, elicited by collagen fiber bundles) delivers information on the 3D 
anatomy of the dermal tissue. Collagen fibers were organized in heterogeneous 
networks, including randomly arranged loose collagen fibers and aligned and 
more compacted collagen bundles (Fig 2c). We sought to confirm that DCs survive 
in our model despite the absence of serum, which would normally be administered 
to culture media to ensure survival of immune cells cultured in vitro. Using a 
Figure 2. CD1c+ DCs actively migrate through the dermal compartment of skin melanoma 
model. In order to analyze fluorescently-labeled CD1c+ DCs distribution over time, skin models 
were imaged with an inverted epifluorescence microscope, 2h and 48h after DC injection. 
A Schematic representation of image acquisition and analysis. Scale bar 1mm. B Comparison 
of dermal areas (Z-volumes) containing DCs at 2h and 48h. Matched color symbols indicate 
differences in Z-volumes in the same skin model, analyzed at two different time points (n=4). 
C PKH26 and second harmonic generation (SHG) signals of multiphoton images, acquired with 
excitation wavelength (λ) of 950nm. PKH26 signal indicates CD1c+ DCs; SHG was generated by 
collagen bundles. D Representative time points during time-lapse recording of skin model at 
2h, 24h and 48h after DC injection. E-G Time-lapse microscopy and single cell tracking of DCs 
showed motility, with (F) median velocity of 3μm/min over 24h. (G) DCs showed characteristic 
amoeboid migration. H Representative time points during time-lapse recording of melanoma 
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BLM cells expressing GFP [λ (excitation) = 950nm]. BLM cells showed high cellular dynamics 
(protrusion, blue arrow and retraction, white arrowhead ). Scale bars, 50μm (unless otherwise 
indicated). Statistical significance was determined by t-test, *p < 0.05.
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time-lapse setting with 120sec time interval between individual scans, areas 
were imaged at 2, 24 and 48 hours after CD1c+ DC injection, for approximately 2 
consecutive hours (Fig 2d). Single-cell tracking and time-lapse recording revealed 
motile DCs, moving along and into collagen networks, maintaining median 
velocities of 3 µm/min for over a period of 24 hours (Fig 2e,  f). Over time, the 
average velocity reduced to approximately 2 µm/min (Fig 2f). Occasionally, small 
clusters of 2-3 DCs were observed to migrate interconnected, with the leading 
cells opening the way for other DCs (not shown). Trafficking CD1c+ DCs adopted a 
typical “hand mirror shape”, characteristic of amoeboid migration. DCs displayed 
a leading edge, consisting of multiple dendrites that intercalated between tissue 
structures, followed by the cell body containing the nucleus, and a posterior tail 
(uropod) (Fig 2g). Additionally, we observed that melanoma BLM cells, expressing 
the fluorescent protein GFP (hereafter referred to as BLM-GFP), were confined by 
collagen fiber bundles and showed intense membrane dynamics, appreciated as 
protrusive and retractive activity (Fig 2h). Altogether, these findings demonstrate 
that the biological composition of the 3D melanoma skin organotypic model 
supports survival of CD1c+ DCs as well as melanoma cells.
CD1c+ DCs directly interact with tumor cells and ingest tumor-derived 
particles 
Immunohistochemistry end point analysis of fixed models revealed that DCs in the 
dermal compartment were in close association with non-immune cells (Fig 3a). Live 
imaging and tracking of DC-tumor cell interactions was performed by two-photon 
imaging of the melanoma skin models (Fig 3b, c). We observed multiple CD1c+ 
DCs directly interacting with BLM-GFP cells. Dynamic DC-tumor cell interactions 
were followed over at least 20min (Fig 3b). DCs in the skin model encountered and 
shortly interacted with live tumor cells. We repeatedly observed that prolonged 
interactions and stable cell engagement were established between DCs and 
tumor-associated cellular microparticles (or blebs) (Fig 3c). Microparticles were 
released into the ECM by BLM-GFP cells and the blebs themselves retained 
the cytoplasmic fluorophore, GFP. We also captured images of sampling and 
engulfment of tumor-derived particles by DCs (Fig 3b,c). Uptake of GFP-containing 
tumor fragment by CD1c+ DCs was imaged by live two-photon microscopy as early 
as a few hours after immune cell injection. Taken together, these observations 
clearly indicate that melanoma skin models represent a promising and valuable 
platform for accurate investigation of cellular interplay and function, in an in vivo-
like skin tissue architecture.
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Discussion
The tissue microenvironment is increasingly recognized to influence a broad range 
of events involved in maintaining homeostasis and regulating host response to 
disease, such as tumors 21, 22. Both conventional in vitro and in vivo studies have 
largely contributed to our understanding of the mechanisms regulating tumor 
development and progression. However, our knowledge in many aspects of the 
immunobiology of human cancer is still poor. 
We here established an in vitro human 3D engineered melanoma skin model 
that closely recreates, in a controlled and titrated system, the in vivo complexity 
of the melanoma microenvironment. The advantage of our model, with respect 
to existing co-culture cell systems, relies on the possibility of bringing different 
Figure 3. Visualization of CD1c+ DCs-tumor cell interaction and uptake of tumor-fragments. 
A Section of 3D melanoma skin model showing immunohistochemical staining for CD45. In brown 
(DAB) CD45 positive DCs, in close proximity to non-immune (CD45 negative) cells. Hematoxylin 
counterstaining, original magnification 20X. B, C Representative time points during time-lapse 
recording of DC (PKH26)-tumor cell (GFP) interaction [λ (excitation) = 950nm]. (B) DC sensed and 
sampled tumor-derived particle (abbreviation: T, tumor fragment). (C) Prolonged interaction of DCs 
with tumor-derived fragments. Tumor cells showed intense membrane dynamics and blebbing. 
Scale bars, 50μm (unless otherwise indicated).
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cell types together in an in vivo-like tissue context. This is in fact the first model 
that places in a non synthetic, human-derived extracellular matrix (ECM), the key 
components of the epidermal, stromal and immune compartments of the tumor 
microenvironment (TME). Moreover, our organotypic model provides a new platform 
that allows real-time, 4 dimensional (X,Y,Z, time) direct observation of melanoma 
interactions with the colonized tissue, in a human setting. 
IHC examination of our model showed that the melanoma skin model displayed 
the morphological features of malignancy-associated human skin. We showed that 
melanoma cells, co-seeded with epidermal cells on a fibroblast-repopulated DED, 
spontaneously relocated in the deepest layer of the epidermis, the stratum basale. 
This observation is particularly interesting as it indicates that, different cell types retain 
their unique characteristics and adapt to each other when cultured in a multi-cellular 
environment. In human skin, in fact, normal melanocytes are located in the stratum 
basale. Upon malignant transformation, melanocytes escape from the growth control 
exerted by epidermal cells and acquire extensive proliferative potential and migratory 
ability, eventually resulting in dermal invasion and distant metastases 13, 23. 
Stromal cells, such as fibroblasts, are key cellular components of the TME 24. 
Fibroblasts can influence proliferation and invasive potential of melanoma cells, 
as well as conferring tumor resistance to  chemotherapy 24, 25. Previous work also 
demonstrated that incorporation of fibroblasts into skin models significantly 
improved epidermal morphogenesis and doubled the life span of skin models to 
up to 6 weeks of culture26. Different approaches have been described to incorporate 
stromal cells in the dermal compartment of HSEs. These include (a) culturing 
fibroblasts for a few (at least 3) weeks to allow deposition of ECM components and 
(b) centrifugal seeding of stromal cells onto acellular DEDs  26, 27. For development 
of skin melanoma models we adapted the centrifugal seeding method previously 
described 26. This approach offers the advantage of considerably reducing the time 
required to obtain a fibroblast-populated dermis, and guarantees reproducible 
seeding efficiency and homogeneous distribution of fibroblasts into DEDs 28.
Onset of an effective anti-tumor immune response requires dendritic cells (DCs) to be 
at the right place at the right time 29. Nearly all steps, from antigen capture to activation 
and effector cell function, depend upon DC positioning and migration in peripheral 
and lymphoid tissues. Within peripheral tissues, such as skin, DCs are the sentinels that 
interact with malignant cells and eventually capture tumor material 30. The two main 
DC populations found in the skin are the epidermal Langerhans cells and the dermal 
CD1c+ DCs 31-33. Isolation of DC subsets from the skin is a complex procedure, which 
requires extensive handling and manipulation. Moreover, it is limited by the availability 
of skin tissue and the relatively low amounts of DCs that can be obtained. The dermal 
CD1c+ DC population is mirrored in the blood by circulating CD1c+ DCs 34. Therefore, 
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blood CD1c+ DCs represent a suitable model for dermal DCs in human skin models. 
Imaging analysis of our melanoma skin model showed that, 72 hours after the injection of 
fluorescently labeled CD1c+ DCs, the dermal area occupied by DCs was bigger than the 
area measured immediately after DC injection. This suggest that the DCs moved from 
the injection site over time. However, fluorescent end-point imaging studies provide a 
static view on dynamic processes, such as migration, and can only give indirect insights 
into positioning mechanisms. Time-lapse second generation harmonic (SHG), suitable for 
collagen visualization combined with fluorescence microscopy, allows visualization of 3D 
topography of tissue structures and delivers insights into DC migration in skin models. 
In 3D environments, DCs employ amoeboid migration 35, 36. In contrast to the slow (less 
than 1µm/min), proteolysis-dependent mesenchymal movement of tumor and stromal 
cells; amoeboid modes are fast (up to 10µm/min for DCs and 5µm/min for monocytes), 
independent of adhesive interactions with tissues and preserve tissue structure 37. 
We recently reported that CD1c+ DCs, co-cultured in vitro with viable melanoma 
BLM cells, ingested tumor-derived blebs or fragments (Chapters 2 and 3 of this 
thesis). Uptake of tumor fragments in vitro, as opposed to membrane binding, was 
demonstrated by culturing CD1c+ DCs and BLM-GFP at 37°C vs 4°C. Consistently, we 
here observed that BLM cells released fluorescently detectable particles in the ECM. 
In addition, we extended previous observations by showing that CD1c+ DCs were 
able to actively take up GFP+-tumor particles in 3D settings. Previous work suggested 
that these tumor-derived blebs favor cell-to-cell communication and are therefore 
implicated in cancer progression, tumor invasion and metastasis, as well as anti-tumor 
drug resistance 9, 10, 38, 39. Alternatively, these particles can be taken up by APCs, function 
as antigen carriers and mediate anti-tumor immunity 40. Notably, CD1c+ DCs were also 
frequently found interacting with viable tumor cells. However, during the many hours 
of imaging, we never observed phagocytosis of intact tumor cells, thus suggesting 
that tumor-derived particles might be the main source of tumor-ingested material. 
In summary, this novel 3D organotypic model mimics the complex melanoma 
TME and allows live investigation of CD1c+ DCs migration and function in an ex vivo-
like tissue. Our model has the potential to provide new insights into the mechanisms 
that underlie melanoma growth and may help the identification of candidate genes 
and molecules involved in this disease-relevant process.
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Supplementary Figure 1. A Representative image of fibroblast distribution through the dermal 
compartment of a 3D model of normal skin (keratinocytes, KC only). B Hematoxylin and eosin 
staining of melanoma skin models with different  KC:melanoma BLM cell ratio.
Supplementary material
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Abstract 
The quality and quantity of the infiltration of immune cells into tumor tissues has 
substantial impact on patients’ clinical outcome and is associated with response to 
immunotherapy. Therefore, the precise analysis of tumor-infiltrating lymphocytes 
(TIL) is becoming an important additional pathological biomarker. Analysis of 
TILs is usually performed semi-quantitatively by pathologists on H&E stained or 
immunostained tissue sections. However, automated quantification outperforms 
semi-quantitative approaches and is becoming the standard. Due to the presence 
of melanin pigment this approach is seriously hampered in melanoma, because the 
spectrum of melanin lies close to that of commonly used immunohistochemical stains. 
Here, we successfully apply a novel multispectral imaging technique to 
enumerate T cells in human primary melanomas. This microscopy technique 
combines imaging with spectroscopy to obtain both, quantitative expression data 
and tissue distribution of different cellular markers. We show that multispectral 
imaging allows complete and accurate analysis of TILs, successfully avoiding melanin 
pigments, in whole slide primary melanoma lesions, which could otherwise not be 
accurately detected by conventional digital image methodologies.
Our study highlights the potency of multispectral imaging to accurately assess 
immune cell infiltrates including those in notoriously difficult tissues, such as 
pigmented melanomas. Quantification of tumor infiltration by different immune 
cell types is crucial in the search for new biomarkers to predict patient responses 
to immunotherapies. Our findings show that this innovative microscopy technique 
is an important extension of the armamentarium in melanoma research.
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Introduction 
Melanoma is a potentially lethal skin cancer generating from the malignant 
transformation of melanocytes, the melanin-producing cells in the skin1,2. Although 
development of successful strategies remains a challenge, the past decade 
uncovered encouraging advances in melanoma management3,4. Perhaps the biggest 
improvement in melanoma therapy comes from immunotherapeutic approaches, in 
particular immunomodulatory monoclonal antibodies (mAbs). Immunomodulatory 
mAbs target molecules (‘checkpoints’) that are crucial in regulating immune 
responses and keeping tumor progression under control3,4. In particular, immune 
checkpoint regulators CTLA-4 and PD-1 have been extensively studied3,4. Clinical 
trials using ipilimumab (anti-CTLA-4 mAb) and/or nivolumab or pembrolizumab (anti-
PD-1 mAbs) have recently reported durable clinical responses and increased overall 
survival (OS)5-8. Nonetheless, costs and toxicity associated with immune checkpoint 
inhibition, urge for the development of biomarkers for predicting the efficacy of 
the treatment and disease outcome, in patients treated with immunotherapy9. The 
availability of predictive biomarkers is of extreme importance to further advance 
this field of cancer immunotherapy.
The crucial role of the patient’s own immune system on clinical outcome is 
demonstrated by the immunological characterization of the tumor microenvironment 
(TME)10,11. Immune cells can infiltrate the core (center) of the tumor or remain 
located in peritumoral areas. The analysis of type, location and density of tumor-
infiltrating immune cell components is referred to as “immune contexture”12. 
Immunohistochemical (IHC) evaluation of this immune contexture resulted in 
the identification of immune cell types that can be either beneficial or harmful 
to patients13-15. For example, high-density infiltration of lymphocytes in the tumor 
core, in particular CD8+ effector T cells, positively correlates with survival of patients 
suffering from melanoma or other cancer types16-19. 
So far, density and location of TILs have been estimated by tissue IHC of limited 
areas of the sample, by independent histopathologic reviews. The total amount of 
infiltrating immune cells is generally calculated by multiplying the number of cells 
counted in one region by the entire surface of the tumor14. Others take advantage 
of the use of semi-automated digital image analysis. This method is based on 
mathematical algorithms that can recognize and quantify cells of interest within 
the tumor area. Although relatively accurate, this methodology is extremely time-
consuming and in the case of melanoma fail because of the melanin pigment20,21. 
As this pigment is also produced by a substantial part of melanomas, it creates 
a high background in bright-field IHC stains22. This melanin signal can obscure 
tumor-infiltrating immune cells or even generate false positive signals, resulting in 
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inaccurate, under- / over- estimated TIL counts when a digital approach is used. 
An established technique for the study of immune infiltrates is melanin bleaching 
with strong oxidants23,24. Although this technique can give satisfactory results in 
many cases, certain antigens (such as CD3 and CD45RO) and the tissue itself can be 
partially destroyed. Besides, conventional chromogens used for antibody detection 
(i.e. DAB) are also affected by the intense oxidative procedure, thus making the 
analyses less accurate25,26.  The use of a red chromogen in the immunostaining 
of melanocytic lesions, if limited to tumor markers, can partially overcome this 
problem27, however it remains not optimal for immune cells detection. Recent 
advances in the field of tissue imaging resulted in the development of multispectral 
imaging applied to whole-slide tissue sections28. This novel technique combines 
imaging with spectroscopy, thereby allowing both quantification and tissue 
distribution of multiple cellular markers in the entire tissue section. Here, we exploit 
multispectral imaging for linear spectral unmixing of melanin pigmentation in 
human primary melanoma biopsies and demonstrate that melanin unmixing allows 
for highly accurate quantification of CD3+ T lymphocytes infiltrating a tumor lesion, 
which could otherwise not be detected by conventional digital image analysis 
because of melanin blurring the images. By comparing quantitative assessment 
of CD3+ T cells, by semi-automated and our fully automated image analysis, we 
show that using traditional approaches melanin pigments lead to significant 
overestimation of T cell counts in primary pigmented lesions. We believe that 
our innovative spectral unmixing technique will be of great value in melanoma 
research, and may contribute to the identification of new biomarkers crucial for 
clinical management of melanoma patients. 
Materials and Methods
Patients 
We obtained tissue sections of 23 primary cutaneous melanomas of patients who 
were enrolled in our dendritic cell vaccination studies at the Radboud university 
medical center (Nijmegen, the Netherlands) and were available at our hospital. 
The studies were approved by the appropriate Medical Ethical Review Board, and 
written informed consent was obtained from all patients.
Immunohistochemistry
Slides of 4-µm thickness were cut from formalin-fixed, paraffin-embedded (FFPE) 
primary melanoma tissue blocks. The slides were deparaffinized, after which antigen 
retrieval followed using 10 mM citrate buffer (Skytek, Utah, United States, pH 6.0) for 
10 min at 96°C. After this pre-treatment, the slides were placed in an Autostainer 480 
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(Thermo scientific, labvision). At first, during the automated procedure, endogenous 
peroxidase was blocked using 3% hydrogen peroxidase (EMD Millipore corporation, 
Darmstadt, Germany) in methanol (EMD Millipore corporation, Darmstadt, Germany) 
followed by primary antibody incubation (anti-CD3, Thermo Scientific, dilution: 
1/40) for 60 min at room temperature. Next, incubation with Brightvision poly-
HRP-anti Ms/Rb/Rt IgG (Immunologic BV, Duiven, Netherlands, Dilution: 1/2) was 
performed for 30 min at room temperature followed by a visualization step with the 
Vector Nova Red substrate kit (Vector laboratories, Burlingame, United States) for 
7 min, at room temperature. Between each step, samples were rinsed using PBS 
(klinipath, Duiven, Netherlands, dilution: 1/10). After visualization, the slides were 
manually counterstained with haematoxylin and enclosed with Quick-D mounting 
medium (Klinipath).
Manual digital analysis
Whole tissue slides were digitally scanned at high resolution by the automated 
scanner Pannoramic 250 (Pannoramic P250, 3DHistech Ltd, Budapest, Hungary). 
The bright-field images were analyzed using the open source-imaging platform, 
Fiji (imageJ 64 Bit for Windows). After manual drawing of the tumor and stroma 
regions, original bright-field images were converted into a “binary”, black and 
white, 8-bit image. In order to discriminate objects of interest from the background, 
a threshold range was set. Thus, all objects in the image, whose pixel values are 
above the threshold, were shown in white; whereas objects in the background, 
having pixel values lying below the threshold, were displayed as black regions. The 
resulting binary image is further processed to separate (segment) cells clustered 
together, which would misrepresent the final result. Hence, segmented images 
were analyzed and single cells counted, by using the automatic particle counting 
plug-in. Each cell detected was outlined and the output image overlaid on a 
duplicate of the original bright-field image, in order to visually verify the success 
of the algorithm.
Spectral library generation for melanin unmixing
Images of single stained tissues and unstained tissue were used to extract the 
spectrum of each chromogen and of tissue melanin pigmentation, respectively, 
with Nuance Multispectral Imaging System (Version 3.0.2, PerkinElmer Inc). The 
chromogens used were haematoxylin for nuclear staining and nova red (Vector 
laboratories, Burlingame, United States) for CD3+ T cells. The extracted spectra built 
a so called spectral library which was used to enable the quantitative separation, or 
unmixing, of the stained markers into its own channel/image, thus removing cross-
talk between chromogens and interfering tissue pigmentation.
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Tissue imaging and quantitative digital analysis
Whole tissue slides were imaged using Vectra Intelligent Slide Analysis System 
(Version 2.0.8, PerkinElmer Inc.) in an automated manner. A selection of 10 to 15 
representative original multispectral images was loaded into an advanced user-
trainable morphologic image analysis software, (InForm Version 2.1, PerkinElmer Inc.) 
which utilizes sophisticated machine learning to allow the user to train it to recognize 
and find morphologic regions of the tissue which then allow the determination 
of which cells are, for instance, in the tumor and which are in the stromal regions 
(fig S1). The analysis software also utilizes the multimarker, multispectral data to 
calculate per-cell and per-cellular-compartment (i.e., nuclear, cytoplasmic, and 
membrane) optical intensity values to score cell positivity for the specific marker 
used as described before33,34. 
All the settings applied to the training images were saved within an algorithm 
allowing batch analysis of multiple original multispectral images of the same tumor. 
A separate algorithm was generated per single patient applying the same settings 
for cell segmentation and positivity score but with different training for tissue 
segmentation due to the numerous morphological differences between and within 
tumors, which is very common in melanoma. 
Statistics
Significance between groups is established using T test performed in Graphpad 
Prism. 
Results 
Semi-automated digital image analysis of T cell infiltrates in human 
primary melanoma is affected by the presence of melanin pigmentation. 
Tissue sections obtained from 23 primary melanoma excisions were stained for 
IHC evaluation of CD3 positive (CD3+) T cells in order to investigate the distribution 
of tumor-infiltrating lymphocytes in primary human melanomas (Fig.  1 and 2). 
Analysis of the tumor areas was accomplished by applying a semi-automated 
algorithm, consisting of four main steps: (I) color threshold, (II) cell segmentation, 
(III) cell counting, and (IV) overlaying of the resulting mask with the original image 
(Fig. 1B-F). In melanoma tissue sections though, the presence of melanin affects 
IHC quantification, due to its high background signal often indistinguishable from 
brown or red chromogens, like DAB and nova red (Fig.2A). Another limitation of the 
semi-automated algorithm is the difficulty in efficiently separating groups of cells, 
from single cells. Clusters of cells are then erroneously reported as a single cell 
(independent of the size of the cell cluster), thus seriously affecting the end results 
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Figure 1. Overview of the semi-automated image analysis process for the assessment of T cell 
density in primary human melanoma. Section of human primary cutaneous melanoma showing im-
munohistochemical staining for CD3. In red CD3 positive (CD3+) T lymphocytes. Hematoxylin coun-
terstaining, original magnification 20X (A). Zoom-in on tumor region indicated in the original image A 
(B). Output image after applying an image color thresholding (C), segmentation (D) and cell counting 
in yellow (E) by using the imaging software Fiji. Processed image after superimposing the segmented 
image with cell borders marked in yellow on the original bright-field image (F). Scale bar 1mm.
of the analysis. In the examples shown in figures 2B and 2C, where CD3+ T cells are 
stained with nova red, the semi-automated algorithm incorrectly identifies melanin 
pigments as cells positive for the specific immunohistochemical marker used and 
fails segmenting clusters of T cells.
Unmixing of melanin and cellular signal components to generate a 
spectral library 
To overcome the above-mentioned limitations in the assessment of immune infiltrates 
in pigmented tumors, we used a multispectral imaging system that combines 
imaging with spectroscopy. We observed that different tumors synthesize melanin 
with varying intensities and distinct spectral characteristics (Fig. 3A, B and C). In 
particular, in our cohort of patients we could identify three different spectra of 
melanin. One of the three measured melanin spectra showed a strong overlap with 
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the spectrum of the nova red chromogen (Fig. 3F) and therefore was responsible 
of the failure of the semi-automated algorithm in the quantification of true positive 
cells, especially in the tumor area. We combined the melanin spectra with the ones 
of heamatoxylin and nova red in a so-called “spectral library” (Fig 3F), which was 
then applied to all of the acquired bright field images. This resulted in new images 
(Fig 4), where the brown melanin signals could be distinguished from the true nova 
red signal and therefore not quantified as positive in the T cells positivity score. 
Comparison of T cell density assessment performed by semi-automated 
or multispectral analysis 
The density of CD3+ T lymphocytes was quantified in both, intratumoral (lymphocytes 
infiltrating the melanoma cell nests) and peritumoral regions (lymphocytes 
surrounding the tumor deposits) of primary cutaneous melanoma. Intratumoral and 
peritumoral regions were defined by fully-automated trainable tissue segmentation, 
based on morphological features (Fig S1). Furthermore, nuclear staining allowed 
the efficient separation (segmentation) of cell clusters, which were then properly 
assessed. The 23 primary tumors analyzed showed a variable level of melanin 
pigmentation, both in terms of pigment intensity and content. The percentage 
of pigmented tumor cells was manually scored, resulting in 14 highly pigmented 
Figure 2. Semi-automated image analysis of highly pigmented melanoma. Assessment of the 
presence of CD3+ T lymphocytes in highly pigmented melanoma tumor using semi-automated 
image analysis. Original immunohistochemical image of human melanoma, containing clusters of 
infiltrating CD3+ T cells (nova red, arrowhead) and brown melanin pigments (arrow) (A).  Output 
image of semi-automated algorithm for image analysis and cell count (B). Overlay of output and 
original multispectral image (C). The image processing presents some limitations (see zoom-in): 
T cells in cluster cannot be efficiently separated (top, arrowhead) and melanin pigments originate 
false positives (bottom, arrow) (B, C). Scale bars 50µm.
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melanomas (>50% pigmented tumor cells) and 9 melanomas, which showed 
between 5% and 20% of pigmented tumor cells. T cell density was assessed using 
both our semi-automated algorithm and fully-automated multispectral analysis 
(Suppl. Table I) (Fig 5A-F). Our results clearly show that the T cell density in highly 
pigmented tumor was significantly higher using conventional analysis, as compared 
to multispectral approach (Fig. 5G). This difference, however, was not significant in 
tumors with low melanin pigmentation (Fig 5H). These findings suggest that linear 
spectral unmixing of melanin from chromogens with spectra close to one of the 
melanin spectra (such as nova red and DAB) is crucial in the assessment of T cell 
density, particularly in highly pigmented melanomas (14 out of 23 patients). In some 
Figure 3. Spectral unmixing in human melanoma tumors reveals different spectra of melanin 
pigmentation. Representative immunohistochemical images of cellular components and melanin 
pigments used to build a spectral library for image analysis of TILs in melanomas. Three differently 
pigmented melanin samples (A, B, C), CD3-nova red positive T lymphocytes D), haematoxylin 
staining of nuclei (E). A spectral library of nova red  (red) and haematoxylin (blue) and 3 different 
Melanin (green, black and yellow) was built in Nuance software using single stained or unstained 
human melanoma tissues respectively (F). Scale bar 20µm.
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tumors, T cell density was slightly higher when quantified by the automated software 
(T cells count in Fig 5 E and F, Suppl. Table I). This was mainly due to a more accurate 
cell segmentation where all the cells are detected and clusters are correctly split. 
Discussion
Analysis of location, type and density of the immune infiltrate and their correlation 
with clinical outcome is of crucial importance in cancer research11,13,14,29. Nowadays, 
the assessment of T cell density in solid tumors is usually investigated with traditional 
IHC analysis and bright-field microscopy14. Here, we compare two different digital 
imaging approaches to estimate the amount of TILs in the tumoral and peritumoral 
area of melanoma primary lesions.
Figure 4. Melanin unmixing reveals T cell infiltrates in melanoma tumor. Melanin unmixing allows 
visualization of infiltrating T lymphocytes in melanoma tumor. Original colored image of human 
melanoma (A). Composite pseudo-fluorescent image containing both melanin (in green) and 
CD3+-nova red T cells (in red) (B). Pseudo-fluorescent images of (C) unmixed CD3+-nova red T cells 
and (D) melanin. Nuclei are shown in blue (haematoxylin staining). Scale bar 50µm.
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At first, we developed and tested a semi-automated digital image approach, 
which was expected to represent a useful tool to assess T cell density in tumor 
areas. Unfortunately, we observed that accuracy, which is of eminent importance 
for proper interpretation of IHC results, was still far from perfect. Especially in 
melanoma samples that contained dark brown melanin pigments in the tumor 
area, a large portion of the immune cells were obscured therefore hampering 
IHC measurements22. This because different colors in bright-field images are 
Figure 5. Comparison of manual and automated cell count in pigmented and non-pigmented 
melanoma. Comparison of the quantitative assessment of CD3+ T lymphocytes in human primary 
melanomas performed by manual image software Fiji (B, E) or fully automated Vectra/InForm 
platform (C, F). For tumor with more than 50% of cells pigmented (A-C) the absolute CD3+ T cell 
counts are significantly higher using the manual (B) compared to the automated (C) analysis, 
because of false positives due to melanin pigmentation. In tumors with no or low pigmentation 
(D-F), the CD3+ T cells counts are comparable in manual (E) vs automated (F) analysis. Dot plots of 
CD3+ T lymphocytes enumeration for pigmented (G) vs. non-pigmented (H) melanomas and the 
combination of the two groups (I). Matched color symbols indicate differences in T cell counts in 
the same tumor, obtained with manual or automated analysis (I). Scale bars 50µm.
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perceived as a mixture of the RGB (red, green, blue) channels and routinely used 
imaging software solutions are not able to discriminate between the single color 
components. Consequently, melanin was detected in all three channels, at different 
intensities20,30. In addition, conventional red and brown chromogens used for IHC 
staining generate signals that are analogous to the background signal caused by 
melanin pigments can also lead to overestimation of the amount of T cells infiltrating 
the tumor, resulting in false positive counts. 
Based on these findings we next applied techniques that were able to discriminate 
between the melanin and red and brown chromogens used for IHC staining. 
We found that multispectral imaging and linear spectral melanin unmixing to 
quantitatively assess the density of CD3+ T lymphocytes infiltrating human primary 
cutaneous melanoma could effectively overcome the limits of the conventional semi 
automated algorithm22,28. A major advantage of multispectral over conventional 
bright-field imaging is the possibility to clearly separate emission spectra of each 
chromogen present in the tissue section. Likewise, the spectrum of melanin, which 
otherwise distorts the nova red chromogen signal, can now be unmixed from the 
original multispectral image. Our findings demonstrate major differences in T cells 
densities dependent on the two methods described. Conventional analysis leads to 
overestimation of T cell infiltration and therefore to possible misinterpretation of the 
data. This is of special importance when comparing different groups of melanoma 
patients exhibiting dissimilar degrees of tissue pigmentation.
Furthermore, the presence of immune pigmented cells, such as melanophages, 
also challenges the quantification of TILs making it difficult to distinguish them 
from CD3+ tumor-infiltrating T cells especially when localized in close proximity31. In 
our melanoma biopsies, melanin pigments specifically co-localized with melanoma 
cells and not with melano-macrophages (data not shown) suggesting that the three 
distinct melanin spectra detected are not a result of enzymatic processing by 
melanophages, but are a specific characteristic of malignant melanocytes. 
Finally, tissue segmentation often also encounters difficulties with conventional 
approaches: stroma located between tumor clusters is difficult to exclude from the 
tumor area using manual definition of the tumor area (data not shown). The tissue 
trainable automated image analysis software allows precise tissue segmentation, 
where even stromal tissue and T cells located in between tumor clusters could 
clearly be distinguished and thus excluded from the tumor tissue. Furthermore, 
T cell clusters were accurately segmented based on nuclear staining and typical 
cell size, thereby overcoming additional limitations of semi-automated analyses.
In conclusion, our study highlights the potency of multispectral imaging to 
accurately assess immune cell infiltrates including those in notoriously difficult 
tissues, such as highly pigmented melanomas. By using this innovative microscopy 
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technique, we recently showed that the density of pre-existing lymphocytes inside 
the tumor and at the tumor margin is an accurate predictor of survival for metastatic 
melanoma patients receiving DC vaccination32. Therefore, we strongly believe that 
this approach is an important addition to the armamentarium in melanoma research, 
where the assessment of tumor infiltration is crucial in the search for new biomarkers 
to predict patient responses to immunotherapies.
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Suppl. Table I. Comparison of tumor T cell density by manual vs automated analysis 
Study number
Manual Vectra
Area (mm²) Number CD3/mm² Area (mm²) Number CD3/mm²
1 63,08 444,0869 123,4401 149,2609
2 4,451 1478,319 25,64852 826,894
3 1,486 1833,109 3,220092 890,401
4 10,412 1115,636 12,74008 1086,342
5 100,972 567,2167 84,48246 929,516
6 16,155 389,6626 58,31399 177,8837
7 20,276 517,9523 64,70396 443,3608
8 9,082 1185,312 18,65365 306,2196
9 26,471 47,0326 95,50739 48,28947
10 47,969 378,6195 95,40543 591,1332
11 18,562 1048,917 15,0673 1366,469
12 13,26 1306,071 45,32296 843,2178
13 12,19 442,2888 30,57088 244,2098
14 11,68 1140,154 17,66768 364,7105
15 12,213 11,95447 10,82412 63,42938
16 6,214 765,5294 6,099012 530,2608
17 5,715 685,3893 4,872096 548,5977
18 117,01 169,4129 209,8617 221,1044
19 2,655 766,4783 5,794596 377,4328
20 7,145 236,9489 9,157 144,4622
21 7,669 177,9893 6,812928 122,349
22 24,744 838,8296 21,0258 241,3278
23 48,948 165,9516 27,21056 170,6309
Supplementary material
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Suppl. Figure 1. Fully-automated digital image analysis of primary melanoma on the Vectra/
Inform platform. Original colored image of a primary human melanoma (A). Trainable tissue seg-
mentation function of the inform software used to automatically identify tumor region (red) and 
stromal region (green) mainly based on morphological features (B). Nuclear cell segmentation 
(green nuclei) exclusively in the stromal compartment (C). Automated CD3 positivity score in the 
stromal region (red nuclei in the green stromal segmented tissue). Scale bar 50μm.
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Summary
The immune system can be divided into two separate but interlocked arms: the innate 
and the adaptive immune response. Bridging of those two arms is orchestrated by 
antigen presenting cells (APCs). In the context of anti-tumor immunity, APCs detect 
the presence of malignant cells. Sensing of ”danger” triggers capture of tumor 
material by APCs and clearance of the threat. Subsequently, APCs prime adaptive 
immune cells against the tumor, which eventually results in a durable and highly 
specific response against malignant cells. It is conceptually established that dendritic 
cells (DCs) are the sentinel APCs of the immune system. The ability of DCs to sense 
signs of danger, and efficiently communicate these to the adaptive immune cells, 
determines the fate of anti-tumor immunity. Success of this communication hinges 
upon the activation status of DCs. Defective or impaired DC activation facilitates 
tolerance towards cancer cells, while fully functional DCs strongly promote cytotoxic 
T cell activation. 
In order to grow and survive, tumors employ several strategies to escape 
immune surveillance. Growing knowledge on the immunosuppressive mechanisms 
that accompany tumor progression indicates that they result in a suppressive tumor 
microenvironment (TME), which inhibits innate and adaptive immune responses 
on several levels. In terms of DC function, the TME is the main artificer of the 
defective activation of DCs. Indeed, malignant cells directly interfere with DC 
basic functions and modulate expression of DC phenotypic markers, as well as 
secretion of cytokines and chemokines. In addition, the tumor influences the 
behavior of normal neighboring stromal and immune cells. This, in turn, generates 
a habitat that favors tumor growth and dissemination, while being hostile towards 
the activation of effective anti-tumor immune responses. The goal of anti-cancer 
therapy is to destroy the tumor. In order to achieve this, the immunosuppressive 
networks of the TME need to be tackled, either by destroying cancer cells 
(conventional chemotherapy) or by “releasing the breaks” on the immune system 
(immunotherapeutic strategies).
The first objective of this thesis was to gain more insights into the impact of tumor-
driven immunosuppression on human naturally-occurring DCs; and to study two 
distinct anti-cancer strategies that have the potential to restore DC activation.
In this thesis we have introduced the relatively new insights that show that the 
efficacy of chemotherapy is in part dependent on the immune system. A lot of effort 
has been devoted into increasing our understanding of the molecular parameters 
that govern the beneficial effects of chemotherapy-induced immunogenic cell death 
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(ICD). Yet, little is known about the immune cells that detect tumor cells undergoing 
ICD. In fact, the role human naturally occurring DC subsets, such as CD1c+ and 
CD16+ myeloid (mDCs) and plasmacytoid (pDCs) DCs, in the context of ICD had 
never been studied. In Chapter 2, we highlighted the unique ability of human CD1c+ 
DCs to mediate anti-tumor immune responses, upon induction of ICD by platinum 
compounds. We showed that, treatment of different human tumor cell lines with 
clinically relevant doses of oxaliplatin (OXP) or cisplatin (CDDP), caused a form of 
cell death consistent with ICD. This confirmed the ability of OXP to induce ICD on 
tumor cells of different origins, and expanded the list of ICD-inducers to include 
the “platinum-sister compound”, CDDP. Platinum-treated tumor cells exposed the 
pro-phagocytic signal, calreticulin (CRT). Exposure of CRT mediated tumor cell 
uptake by human DC subsets, as confirmed by peptide-binding blocking assays. 
Interestingly, uptake of tumor material by DCs was not abrogated by blocking 
of the CRT receptor, CD91; pointing towards the involvement of other receptors 
in mediating binding of CRT. We next showed that sensing of the “ICD-signals” 
(HSPs, ATP and HMGB1) contributed to the induction of maturation of mDCs and 
pDCs. Finally, we reported that, although all DC subsets were able to mature upon 
interaction with platinum-treated tumor cells, only CD1c+ DCs effectively stimulated 
proliferation of T cells. These novel findings suggest functional specialization 
between human naturally occurring DC subsets, in response to the induction of 
ICD by chemotherapeutic drugs.
The tumor-DCs interplay markedly suppresses maturation and function of DCs. 
As reported in Chapter 3, co-culture of DC and tumor cells resulted in a down-
modulation of the surface expression of co-stimulatory molecules (CD80, CD86) 
and major histocompatibility class (MHC) I and II molecules. This was accompanied 
by reduced secretion of the pro-inflammatory cytokine TNF-α, as well as increased 
production of the anti-inflammatory cytokine IL-10; which ultimately resulted in 
impaired induction of T cell proliferation by DCs. Blockade of the inhibitory CD47/
SIRPα signaling pathway has shown therapeutic efficacy in various preclinical models 
of malignancies. This beneficial effect relies upon the ability of APCs to take up 
tumor material and induce adaptive immunity 1. Phagocytosis is regulated by the 
balance between pro-phagocytic and anti-phagocytic cues provided by target 
cells 2. Evidence shows that the dominant “eat me” signal CRT is counterbalanced 
by the “don’t eat me” tag given by CD47 3. In Chapter 3 we reported that increased 
uptake of tumor material by human CD1c+ DCs was determined by the binding 
of blocking moAbs against CD47. The uptake of tumor fragments induced DC 
maturation and counteracted tumor-driven suppression of DCs. In addition, previous 
studies demonstrated that anti-CD47-mediated tumor clearance by phagocytic 
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cells in vivo, was enhanced in the presence of immunogenic stimuli, derived from 
cells undergoing immunogenic apoptosis. Although in our settings, combination 
of platinum treatment with anti-CD47 moAbs did not augment phagocytosis by 
DCs, we could observe upregulation of the phenotypic marker CD86. In summary, 
our observations not only expand the knowledge on the role of naturally-occurring 
DCs in the context of tumor-mediated immunosuppression; but they also provide 
a rationale for further investigation of the potential cooperation of conventional 
chemotherapy with immunotherapy. 
In multiple parts of this thesis, we have underscored the concept that, the cell 
biological context and the heterotypic crosstalk within the TME are key determinants 
of the multi-step process that controls effective activation of anti-tumor immunity. 
Because of the lack of physiological complexity of two-dimensional (2D) cell 
monolayers, another part of this work aimed at exploring novel techniques that will 
contribute to our understanding of the complexity of in vivo tissues. 
Chapter 4 covers the development of a three-dimensional (3D) organotypic model 
of human skin melanoma to analyze DC-tumor cross talk in a 3D environment. 
Skin is characterized by a defined molecular composition and stiffness and by the 
presence of physical interfaces, which are difficult to faithfully reproduce using 
collagen matrices. The use of a human-derived dermal component provides 
the correct space and guidance, and acts as a physical barrier by the basement 
membrane, facilitating or restricting cell motility and interaction. Moreover, an in 
vitro model for melanoma model offers the advantage of modulating the local 
cellular environment, in a controllable and reproducible way, by titrating cell types 
and numbers; whilst ensuring the survival of all cell types involved. Furthermore, 
this reconstructed 3D environment provides a potential platform to study migration 
and invasion of cancer cells into surrounding tissues, assess the contribution of other 
relevant cells of the tissue in cancer development, as well as investigate regulation 
of DC functional properties within the local TME. In this respect, we show that 
DCs efficiently migrated along the extracellular meshwork and interacted with 
invasive tumor cells (found grouped in clusters or as single cells in the dermis), 
which finally resulted in engulfment of tumor material by DCs. In summary, malignant 
and non-malignant cells retain their basic functions (such as tumor cell invasion; 
DC migration and uptake), when cultured within this multicellular reconstitution of 
human melanoma skin tissue. Our observations indicate that this skin melanoma 
model can be exploited to gather insights into the dynamics of the TME; and it has 
multiple advantages over conventional monolayer co-cultures by the presence of 
physiological complexity.
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During the past decade, different types of immunotherapies became available for 
the treatment of various tumors, including melanoma. Despite long-term therapeutic 
benefit in a distinct number of patients, there are still some challenges ahead, 
mostly associated with high costs, potential toxicity and suboptimal efficacy of 
immunotherapeutic strategies.  Therefore, there is an urgent need to identify early 
biomarkers that predict potential efficacy of immunotherapy. The quantification 
of cells of the innate and adaptive immune system that infiltrate tumors is crucial 
in this search. Late advances in the field of cancer immunology have shown that 
infiltration of immune cells, such as CD3+ lymphocytes, within the TME may impact 
the induction of tumor-specific immune responses. Chapter 5 highlights the potency 
of multispectral imaging (MSI) to accurately assess immune cell infiltrates, including 
those in notoriously difficult tissues such as pigmented melanomas. The innovative 
MSI technique combines imaging with spectroscopy, to obtain accurate information 
about quantitative expression data and tissue distribution of different cell types 
within the TME. With respect to melanoma, the presence of dark melanin pigments 
in the tumor area can often obscure immune cells and/or lead to false positive 
cell classification, both cases hampering analysis and quantification of immune cell 
composition. In this chapter, we have compared two different T cell quantification 
methodologies and demonstrate that multispectral unmixing of tissue images 
overcomes this difficulty, thereby facilitating a very accurate enumeration of tumor 
infiltrating T lymphocytes in melanomas. 
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Discussion and future perspectives 
Immunogenic cell death
Cell death, as a byproduct of tissue renewal and cell turnover, occurs continuously in 
the human body through apoptosis. In principle, cell death and damage are processes 
that alert the immune system; as an exception, the process of apoptosis involves a series 
of morphological changes that are immunologically silent. Apoptosis is characterized 
by membrane integrity and disintegration of the cell into apoptotic bodies, which are 
efficiently cleared by neighboring cells. Therefore, apoptosis does not lead to activation 
of the adaptive immune response and subsequent adverse autoimmune reactions. 
By contrast, cells succumbing to necrosis, undergo plasma membrane disruption and 
leakage of cellular content into the intercellular space. This results in inflammatory 
immune responses 4. Although the equation “apoptosis equals immunologically-silent 
cell death” has been taught in textbooks for decades, recent studies have demonstrated 
that this assumption is an incorrect generalization. Rather, apoptosis seems to occur 
through a non-uniform series of molecular and biochemical events; meaning that distinct 
pathways may lead to cell death and induce stimulus-specific cellular alterations, before 
the cells adopt the classical morphological characteristics of apoptosis 5. 
Highly proliferative tumor cells exist in a continuous state of stress, and cell death is a 
common feature 6. However, physiological death of malignant cells, or chemotherapy-
induced cell death in general, do not overcome the immunosuppressive nature of the 
TME. Only when tumor cells succumb to a defined subset of cytotoxic agents, does 
their demise have the potential to trigger highly specific anti-tumor immunity 7,8. Thus, 
subcutaneous injection of chemotherapy-treated tumor cells in mice with a functional 
immune system (and in the absence of any adjuvants), activates a specific anti-tumor 
immune response, which protects the animal from a subsequent challenge with 
viable tumor cells of the same origin 9. Moreover, studies using immunocompetent 
versus immunodeficient mice revealed that treatment with certain chemotherapeutic 
drugs are more effective in eradicating tumors in the presence of an intact immune 
system 10,11. In other words, functional innate and adaptive immune components are 
an essential contribution to the beneficial therapeutic outcome of chemotherapy, 
highlighting the clinical relevance of ICD. 
Chemotherapy induces ICD
The immunostimulatory activity of certain chemotherapeutic drugs, including some 
platinum-based agents, was recently recognized12,13, 107. As presented in this thesis 
(Chapters 2 and 3), treatment of tumor cells with OXP or CDDP favors the release 
of ‘danger’ signals, or damaged-associated molecular patterns (DAMPs), which 
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function as immunological adjuvants on DCs. OXP and CDDP are alkylating agents 
that exert their cytotoxic effect by binding genomic DNA in the nucleus and forming 
crosslinks with DNA strands. The result of such adducts stops DNA synthesis and 
repair, thus leading to cell death. Despite sharing similar mechanisms of action, OXP 
and CDDP have different immunogenic potential. OXP causes a cellular response 
that culminates with endoplasmic reticulum (ER) stress and exposure of intracellular 
ER-associated DAMPs, like CRT and HSPs. Unresolved ER stress eventually leads 
to protein degradation, disruption of mitochondrial permeability and ultimately 
cell death 14,15. By contrast, CDDP was never considered an ICD inducer as it fails 
to provoke ER stress; unless it is co-administered with an ER stressor, such as 
tunicamycin 10,16,17. Curiously, it has recently been reported that CDDP can promote 
CRT exposure by a - yet to be identified - mechanism that involves binding of 
chemokines, such as IL-8, to their GPCR receptors 18. This consolidates our findings 
that suggest a role for CDDP as ICD inducer, and demonstrates that numerous 
details on the molecular events that define immunogenicity remain to be defined. 
The “key-lock paradigm” in DC activation
A crucial question is how the immune system can effectively distinguish between 
different cell death modalities. A possible explanation is provided by the mechanisms 
that lead to CRT exposure. We briefly explained that prolonged ER stress causes 
translocation of intracellular molecules to the outer leaflet of the plasma membrane. 
This means that upregulation of surface CRT can be detected not only upon 
immunogenic cell death, but also in later stages of apoptosis (also called secondary 
necrosis). Although the details are not fully understood yet, it seems that pre-
apoptotic exposure of CRT (as it happens upon ICD induction) relies upon the 
concomitant translocation of the ER-associated molecule ERp57, as demonstrated 
by abrogation of CRT surface expression in ERp57-/- cells 19. In contrast, exposure 
of CRT occurring at later time points is independent on ERp57. This suggests that, 
the defined temporal sequence and the combination of immunogenic events are 
decisive to provide the security tokens to gain access to the initiation of a productive 
anti-tumor response 20. In this analogy, only the correct key-set (DAMPs) can open 
the locks (receptors), which make the way to DC maturation.
In vivo depletion of DCs abrogates tumor-specific immune cell activation, confirming 
that DCs are necessary for mounting effective immune responses against dying tumor 
cells following ICD 9,21. However, the presence of DCs per se is not sufficient to trigger 
T cell priming against tumor-associated antigens (TAA) 22. The immunostimulatory 
effect of CDDP in vivo, as evidenced by increased co-stimulatory molecule expression 
(CD80, CD86) on myeloid DCs, and subsequent induction of TAA-specific cytotoxic 
T cells, was abolished in mice lacking CD80 and CD86 on APCs 22. 
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The multistep process that leads to DC maturation consists of (at least) three 
defined parameters involving ICD-related DAMPs, released by dying tumor cells, 
and their specific receptors on DCs: recruitment, engulfment, activation. DCs need 
to be recruited to the proximity of dying tumor cells, they have to take up tumor 
antigens and then respond to activating stimuli to undergo phenotypical maturation 
and functional activation. If all these three steps are taken, DCs will merge the signals 
emanated by ICD-DAMPs and converge them into one command for launching an 
immune response. Absence of one or more of these ‘danger’ signals abrogates DC 
maturation and effective activation of the immune system. Accordingly, addition 
of recombinant CRT is not sufficient to dictate cellular immunogenicity and induce 
DC maturation 23. Although decisive for uptake, CRT does not provide maturation 
signals, which have to come from other cellular factors. CDDP-treatment of tumor 
cells in vitro, indirectly induces DC maturation, through the stimulatory activity of 
DAMPs, such as HMGB1 24,25. The binding of HMGB1 to its receptor, TLR4, seems to 
modulate DC function by inhibiting processing of tumor-antigens. Thus, tlr4-/-  DCs 
fail to perform cross presentation to CD8+ T cells, in vivo 21. Interestingly, absence 
of TLR4 does not affect expression of co-stimulatory molecule on DCs in response 
to HMGB1 stimulation. This suggests that additional locks might match the same 
key to unlocking phenotypical DC maturation 21,25. 
In other words, if the delivery of three different types of ‘danger’ signals 
(recruitment, engulfment, activation) is undoubtedly required for DC activation, 
there seem to be multiple ‘key-lock combinations’ that may act in concert to induce 
effective anti-tumor responses. In Chapter 2 we show that addition of blocking 
antibodies directed against CRT significantly reduced dying tumor-cell uptake by 
myeloid DCs. However, blockade of the most described CRT receptor, CD91, failed 
to impair tumor cell engulfment; pointing to the existence of additional players for 
CRT recognition. Previous studies indicated the scavenger receptor class-A (SR-A, 
also known as CD204) and the scavenger receptor expressed by endothelial cell-1 
(SREC-I) as additional CRT-receptors. However, it must be noted the evidence is 
limited to a small number of observations, mostly based on competition studies 
that showed that binding of soluble CRT to APCs was efficiently competed by the 
addition of the scavenger receptor ligand, fucoidan 26,27. In addition, recombinant 
expression of SREC-I in macrophages augmented recognition of CRT, further 
supporting SREC-I function in ecto-CRT binding 27. Our microarray analysis on 
primary DCs revealed differences in expression levels for SR-A and SREC-I between 
DC subsets. Both receptors, show high expression on human CD1c+ DCs while the 
expression on CD16+ DCs and pDCs is much lower. Although different receptors 
have been proposed to bind ecto-CRT, the actual contribution of each receptor to 
apoptotic cell engulfment have not yet been fully elucidated. 
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Human innate effector cells in ICD
Although many of the molecular characteristics that define immunogenic key-lock 
systems are being identified, our understanding at the level of the responding innate 
effectors, such as phagocytes, is still far from complete. This is due to the fact that, 
evidence of central role of DCs as main mediators of ICD is mostly based on studies 
performed with murine APCs or with human monocytes or moDCs. The findings 
presented in Chapter 2 propose, for the first time that, in the context of platinum-
induced ICD, induction of a T cell response relies on the critical contribution of 
certain DC subsets. In fact, we show that CD1c+ DCs are more efficient than CD16+ 
DCs and pDCs in stimulating ICD-mediated T cell proliferation. Further investigation 
should include studies on other naturally occurring DC subsets in humans, including 
tissue-resident and other blood circulating DCs. CD141+ DCs in humans and its 
murine equivalent CD8α+ DCs were described to be endowed with potent ability to 
prime tumor antigen specific immune responses 28,29,30. Hence, it would be crucial 
to also understand the role of this DC population in ICD-responses. Unveiling 
the molecular pathways, activated upon engagement of receptors on DCs by 
ICD-DAMPs, is pivotal to understand whether these key-lock interactions can be 
exploited to increase the efficacy of immunogenic inducers, and to develop new 
strategies for cancer therapy. 
CD47 in the tumor microenvironment limits anti-tumor 
immunity
Initially described as a regulator of cell clearance in physiological conditions for 
circulating erythrocytes, CD47 was soon reported to be widely expressed on nearly 
every cell type in the body and, most intriguingly, to be markedly upregulated 
on malignant cells 31. It became clear that overexpression of CD47 on tumor cells 
delivers an inhibitory message to both innate and adaptive immune cells, with the 
final effect of weakening the host immune system against cancer. Hence, CD47 is 
considered an adverse prognostic factor. Accordingly, analysis of immune infiltrate 
in mice revealed that high expression of CD47 in the TME is inversely correlated 
with T cell infiltrates; whereas blockade of CD47 enhances CD8+ T cell migration in 
the tumor and subsequently augments T cell-dependent, intra-tumoral granzyme 
B activity that induces death of malignant cells 32. 
CD47 on tumor cells
The most studied role of CD47 is linked to its ability to regulate immune evasion. 
Thus, blockade of CD47 in vivo restored macrophage-mediated immune 
surveillance, by reducing the ability of CD47 on tumor cells to engage SIRPα 
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on tumor-associated macrophages 33. Both in vitro and in vivo studies provided 
evidence that CD47/SIRPα pathway has a negative effect on uptake by APCs 34-36. As 
discussed in Chapter 3, CD47 on melanoma cells blocks uptake of tumor material 
by human macrophages, moDCs and the naturally-occurring DC subset, CD1c+ 
DCs and subsequently inhibits DC maturation and expression of co-stimulatory 
molecules. We therefore investigated the effect of CD47 blockade in co-cultures 
of tumor cells and DCs. Analysis of phagocytosis, by both flow cytometry and 
fluorescence microscopy, showed that addition of the anti-CD47 blocking antibody 
B6H12, yielded significant increase of uptake relative to IgG control or non-blocking 
anti-CD47 antibody, 2D3. Similarly to what we observed during time-lapse imaging 
of the reconstructed melanoma microenvironment (Chapter 4), DCs do not take 
up whole tumor cells, but rather engulf tumor particles. Besides impairing DC 
maturation, ligation of SIRPα with CD47-Fc fusion protein was shown to abrogate 
the migration of murine Langerhans cells (LCs) in vivo and in vitro, in response to 
inflammatory stimuli 37. Moreover, it is proposed that, the downstream inhibitory 
signaling delivered to macrophages or DCs via SIRPα engagement, induces the 
formation of “giant cells”, generated by the fusion of the tumor cell with phagocyte. 
As described for melanoma cells fused with macrophages, this cell-to-cell fusion 
may favor tumor dissemination and metastasis 38. Although this mechanism remains 
controversial for the lack of proof of concept in vivo, it is certainly intriguing and 
may be not be completely excluded. 
One of the additional names by which we identify CD47 is “integrin-associated 
protein (IAP)”. CD47 was initially shown to associate with α-integrins (in particular α3βV) 
and together regulate neutrophil transmigration through the endothelium, during 
inflammatory responses 39. Likewise, CD47 on lymphoma cells stimulates malignant 
cell migration through a tight cooperation with α4β1 integrins 
40. Accordingly, the 
αVβ3 integrin (vitronectin receptor)-dependent migration of melanoma, prostate 
cancer and ovarian cancer cells was markedly reduced by the addition of neutralizing 
antibodies against CD47 41.
The first identified endogenous ligand for CD47 was thrombospondin-1 
(TSP-1). TSP-1 is a calcium binding protein and participates in multiple biological 
processes 42. High levels of TSP-1 are commonly found in stromal fibroblasts and 
endothelial cells within tumors 43,44. Binding of TSP-1 to CD47 induces activation of 
the downstream signaling pathway PI3K/Akt, which has been reported either to 
induce apoptosis or to enhance proliferation and survival of malignant astrocytoma 
cells 45,46. These observations are somewhat paradoxical and thus far, the molecular 
basis of CD47-induced programmed cell death/survival are not fully understood. 
Further investigation on the mechanisms regulating therapeutic resistance in cancer 
cells, suggested that TSP-1/CD47 interaction may (either directly or indirectly) 
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mediate tumor sensitivity to anti-cancer therapy. In human prostate cancer or gastric 
cancer cells, activation of the drug-resistance gene, taxol-resistant gene 1 (Txr1) 
and expression of Txr1 protein, dramatically down-regulated TSP-1. Lack of TSP-1 
in turn, conferred resistance to taxol and OXP 47. Indication of the involvement of 
CD47 signalling was given by stimulation of CD47 with exogenous administration 
of TSP-1 or anti-CD47 moAbs, reverting drug resistance and increasing cellular 
sensitivity to taxanes 47. 
CD47 on immune cells
Professional APCs, such as monocytes, macrophages and DCs, co-express SIRPα 
and CD47. Therefore, in a complex cellular environment as found within the TME, 
APCs can be stimulated either by SIRPa-engagement (blocking of phagocytosis 
and inhibition of DC maturation and migration), or by CD47-binding to its cognate 
receptors and ligands.
Expression of CD47 on DCs mediates a series of complex – yet not fully understood 
– cellular mechanisms that regulate DC activation and migration. Blocking of CD47 
on murine LCs suppressed the expression of CD80 and CD86, and significantly 
affected migration of LCs from the epidermis into the draining lymphnode, following 
treatment with the proinflammatory cytokine TNF-α 48 Accordingly, absence of CD47 
on myeloid DCs of skin in mice, impaired skin DC migration, trafficking to secondary 
lymphoid organs and T-cell priming, both at steady state and under inflammatory 
conditions 49,50 Altogether, these observations suggest that CD47 expression is 
required on DCs for efficient DC trafficking.
By contrast, CD47 may also reduce the efficacy of immune responses by inducing 
tolerance towards the tumor. In particular, activation of CD47, by tumor-secreted 
TSP-1 or anti-C47 moAbs, inhibits DC maturation and function, observed as 
down-modulation MHC molecules and co-stimulatory molecules, inhibition of pro-
inflammatory cytokine (IL12, TNFα and IL6) secretion and impaired T- cell stimulation 
by DCs 50. Moreover, it seems that CD47 stimulation may induce clearance of DCs 
by triggering programmed cell death 51.
CD47 expression was also reported on T cells where, upon binding of TSP-1, 
it serves as a self-control negative regulator of inflammation and activation of Th1 
responses 52,53. This effect seems to be in part dependent on the inhibition of the 
autocrine activating function of hydrogen sulfide signaling in T cells 54-56. As a result, 
T cells become hyporesponsive or anergic 57. Additionally, CD47/TSP signaling 
triggers the conversion of naïve or memory CD4+CD25+ T cells into regulatory T cells 
(Tregs) in response to inflammation 58. Moreover, TSP-1/CD47 interaction on T cells 
has been described to cause profound inhibition of the nitric oxide/cGMP signaling, 
which in turn regulates several death/survival pathways 59. 
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In conclusion, given the broad expression of CD47 and its role in regulating 
multiple cellular processes, it represents a potential target for therapeutic blockade 
in cancer patients. In fact, treatment with CD47 blocking antibodies, which can 
inhibit both SIRPα and TSP1 binding to CD47, could directly modulate innate as well 
as adaptive anti-tumor immunity. 
Combining immunotherapy with strategies that increase tumor 
immunogenicity
Phagocytosis requires the coordinated expression of “eat me” signals and disruption 
of “don’t eat me” signals. In Chapter 3 we exploited the possibility of inducing 
immunogenic pro-phagocytic signals (such as CRT), while blocking the most potent 
anti-phagocytic signal described to date, CD47. We show that either addition of 
anti-CD47 moAbs to live cells or platinum treatment alone enhanced tumor uptake 
by DCs. However, combining chemotherapy with CD47 blockade did not potentiate 
phagocytosis. Many factors might be responsible for the lack of a synergistic effect. 
The significant ICD-induced upregulation of surface CRT might dominate over the 
targeting of CD47 with blocking antibodies, which may in turn be insufficient to 
warrant induction of cellular engulfment. A second possible explanation may be 
that, upon induction of apoptosis, CD47 alters its plasma membrane distribution. 
In particular, CD47 on dying cells redistributes into patches that were described to 
decrease its ability to engage SIRPα 60. Additionally, in situ competition with other 
CD47 ligands, such as integrins or TSP-1, might compromise CD47 availability for 
the binding of blocking moAbs. 
In this regard, it is worth mentioning that upon ICD induction, TSP-1 is actively 
secreted into the extracellular matrix, where it serves as an “eat me” signal, in 
addition to CRT. TSP-1 functions as a bridging molecule between apoptotic 
and phagocytic cells. In particular, TSP-1 binds to APCs via the multi-molecular, 
TSP-1/CD36/αv-integrins (αvβ3 or αvβ5) complex and triggers the formation 
of protein complexes that increase APC phagocytic ability. 61-64. In support 
of these findings, blockade of any one of the elements involved in the TSP-1/
CD36/αvβ3 complex, resulted in abrogated phagocytosis of dying cells by human 
macrophages62,63. 
Despite the lack of a synergistic effect between ICD and CD47 blockade on 
tumor cell uptake by CD1c+ DCs, we reported a potential effect on DC maturation 
when chemotherapy was administered before anti-CD47 blocking antibodies. In 
support of our observation, in vivo administration of chemotherapy before, but not 
after, treatment with anti-CD47 moAbs promoted tumor cell death, which in turn 
enhanced engulfment of tumor cells by APCs and enabled processing and cross- 
presentation of tumor antigens to CD8+ T cells. Interestingly, this study underscored 
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the fact that cross-prime of cytotoxic T cells, in the presence of CD47 blocking 
agents and chemotherapy-treatment, was almost exclusively depended on DCs 
rather than macrophages 65.
In this thesis, we have extensively discussed the ability of chemotherapeutic 
drugs to induce ICD. Additionally, other therapeutic modalities, including radiation 
therapy, have been reported to act as ICD inducers, and showed therapeutic 
potential in combination with CD47 blockade 7. In particular, blockade of CD47 or its 
deficiency, in combination with ionizing radiation (IR) resulted in increased radiation 
sensitivity of implanted melanoma or squamous carcinoma cells, which eventually 
caused delay in tumor growth, in vivo. This effect was associated with enhanced 
blood flow, improved tumor oxygenation and increased infiltration of cytotoxic 
lymphocytes 66,67. Moreover, CD47 blockade seems to provide radioprotection of 
normal soft tissue, bone marrow and tumor-infiltrating leukocytes, by activation 
of pro-survival mechanisms regulating autophagy 67. In other words, while 
immunogenic apoptosis, as a result of chemo- or radiation therapy, is an important 
contributor of anticancer immune responses; the combination of ICD induction 
with moAbs, targeting malignant cells, may further increase the therapeutic effect 
of these strategies. Thus, if further investigation confirms safety for host cells in the 
tumor stroma, in combination with damage to tumor cells caused by treatment, 
this approach may shed light on new complementary combination strategies for 
future trials.
Modelling cancer in 3D
Albeit informative for basic aspects of cancer biology, two-dimensional (2D) culture 
systems are a poor copy of the in vivo cellular environment, as they do not accurately 
mimic the meshwork of human tissues. In vivo, cells face complex and structurally 
heterogeneous 3D tissue architectures and are exposed to a multitude of cellular 
and extracellular matrix (ECM) parameters, which influence tumor growth and 
the ability of stromal and immune cells to orchestrate immune responses locally. 
Chapter 4 presents an in vitro 3D organotypic skin model of melanoma, which will 
serve as a model of malignancy to deepen our understanding of the drivers of 
cancer and immune evasion. 
Three exciting facets summarize the potential of our in vitro 3D model for tumor-
immunology research. Firstly, the ability of ensuring the correct geometry and 
spatial distribution of cells. Secondly, the capacity to experimentally manipulate 
each component of the TME. Thirdly, the possibility to investigate normal and 
malignant cell regulation within the local TME, and how this changes during cancer 
related inflammation as opposed to steady state.
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Possibilities and challenges 
Tumor growth and dissemination
Tumor cell invasion into adjacent tissues is a key step of cancer dissemination that 
leads to metastases. 3D cancer models offer the unique possibility to investigate 
such processes, which would be otherwise impossible in conventional cell cultures. 
Melanoma cell lines, obtained from different stages of tumor progression, show 
characteristic invasive behavior when cultured in 3D skin reconstructs. Thus, 
cells derived from radial growth phase (RGP) lesions, characterized by limited 
invasiveness, form nests in the epidermis and leave the BM intact; whereas cells 
from vertical growth phase (VGP) invade the dermal compartment 68,69. Researchers 
have also shown that dermal invasion, mediated by the proteolytic activity of matrix 
metalloproteinases (MMPs), is strictly dependent on the interaction of melanoma 
cells with keratinocytes 70. Metastatic melanoma cell lines, unable to degrade the BM 
and migrate through the dermis when cultured alone on DEDs, actively invaded in 
the presence of adjacent normal epidermal cells. In our model, we tested the growth 
behaviors of a panel of established metastatic melanoma cell lines. Interestingly we 
observed that the BLM melanoma cell line formed tumor nests at the epidermal-
dermal junction and invaded the dermis mostly as single cells; while a distinct cell 
line, Mel-624, proliferated forming larger and more compact groups of cells and 
invaded as a bulk of malignant cells (data not shown). 
Conventional anti-cancer therapy
Organotypic cancer models are valuable platforms to unravel mechanisms of resistance 
to targeted anti-cancer therapies. Studies have shown that growing cells in 3D confers 
resistance to chemotherapy, as compared to cells grown in 2D monolayers. One of 
the possible reasons is that the drug penetration through multicellular structures is 
heterogeneous. The quiescent population sequestered on the inside of the cellular 
cluster is less exposed to the drug than the cells on the outside of the cluster and will 
likely remain protected from the drug. If therapy is halted too early, these protected 
cells may be able to re-enter the cell cycle and recapitulate a tumor that was shrunk 
but not completely killed 71-73. In addition to this, 3D cell cultures profoundly affect 
gene expression and likely influence regulation of genes involved in drug resistance 74. 
Hence, 3D models offer the opportunity to validate multi-drug therapy regimens in 
vitro, before proceeding to pre-clinical testing and ultimately clinical trials. This may 
greatly improve the understanding of cancer biology, eliminate poor drug candidates 
and reveal new physiologically relevant targets that might have been missed in 2D 
studies. Surely, there are certain aspects of efficacy and toxicity that will always require 
evaluation in animal models prior to human clinical trials. 
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In this view, investigation of ICD-related mechanisms, induced by chemotherapy 
or radiation therapy, may greatly benefit from a 3D approach that includes tumor, 
stromal and immune compartments. We attempted to exploit this aspect and 
performed preliminary experiments to test whether chemotherapy treatment would 
affect skin morphology and tumor growth. We observed that increasing drug dosage 
and treatment duration augments cancer cell death, preeminently in compact tumor 
clusters, without dramatically disturbing normal tissue cells (data not shown). In vivo 
studies reported that DAMP release upon CDDP treatment favored the intra-tumor 
recruitment of inflammatory APCs (macrophages and DCs) 22,75. Therefore, it would 
be of particular relevance using our model to evaluate the effect of ICD on the 
local environment (that includes not only immune cells, but also epidermal cells and 
fibroblasts), in order to understand how this influences DC responses. 
Immunotherapy targeting cellular checkpoints
In Chapter 4 we showed that DCs encounter tumor cells, sense their presence and 
efficiently take up tumor material. This process may likely influence their phenotype 
and activation status, as suggested by our co-culture experiments performed in 
conventional 2D cultures (described in Chapter 3). Conceivably, the local TME also 
plays a role in shaping DC behavior. Thus, as a desirable follow-up it would be to 
crucial to confirm our 2D data in a more complex 3D system. Next, we may further 
explore the addition of moAbs targeting inhibitory molecules on tumor cells, such 
as the “don’t eat me” signal CD47. Alternatively, we could exploit the use of newly 
developed moAbs targeting the CD47 receptor, SIRPα on DCs 76. Because CD47 is 
a ubiquitous molecule, broadly expressed on non-malignant and malignant cells, 
targeting SIRPα in our 3D model might be more informative than employing moAbs 
against CD47. This would provide deeper understanding of the role of CD47-SIRPα 
interactions in the context of DC function. 
The 3D skin melanoma model, as presented in this thesis, was generated using 
a combination of primary human factors (dermis, KCs, Fbs, DCs) and cell lines 
(melanoma cell lines). This seems comprehensible as the primary goal of our study was 
to prove feasibility, reproducibility and applicability of the 3D tissue reconstruction 
into distinct aspects of cancer research. Nevertheless, our 3D organotypic model 
may also become a useful tool to study tumor-associated effects on the adaptive 
immune system. The integration of adaptive immune cells within a reconstructed 
TME requires extra care, particularly in the context of human leukocyte antigen 
(HLA) matching. For this reason, during the time of completion of this thesis, we have 
been exploring the possibility of taking the model to the next level and attempted 
to inoculate tumor and stromal components derived from tumor biopsies. This will 
be followed by the addition of immune cells, isolated from the same patient. The 
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model may therefore become extremely relevant to investigate mechanisms that 
regulate checkpoint inhibition by immunotherapy, such as those related to the use 
of anti-CTLA-4 or anti-PD-1 moAbs in melanoma treatment.
Discovery of new biomarkers for immunotherapy
T cell-mediated anti-tumor immunity can be exploited therapeutically in several 
ways, including cell-based immunotherapy (such as DC vaccination strategies and 
adoptive T cell transfer) and antibody-based immunotherapy (such as anti-CTLA-4 
or anti-PD-1). These therapeutic approaches have shown significant success in a 
number of patients. However, we still do not understand why some patients respond 
very well to immunotherapy, while others do not. The discovery of cellular and 
molecular biomarkers that can predict clinical benefit of distinct anti-tumor therapies 
is, therefore, a crucial need. As recently reported by our group, accurate analysis of 
density and distribution of T cell infiltrates in primary melanomas, assessed by the 
multispectral imaging approach presented in Chapter 5, can be a potential biomarker 
for treatment selection. In particular, the presence of large numbers of CD3+ T cells 
inside the primary tumor, as compared to peritumoral regions, correlates with long 
survival of metastatic melanoma patients who received DC vaccination, even several 
years after primary tumor resection 77. As mentioned earlier in this thesis, the fate 
of clinical efficacy of anti-cancer treatments can be mostly attributed to a complex 
- yet not fully understood - TME. By supporting a heterogeneous growth of cells 
in 3D and offering the possibility to manipulate the local tumor environment, our 
organotypic model of melanoma could be used to explore the role of key cellular 
and molecular components that determine the induction of anti-tumor immunity. 
This will greatly contribute to our growing knowledge about the TME, and especially 
how it can be manipulated in a therapeutic setting, ultimately supporting future 
biomarker identification for personalized anti-cancer therapy. 
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Nederlandse samenvatting
Onze afweer bestaat uit twee verschillende onderdelen: Het aangeboren 
immuunsysteem en het adaptieve immuunsysteem. Deze systemen zijn verbonden 
door het functioneren van antigen presenterende cellen (APCs). In het aangeboren 
immuunsysteem tasten APCs hun directe omgeving af voor pathogenen of, in 
de context van kanker, maligne cellen. Wanneer bepaalde signalen van dreiging 
herkent worden, nemen APCs tumormateriaal op via fagocytose. Vervolgens, 
in het adaptieve systeem, activeren APCs andere immuuncellen (T lymfocyten), 
resulterend in langdurige bescherming tegen kankercellen. De dendritische cel (DC) 
staat bekend als een professionele APC en is, in de context van kanker, centraal 
voor de herkenning en verwijdering van tumormateriaal. Succes van een anti-tumor 
respons hangt logischerwijs samen DC functionaliteit. Wanneer activiteit van DCs 
wordt verzwakt leidt dit tot immuun tolerantie voor kankercellen, terwijl functionele 
DCs T lymfocyten kunnen instrueren om kankercellen onschadelijk te maken. 
Tumorprogressie gaat vaak gepaard met verscheidene mechanismes die het 
immuunsysteem onderdrukken waardoor de tumor detectie en destructie voorkomt. 
Zodoende vormt zich een tumor micro-omgeving (TME, uit het Engels: tumor 
microenvironment) die immunologisch onderdrukt wordt en waarin verschillende 
immuuncellen, waaronder DCs, verzwakt zijn. In de TME interfereren kankercellen 
direct met DC functie waardoor expressie van specifieke DC markers wordt 
gemoduleerd en secretie van ontstekings moleculen wordt verlaagd. Daarnaast 
beïnvloed de tumor ook de werking van gezonde cellen in het omliggende weefsel. 
Dit leidt tot een omgeving die tumorprogressie en metastase bevordert terwijl een 
mogelijke immuun respons onderdrukt wordt.
Het doel van anti-kanker behandelingen is om de tumor te vernietigen. Om 
dit doel te bereiken zal het onderdrukte immuunsysteem vrij gemaakt moeten 
worden. Dit kan enerzijds via vernietiging van de kankercellen (met conventionele 
chemotherapie) of door immunologische remmen los te laten (immuuntherapie). 
Het eerste doel van dit proefschrift was het verkrijgen van meer inzicht op het 
effect van immuun onderdrukking op humane DCs; en op twee verschillende kanker 
therapieën die, in potentie, DC functie zouden kunnen herstellen. 
In dit proefschrift demonstreren we dat effectiviteit van chemotherapie gedeeltelijk 
afhankelijk is van ons immuunsysteem. Veel onderzoek is verricht naar moleculaire 
parameters die gunstig zijn voor chemotherapie geïnduceerde immunogene 
celdood (ICD, uit het Engels: immunogenic cell death). Niettemin is er weinig 
bekend over immuuncellen die tumorcellen herkennen die ICD ondergaan. Sterker 
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nog, de rol van humane circulerende DC subsets, zoals CD1c+ en CD16+ myeloide 
(mDCs) en plasmacytoide (pDCs) DCs, is in de context van ICD nooit bestudeerd. 
In Hoofdstuk 2 belichten we het unieke vermogen van humane CD1c+ DCs om anti-
tumor reacties op te wekken na inductie van ICD met platinum drugs. We stelden 
vast dat behandeling van verschillende tumorcellijnen met een klinisch relevante 
dosis van oxaliplatin (OXP) of cisplatin (CDDP) celdood veroorzaakt die consistent is 
met ICD. Deze waarneming bevestigt het vermogen van OXP om ICD op tumorcellen 
van verschillende afkomst te bewerkstellingen en voegt CDDP toe aan de lijst van 
ICD drugs. Behandeling van kankercellen met platinum drugs brengt calreticulin 
(CRT) tot expressie. Blootstelling van CRT zorgde voor fagocytose van tumorcellen 
door humane DC subsets. Opvallend was dat opname van tumormateriaal door DCs 
niet stopte na blokkade van de CRT receptor CD91. Deze waarneming suggereert 
dat naast CD91 ook andere receptoren betrokken zijn in CRT interactie. Daarnaast 
demonstreerden we dat detectie van de ICD signalen (HSPs, ATP and HMGB1) 
bijdragen aan mDC en pDC maturatie. Ten slotte hebben we vastgesteld dat, hoewel 
alle DC subsets matureren na contact met platinum behandelde tumorcellen, alleen 
CD1c+ DCs effectief T-cel vermenigvuldiging stimuleren. Deze nieuwe bevindingen 
suggereren een specialisatie van specifieke humane DC subsets in reactie op ICD 
door chemotherapie. 
De interactie tussen tumorcellen en DCs interfereert met DC functie. In 
Hoofdstuk 3 resulteerde celkweek van DCs met tumorcellen in een verminderde 
expressie van co-stimulatoire moleculen (CD80, CD 86) en het major histocompatibility 
complex (MHC) I en II. Dit ging gepaard met een verminderde secretie van het pro-
inflammatoire cytokine TNF-α en verhoogde secretie van het anti-inflammatoire 
cytokine IL-10. Deze veranderingen leidden uiteindelijk tot een verzwakte inductie 
van T-cel proliferatie door DCs.
Blokkade van de remmende CD47/SIRPα signaaltransductie heeft therapeutische 
effectiviteit in verschillende pre-klinische tumormodellen. Dit voordelige effect 
hangt af van het vermogen van APCs om tumormateriaal op te nemen en het 
adaptieve immuunsysteem te activeren. Fagocytose wordt gereguleerd door een 
balans van tussen pro- en anti-fagocytose signalen van defecte cellen. Data laat zien 
dat het dominante ‘’eat me’’ signaal CRT wordt tegengewerkt door het “don’t eat 
me” signaal van CD47. In Hoofdstuk 3 beschrijven we dat blokkering van CD47 zorgt 
voor een verhoogde opname van tumormateriaal door humane CD1c+ DCs. De 
opname van tumorfragmenten induceerde DC activiteit en ging immunosupressie 
tegen. Daarnaast hebben in vivo studies gedemonstreerd dat blokkade van CD47 
in combinatie met immunogene stimuli leidt tot een verbeterde anti-tumor respons. 
Hoewel in onze studie de combinatie van platinum behandeling met anti-CD47 
antilichamen het fagocyterende vermogen van DCs niet veranderde, observeerden 
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we wel een verhoging van de co-stimulatoire marker CD86. De waarnemingen in 
hoofdstuk 3 vergroten onze kennis van de rol van DCs in de context van immuun 
onderdrukking door tumoren, en geven een rationaal voor verder onderzoek naar 
combinatie tussen chemo- en immunotherapie. 
DC activiteit wordt beïnvloedt door een complex proces waarin twee factoren een 
belangrijke rol spelen; cel-cel contacten en de celbiologische context waarin de 
DCs zich bevinden. Gezien deze complexiteit moeilijk te vangen is in conventionele 
2D modellen, hebben we een innovatief 3D huidmodel ontwikkeld om immuniteit 
in melanoom te bestuderen. 
Hoofdstuk 4 omschrijft de ontwikkeling van een 3D organotypisch model van de 
humane melanoom om interacties tussen DCs tumorcellen in een 3D structuur te 
bestuderen. De huid wordt gekarakteriseerd door een moleculaire compositie, een 
rigide organisatie en aanwezigheid van fysieke barrière, welke moeilijk na te bootsen 
in een collageen matrix. Het gebruik van dermale componenten van humane 
herkomst zorgt voor een correcte ruimtelijke indeling en voorziet een fysieke 
barrière via het basale membraan waarin celmigratie en cel-cel interacties worden 
bevorderd. Daarnaast biedt dit model de mogelijkheid om lokaal gecontroleerd de 
cellulaire omgeving te moduleren, waarbij celdood tot een minimum wordt beperkt. 
Tevens biedt een gereconstrueerde 3D micro-omgeving een potentieel platform 
om migratie en invasie van kankercellen in omringend weefsel te bestuderen, de 
bijdrage van stromacellen in kanker progressie te analyseren en DC functie in de 
TME te onderzoeken. Via dit model demonstreren we dat DCs efficiënt migreren 
langs het extracellulaire netwerk, interactie vormen met maligne tumorcellen 
waardoor DCs tumormateriaal opnemen. Verder hebben we vastgesteld dat 
maligne en gezonde cellen hun basis functies behouden in dit huidmodel voor 
melanoom. Samenvattend suggereren onze waarnemingen dat het huidmelanoom 
model superieur is over huidige modellen en ingezet kan worden om complexe 
processen in de TME te bestuderen. 
In het laatste decennium zijn verschillende immuuntherapieën beschikbaar gemaakt 
voor behandeling van verschillende tumoren, inclusief melanoom. Ondanks dat 
deze behandelingen therapeutisch effectiviteit hebben in een aanzienlijk deel van 
de patiënten, zijn er nog veel obstakels die overwonnen moeten worden. Zo zijn 
de huidige therapieën duur, potentieel cytotoxisch en suboptimaal. Daarom is de 
vraag naar biomarkers die in een vroeg stadium effectiviteit van een bepaalde 
immunotherapie kunnen voorspellen hoog. Het kwantificeren van immuuncellen 
die tumoren infiltreren is een belangrijke factor in de zoektocht naar nieuwe 
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biomarkers. Recent onderzoek in het veld van tumor immunologie demonstreerde 
dat infiltratie van immuuncellen, zoals CD3+ T-lymfocyten, binnen de TME invloed 
hebben op de inductie van tumor specifieke immuunreactie. Hoofstuk 5 behandelt 
de potentie van multispectral imaging (MSI) om accuraat immuuncel infiltraten 
the karakteriseren, ook in weefsel wat karakterisatie voorheen bemoeilijkte. De 
innovatieve MSI techniek combineert imaging met spectroscopy om kwantitatief 
de expressie en distributie van verschillende celtypen in de TME te bepalen. In 
melanoom interfereren donkere melanine pigmenten met de juiste karakterisatie 
van verschillende celtypes van het immuunsysteem. In dit hoofdstuk, hebben we 
twee methodes toegepast om T cel infiltratie te kwantificeren en stelden we vast dat 
gebruik van unmixing in multispectral imaging leidde tot een accurate vaststelling 
van infiltrerende T lymfocyten in melanoom. 
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Riassunto in italiano
Il sistema immunitario è l’insieme delle nostre naturali armi di difesa ed è costituito 
da due “armate”, distinte tra loro ma strettamente interconnesse: quella del sistema 
immunitario innato e quella dell’adattivo. Queste due armate sono coordinate 
dalle cellule che presentano l’antigene (APCs, dall’inglese: antigen presenting 
cells). A seguito dell’insorgenza del tumore, le APCs percepiscono la minaccia e 
rilevano la presenza di cellule maligne. Ciò fa scattare la cattura (fagocitosi) di 
materiale derivante dalle cellule tumorali (antigeni tumorali) da parte delle APCs 
e ne stimola l’attivazione. Le APCs, così attivate, istruiscono le cellule del sistema 
immunitario adattivo a riconoscere il tumore. Il successo di questa azione culmina 
con la stimolazione di una risposta immunitaria durevole ed altamente specifica che 
distrugge le cellule maligne. 
Grazie a queste peculiari caratteristiche, le cellule dendritiche (DCs, dall’inglese 
dendritic cells), un tipo specifico di APCs, sono definite le sentinelle del sistema 
immunitario.  L’efficienza con la quale le cellule dendritiche percepiscono i segnali 
di pericolo e li comunicano all’armata del sistema adattivo, determina il destino 
della risposta anti-tumorale. Questa efficienza dipende dal loro stato di attivazione: 
un’attivazione parziale o difettosa delle cellule dendritiche genera uno stato di 
tolleranza verso le cellule maligne; al contrario, cellule dendritiche funzionali 
favoriscono l’eliminazione del tumore, da parte delle cellule T linfocitarie del 
sistema adattivo.
Tuttavia, al fine di sfuggire alla sorveglianza immunitaria e sopravvivere, le cellule 
tumorali si servono di strategie definite immunosoppressive, ossia che sopprimono 
la risposta immunitaria. Lo studio di queste strategie ha fatto luce sull’esistenza di 
un micro-ambiente (o habitat) tumorale, che è stato dimostrato essere il principale 
artefice della mancata attivazione delle cellule dendritiche. Nel micro-ambiente 
tumorale le cellule maligne possono, da una parte, interferire direttamente con le 
principali funzioni delle cellule dendritiche; dall’altra, modulare il comportamento 
di altre cellule sane che si trovano in prossimità. In questo modo, il tumore 
genera un habitat favorevole per la propria crescita ed ostile verso l’attivazione di 
risposte immunitarie efficaci. L’intento delle terapie oncologiche è quindi quello 
di distruggere le cellule tumorali (come nella chemioterapia convenzionale) ed 
annientare i meccanismi immunosoppressivi che impediscono un’adeguata azione 
anti-tumorale (attraverso l’immunoterapia). 
I primi obiettivi di questa tesi sono stati quelli di studiare l’attività immunosoppressiva 
delle cellule tumorali a danno delle cellule dendritiche, e verificare la potenzialità di 
due distinte strategie anti-tumorali di rispristinarne la corretta attivazione.
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L’efficacia della chemioterapia dipende, in parte, dalla presenza di un sistema 
immunitario funzionale. Gli agenti chemioterapici esercitano la loro azione 
causando la morte delle cellule tumorali, che in alcuni casi può avere caratteristiche 
immunogeniche (ICD, dall’inglese immunogenic cell death), ossia che stimola una 
risposta immunitaria. I parametri molecolari che determinano l’effetto benefico 
della ICD sono stati al centro di molti studi nell’ultimo decennio. Tuttavia, resta 
ancora da capire quali sono le principali cellule immunitarie che, a seguito del 
trattamento con farmaci chemioterapici, rilevano le cellule tumorali danneggiate. In 
particolare, il ruolo delle sentinelle del sistema immunitario – le cellule dendritiche – 
in questo contesto non è mai stato delineato. Nel Capitolo 2, abbiamo confrontato 
diverse classi di cellule dendritiche presenti nel sangue: le mieloidi, CD1c+ DCs e 
CD16+ DCs, e le plasmacitoidi, pDCs; evidenziando la capacità unica delle CD1c+ 
DCs di mediare una risposta immunitaria anti-tumorale, a seguito dell’induzione 
di ICD. Abbiamo riportato che, il trattamento di diverse linee cellulari tumorali 
umane, con dosi clinicamente rilevanti di agenti chemioterapici a base di platino, 
quali l’oxaliplatino (OXP) o il cisplatino (CDDP), causa una forma di morte cellulare 
compatibile con ICD. Le cellule tumorali che subiscono ICD espongono sulla loro 
superficie la molecola calreticulina (CRT), che funge da segnale “eat me” (trad. 
“mangiami”) riconosciuto dalle cellule immunitarie. La presenza della CRT facilita 
la cattura delle cellule tumorali da parte delle cellule dendritiche, come confermato 
dall’utilizzo di peptidi bloccanti che interferiscono con questa interazione. Abbiamo 
inoltre dimostrato che, i segnali rilasciati dalle cellule tumorali in risposta alla ICD 
(HSP, ATP e HMGB1) contribuiscono alla maturazione delle cellule dendritiche. 
Nonostante l’avvenuta maturazione di tutte le classi di cellule dendritiche osservate 
nello studio, solo le CD1c+ DCs sono in grado di stimolare la proliferazione delle 
cellule T linfocitarie. Questi nuovi risultati suggeriscono una specializzazione 
funzionale delle diverse classi di cellule dendritiche, in risposta al trattamento 
chemioterapico che causa ICD. 
L’interazione tra le cellule tumorali e le cellule dendritiche ha un effetto drammatico 
sull’attivazione e sulla funzionalità delle sentinelle del sistema immunitario. Come 
descritto nel Capitolo 3, la presenza di cellule tumorali causa una diminuzione 
dell’espressione di marcatori di superficie, quali le molecole co-stimolatorie 
(CD80, CD86) ed il complesso maggiore di istocompatibilità (MHC, dall’inglese: 
major histocompatibility complex). Questa modulazione è accompagnata da una 
ridotta secrezione della citochina pro-infiammatoria TNF-α, e dall’aumento della 
produzione della citochina anti-infiammatoria IL-10. Il risultato di tali cambiamenti è 
un’alterazione nella capacità delle cellule dendritiche di stimolare la proliferazione 
delle cellule T linfocitarie. 
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Il blocco della via di segnalazione inibitoria mediata dalla proteina di membrana 
CD47 ha mostrato efficacia terapeutica in vari modelli murini di tumori maligni. 
Il vantaggio di questa strategia si basa sulla possibilità di ripristinare la cattura 
(fagocitosi), da parte delle cellule dendritiche, di materiale derivante dalle 
cellule maligne e stimolare così l’immunità adattativa. La fagocitosi è regolata 
dal bilanciamento tra segnali pro-fagocitici ed anti-fagocitici, forniti dalle cellule 
bersaglio. Sulle cellule tumorali, il segnale “eat me” (trad. “mangiami”), generato 
dalla molecola CRT (descritta nel capitolo 2), è controbilanciato dal segnale “don’t 
eat me” (trad. “non mangiarmi”), fornito dalla molecola CD47. 
Nel capitolo 3 abbiamo riportato che il blocco del segnale “don’t eat me”, 
CD47, attraverso l’utilizzo di specifici anticorpi monoclonali, aumenta la cattura di 
antigeni tumorali da parte delle cellule dendritiche, CD1c+ DCs. Il potenziamento 
della fagocitosi stimola a sua volta la maturazione delle cellule dendritiche e 
contrasta l’immunosoppressione provocata dal tumore. Studi su modelli animali 
hanno dimostrato che l’effetto del blocco del segnale “don’t eat me”, CD47, può 
essere ulteriormente potenziato dal trattamento chemioterapico, che induce 
morte tumorale ed è accompagnato dall’espressione del segnale “eat me”, 
CRT. La combinazione di queste due strategie anti-tumorali non ha mostrato un 
aumento della fagocitosi da parte delle CD1c+ DCs; tuttavia, abbiamo riportato un 
aumento dell’espressione del marcatore di maturazione, CD86. Non solo queste 
osservazioni ampliano le nostre conoscenze sul ruolo delle cellule dendritiche nel 
contesto dell’immunosoppressione mediata dal tumore; ma forniscono anche una 
base razionale per approfondire lo studio della cooperazione tra la chemioterapia 
convenzionale e le nuove strategie oncologiche basate sull’immunoterapia. 
In questa tesi abbiamo sottolineato più volte il concetto che, il contesto biologico del 
micro-ambiente tumorale e la comunicazione tra le cellule, sono determinanti chiave 
del processo che controlla l’attivazione della risposta anti-tumorale. A causa della 
mancanza di complessità fisiologica che caratterizza le colture cellulari in monostrato 
bi-dimensionale (2D), un’altra parte di questo lavoro è stata dedicata ad esplorare 
nuove tecniche, che contribuiranno alla nostra comprensione della complessità dei 
tessuti in vivo.
Il Capitolo 4 descrive lo sviluppo di un modello tri-dimensionale (3D) di tumore 
della pelle: il melanoma cutaneo. Questo modello permette di osservare e studiare 
la comunicazione tra cellule maligne e cellule sane, in un micro-ambiente tumorale 
molto simile al tessuto umano. 
La pelle è caratterizzata da una composizione molecolare definita e dalla 
presenza di interfacce fisiche, che sono difficili da riprodurre fedelmente utilizzando 
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matrici di collagene. L’utilizzo di una componente dermica di derivazione umana 
fornisce lo spazio e l’orientamento corretto. Inoltre, la membrana basale agisce 
come una barriera fisica che favorisce o limita la motilità e l’interazione cellulare. 
Un ulteriore vantaggio di questo modello di melanoma cutaneo in vitro è dato 
dalla possibilità di modulare l’ambiente cellulare locale, in modo controllabile e 
riproducibile, titolando quantità e tipologie cellulari, e garantendo nel contempo 
la sopravvivenza di tutti i tipi di cellule coinvolte. Questo modello rappresenta una 
piattaforma sulla quale studiare la migrazione e l’invasione delle cellule tumorali nei 
tessuti circostanti, il contributo di altre cellule sane nello sviluppo del tumore, nonché 
indagare la regolazione delle proprietà funzionali delle cellule dendritiche all’interno 
del micro-ambiente tumorale. A questo proposito, abbiamo osservato che le cellule 
dendritiche, dopo aver migrato lungo il reticolo extracellulare, interagiscono con 
le cellule maligne e le catturano. Ciò indica che il nostro modello 3D di melanoma 
cutaneo può essere sfruttato per studiare nel dettaglio le intricate dinamiche 
cellulari del micro-ambiente tumorale, ed offre molteplici vantaggi rispetto agli 
approcci convenzionali di culture 2D monostrato, che mancano della complessità 
fisiologica tipica dei tessuti umani. 
Nell’ultimo decennio, le strategie immunoterapiche hanno trovato applicazione per 
il trattamento di diverse forme tumorali, tra cui il melanoma cutaneo. Nonostante 
il beneficio terapeutico osservato in molti pazienti, alcune sfide restano ancora 
da affrontare. Queste sono associate a costi elevati, ad una potenziale tossicità e 
al rischio di una mancata risposta terapeutica. Pertanto, vi è un urgente bisogno 
di identificare biomarcatori precoci che possano aiutare a predire l’efficacia della 
terapia. Un aspetto fondamentale in tal senso è la quantificazione delle cellule 
del sistema immunitario che infiltrano i tumori. I recenti progressi nel campo della 
immunologia oncologica hanno dimostrato che l’infiltrazione di cellule immunitarie, 
come le cellule T linfocitarie, all’interno del micro-ambiente tumorale può influenzare 
la stimolazione di specifiche risposte immunitarie anti-tumorali. Il Capitolo 5 mette in 
evidenza il vantaggio della diagnostica per immagini multispettrali (MSI, dall’inglese: 
multispectral imaging), per valutare con precisione gli infiltrati cellulari in tessuti 
notoriamente difficili, come il melanoma pigmentato. La tecnica innovativa MSI 
combina l’imaging con la spettroscopia, al fine di ottenere informazioni quantitative 
e qualitative accurate, circa la distribuzione di diversi tipi di cellule all’interno del 
micro-ambiente tumorale. Il melanoma cutaneo è spesso caratterizzato dalla 
presenza di pigmenti scuri di melanina che possono oscurare la presenza di cellule 
immunitarie o falsarne la classificazione, in entrambi i casi ostacolando l’analisi e la 
quantificazione della composizione cellulare del tessuto. In questo capitolo, abbiamo 
confrontato due diverse metodologie di quantificazione delle cellule T linfocitarie 
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nel melanoma, la “classica” diagnostica per immagini e l’innovativa tecnica MSI. LE 
nostre osservazioni hanno dimostrato che, il principio di separazione degli spettri 
di un’immagine, sul quale si basa la tecnica MSI, risolve le difficoltà legate all’analisi 
classica e permette in tal modo un’enumerazione estremamente accurata della 
componente T linfocitaria che infiltra il melanoma.
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